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INTRODUCTION
At the start of this doctoral study (October
1997), the molecular (cyto)genetic and clinical
picture of neuroblastoma comprised three types
of tumors1, 2. A first type was typically found in
infants (children under the age of 1 year at
diagnosis) and characterized by a near-triploid
DNA content. Patients with this type of tumor had
a high survival probability. A second type of
tumor was found in children over the age of 1
year, with a near-diploid or near-tetraploid DNA
content, and exhibited MYCN amplification (MNA)
and deletion of the short arm of chromosome 1.
Despite intensive and multi-modal therapy, these
patients had a dismal survival probability. A third
type of tumor was clinically and genetically less
clearly defined. These tumors shared many
characteristics of type 2 tumors, but did not
exhibit MYCN amplification. The prognosis for
these patients was difficult to predict, and
sometimes referred to as ‘intermediate’.
Genetic research on neuroblastoma had mainly
focused on the study of the prognostic value and
the functional role of MYCN amplification, and on
the search for tumor suppressor genes located on
the distal part of the short arm of chromosome 1.
In addition, at least 7 other chromosomal regions
were identified that showed frequent loss of
heterozygosity (LOH), and in the mid 1990’s,
fluorescent in situ hybridization (FISH) studies
demonstrated the frequent occurrence of
unbalanced 17q translocations in cell lines and
tumors.
Although these studies yielded significant and
valuable insights in the genetic basis of
neuroblastoma, the applied FISH and allelotyping
methods were limited in the sense that only a
few selected regions were studied
simultaneously, leaving the majority of the
genome unexamined. Furthermore, metaphase
cytogenetic analysis of neuroblastoma was often
hampered by a low mitotic index of the tumor
cells, resulting in a biased analysis of high stage
tumors that tended to grow better in vitro. We
therefore decided to apply a new method called
‘comparative genomic hybridization’ (CGH3, 4)
that allowed detection of gains and losses in the
tumor genome. Particular advantages of this
technique are the possibility to screen the
complete genome in a single FISH experiment,
without the need for culturing the tumor cells.
The methodology is based on differential labeling
of tumor and normal control DNA and
simultaneous hybridization on normal metaphase
chromosomes fixed on a microscope slide. The
ratios of red to green fluorescent intensities along
the chromosome axis reflect the relative copy
number for each chromosomal region, and
pinpoint losses, gains, and DNA amplifications
(Figure 1).
Preliminary studies in our laboratory validated
the CGH method on well-characterized
neuroblastoma cell lines and a small series of
primary tumors5, 6. Advanced and detailed
analyses of multiple large series of primary
biopsies are described in Chapter 2.
Despite significant new insights in the genomic
heterogeneity described in Chapter 2, only few
genes have been recognized to play a role in
neuroblastoma, and if so, only in a subgroup of
tumors (e.g. MYCN and CASP8). Therefore, a new
strategy was outlined in our laboratory to identify
and study differentially expressed transcripts in
the various genetic subgroups. It is well known
that the transcriptome is the driving force for
proliferation, differentiation and apoptosis, and
that changes in expression patterns can lead to
malignant transformation. Studying these
changes can identify genes that are implicated in
the complex process of oncogenesis, and might
pinpoint genes that have diagnostic or prognostic
discriminatory power.
Figure 1 : Comparative genomic hybridization
DNA is extracted from both tumor and reference
(normal control) samples and labelled using a green
and red fluorescent dye, respectively. The samples are
mixed together in the presence of Cot1 DNA, which
blocks repetitive sequences. The mixture of DNA is then
competitively hybridized onto normal metaphase
chromosomes. Fluorescent images are digitally
captured and analyzed with specific software to
determine the fluorescent ratio along the chromosome
axis, which reflects the relative copy number for each
chromosomal region in the tumor genome. In this
scheme, red segments are underrepresented in the
tumor (e.g. due to a deletion), whereas green regions
are overrepresented (e.g. duplication). Yellow areas
represent regions of the chromosome in which the DNA
copy numbers are the same between the two samples.
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To this purpose, suppression subtractive
hybridization (SSH7) was applied to extract
relevant neuroblastoma genes on a transcriptome
wide basis. This PCR based method allows
specific amplification of differentially expressed
genes, including low abundant transcripts, by
comparing two neuroblastoma cell lines that
belong to different genetic subgroups (Figure 2).
An important step in the study of differential
gene expression analysis based on subtractive
cDNA cloning is the verification of the differential
expression status of the isolated clones. As
Northern blot hybridization requires large
amounts of RNA, and constitutes a labor
intensive method which is not particularly
sensitive, we decided to introduce quantitative
RT-PCR8 in our search for relevant neuroblastoma
genes. In Chapter 3, we describe the
development of an optimized and validated cost-
effective real time RT-PCR assay, and provide an
adequate solution for the old problem of gene
expression normalization. Based on this technical
framework, we screened putative differentially
expressed clones in cell lines and primary
tumors, and identified new candidate genes and
predictors for clinical outcome.
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Figure 2 : Subtractive cDNA cloning strategy for
identification of differentially expressed genes between
cell lines IMR-32 and SK-N-SH, belonging to different
genetic subgroups of neuroblastoma. Suppression
subtractive hybridization allows specific amplification of
transcripts that are specifically expressed in one cell
line versus the other. After elimination of false positive
clones through differential screening, the differential
expression status is verified and the relevance is
determined by expression profiling of well characterized
cell lines and primary tumor biopsies.
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LINICAL ASPECTS
Neuroblastoma is the most frequent extra-
cranial solid tumor in children, preceded in
frequency by acute lymphoblastic leukemia and
brain tumors1. Neuroblastoma comprises 10% of
all childhood malignancies, with a yearly
incidence of 1/100 000 children in the Western
world. The median age of diagnosis is less than
two years and almost 90% of patients diagnosed
by the age of 5 years. Despite recent advances in
understanding the biology of this disease,
neuroblastoma still accounts for more deaths in
childhood than any other cancer2.
Neuroblastoma tumors arise from primitive
sympathetic cells that are derived from the
neural crest. During embryonic development,
pluripotent cells migrate from the neural crest to
give rise to –amongst others- the sympathetic
ganglia and the adrenal medulla. Accordingly, the
primary tumors are most often found along the
abdominal (30%) or thoracic sympathetic chain
ganglia (20%) and in the adrenal gland (35%)1
(Figure 1).
Because neuroblastoma tumors are derived from
postganglionic sympathetic neuron precursor
cells, they most often show an adrenergic
neurotransmitter phenotype. More than 90% of
the tumors produce catecholamines, which is an
important and relatively easy assessable
diagnostic marker, since these products and their
metabolites can be measured in serum and
urine3. Homovanillic acid (HVA) and
vanillylmandelic acid (VMA) are the urinary
catecholamine metabolites usually measured in
neuroblastoma for diagnostic purpose and follow-
up.
Based on the localization of the primary tumor,
lymph node involvement and the pattern of
metastasis, neuroblastomas can be classified into
different stages. The first staging system was
proposed in 1971 by Evans and colleagues4, and
evolved into the International Neuroblastoma
Staging System in the late 1980s with revisions
in 19935. Internationally accepted criteria for
confirming the diagnosis of neuroblastoma, initial
patient evaluation, and staging are incorporated
in this system.
Stage 1 neuroblastomas are localized tumors that
allow complete gross excision.  Stage 2A and 2B
are localized tumors with incomplete gross
excision. In stage 2A the ipsilateral nonadherent
lymph nodes are negative for tumor
microscopically, in stage 2B they are positive.
Stage 3 tumors are unresectable unilateral
tumors infiltrating across the midline. Stage 4
tumors show remote disease involving the
skeleton, liver and other organs, and distant
lymph nodes. The group of stage 4S tumors have
metastases restricted to liver, skin and/or or
bone marrow but not to the skeleton. Stage 4S is
limited to infants less than 1 year old.
The most important clinical variables that predict
outcome are the stage of disease and the age of
the patient at diagnosis. The outcome of infants
less than 1 year of age is substantially better
than older patients with the same stage of
disease, particularly those with more advanced
stages of disease. The exception to this is stage
4S, which has –despite widespread metastases- a
similar outlook as stages 1 and 2. Based on stage
and age, three broad risk groups can be defined2
(Figure 2). A group of patients who require
surgery alone with additional treatment only if
there are life- or functioning-threatening
symptoms or recurrence, encompasses stage 1, 2
and 4S neuroblastoma, and accounts for one
quarter of all patients, with an overall survival
rate of 85%. An intermediate group of patients
who are treated with conventional chemotherapy
and surgical resection of the primary tumor have
approximately a 60% probability of survival. This
group includes patients with stage 3
neuroblastoma and infants with stage 4 disease,
and accounts for approximately one quarter of all
children. Patients with poor-prognosis
neuroblastoma, defined as stage 4 disease over
the age of one year, make up the largest group,
C
Figure 1: Distribution of the sympathetic nervous
system in children, including the adrenal medulla (a),
sympathetic side chains and ganglia (b), and the
retroperitoneal paraganglia (c) (adapted from source:
NKI, Amsterdam, the Netherlands).
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comprising half of all patients. Despite
multimodal therapy including chemotherapy,
surgical resection of the primary tumor and
myeloablative therapy with hematopoietic stem
cell rescue, only 15-25% of the stage 4 patients
are long-term survivors.
In agreement with the above described large
differences in individual survival probability,
neuroblastoma is often described as enigmatic
because the tumor exhibits three distinct
patterns of clinical behaviour6: life-threatening
progression, maturation into ganglioneuroma or
ganglioneuroblastoma (see further), or
spontaneous regression. The incidence of the
latter phenomenon in neuroblastoma is between
10-100 fold more frequent than in any other
human cancer. The most striking examples of
neuroblastoma regression include cases where
primary tumor and metastases disappear without
treatment. Spontaneous regression is most often
found for the stage 4S neuroblastoma in infants.
In addition, post-surgical residual disease from
stage 2 neuroblastoma usually regresses
completely7. It has been postulated that a
delayed natural occurring apoptosis mechanism is
responsible for the observed regression8.
Alternatively, immunological cytolytic processes
guided by natural IgM antibodies might play a
role in the regression of malignant
neuroblastoma cells9.
The regression behavior of clinically manifested
neuroblastoma tumors is reminiscent to the
naturally occurring or programmed cell death
during development of the nervous system. This
trimming process, referred to as involution10, 11 is
characterized by massive death of still immature
neuroblasts before differentiation. In this context,
a very high frequency of microscopic aggregates
of immature neural crest cells has been observed
inside and outside of the adrenal gland at
autopsy of infants younger than 3 months who
died of non-tumor-related causes12. The
incidence of so-called ‘neuroblastoma in situ’ is
by far exceeding the frequency of clinically
detected cases of neuroblastoma, implying that
these in situ lesions undergo spontaneous
regression or involution. It’s still an open
question whether neuroblastoma in situ
represents embryonic remnants of sympathetic
nervous system development, or
hyperplastic/neoplastic lesions. Likewise, mass
screening studies aiming at the preclinical
detection of neuroblastoma revealed a doubled
frequency in low stage prognostic favorable
tumors without a concomitant decrease in
advanced stage neuroblastoma13. These data
demonstrate that mass screening studies result
in overdiagnosis of otherwise regressing tumors,
and suggest that low stage tumors do not
progress to advanced stages of disease.
Alternatively, the higher incidence of tumors as a
result from screening studies might partially be
explained by the detection of nests of non-
transformed neuroblasts, not yet eliminated in
the normal process of trimming the nervous
system.
ATHOLOGY
Neuroblastoma belongs to the small round
blue cell tumors of childhood, which is a
descriptive category of a number of malignant
tumors that tend to occur in childhood with a
similar histological appearance of uniformly sized
round cells, with large dark nuclei and scant
cytoplasm (Figure 3). Other tumors that fit into
this category are primitive neuroectodermal
tumors (PNET), Ewing’s sarcoma, Wilms’ tumor,
rhabdomyosarcoma, desmoplastic small round
blue cell tumor, non-Hodgkin lymphoma and
acute leukemia.
A subset of neuroblastomas has the capacity for
spontaneous or therapy induced maturation, thus
mimicking the physiological pathways of
sympathetic neuroblasts. Invading normal
Schwann cells in the tumor are believed to play a
role in the differentiation process by providing
the necessary differentiation factors14.
Ganglioneuroma is the fully differentiated and
benign counterpart of neuroblastoma. It is
composed of mature ganglion and Schwann cells.
In ganglioneuroblastoma, both mature and
immature cells are present. These three classic
histopathological patterns of neuroblastic tumors
(neuroblastoma, ganglio-neuroblastoma and
ganglioneuroma) reflect a continuous spectrum of
maturation and differentiation, and are correlated
with clinical outcome. Based on age at diagnosis
and histological morphology (i.e. the fraction of
Schwann stroma, differentiation status of the
neuroblastic cells, and the mitosis-karyorrhexis
index), an International Neuroblastoma Pathology
Classification (INPC) system was developed, in
which favorable and unfavorable histological
P
Figure 2: Progression free survival of patients with
neuroblastoma, classified according to patient age at
diagnosis and tumor stage (adapted from ref. 2).
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groups are distinguished15, 16 (Figure 3). A recent
study assessed the value of this system by
multivariate regression analysis including known
genetic defects with adverse prognosis (see
further), and confirmed the prognostic power of
the INPC system17.
YMPATHETIC NERVOUS SYSTEM
DEVELOPMENT
The human nervous system consists of the
central nervous system (CNS) (comprising the
brain and the spinal cord) and the peripheral
nervous system (PNS), which links the CNS with
the body’s sense receptors, muscles, and glands.
The PNS is divided in two components : the
somatic or skeletal nervous system, which
controls voluntary movement, and the autonomic
nervous system, which regulates inner organ
function via the sympathetic, parasympathetic
ganglia, or enteric ganglia. The main role of the
sympathetic nervous system (SNS) is to control
stress response.
The nervous system originates from the neural
plate, an embryonic structure evolving from the
ectodermal germ layer during the third week of
gestation. Little is known with respect to the
genes and processes implicated in the early
development of the human nervous system.
Furthermore, most of the information we
currently have on this subject is based on animal
systems. There, the process of neural induction is
initiated and guided by several growth factors
(such as bone morphogenetic protein, fibroblast
growth factor, and wingless family members) and
transcriptional responses to these factors
(belonging to the Snail, Pax and Zic transcription
factor families)18. During the process of
neurulation, the neural plate invaginates
ventrally and closes in order to form the neural
tube (which will give rise to the CNS).
During this closure, neural crest cells originate at
the interface between the closing neural tube and
the dorsal ectoderm (Figure 4). These pluripotent
migratory cells are unique in that they generate
multiple cell types contributing to different
functionally unrelated tissues located all over the
body, such as melanocytes in the skin, cartilage
and facial bones, neurons and support cells of the
PNS, and neuroendocrine cells in the adrenal
medulla and thyroid19. The ultimate cell fate is
largely determined by region- and cell-type
specific transcription factors, as well as signalling
molecules encountered during migration20, 21.
Important transcription factors that play a role in
SNS development are ARIX (PHOX2A), PMX2B
(PHOX2B), ASCL1 (HASH1), and HAND2
(dHAND).
The adult SNS consists of neuroendrocrine
adrenal chromaffin cells, and sympathetic
neurons and supportive cells. However, during
prenatal and early postnatal life, several
additional cell types are present that regress or
mature, such as clusters of immature
neuroblastic cells in the adrenal gland, and extra-
adrenal chromaffin cells that form the
Figure 3: According to the INPC, neuroblastoma is
defined as a neuroblastic, Schwannian stroma-poor
tumor, with subtype classification depending on the
degree of neuroblastic differentiation. Top:
undifferentiated subtype, composed of undifferentiated
neuroblasts without discernable neuropil (original
magnification x200); Middle: poorly differentiated
subtype, composed of undifferentiated neuroblastic
cells with clearly recognizable neuropil (original
magnification x200); Bottom: differentiating subtype,
showing both nuclear and cytoplasmic differentiation
(original magnification x400) (reproduced from ref.15).
S
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paraganglia, or that are found as small intensely
fluorescent (SIF) cells in sympathetic ganglia
(reviewed in 22). Expression studies indicated
that neuroblastomas share expression patterns
with developing SNS cells. Differentiating tumors
(having prognostically favorable characteristics)
are thought to progress along an extra-adrenal
chromaffin lineage, and undifferentiated
aggressive tumors display marker expression
mirroring that of early sympathetic neuroblasts of
the ganglia and adrenal gland23, 24.
In view of the importance of neurotrophin
signalling in normal neural development, a
number of studies investigated this pathway in
neuroblastoma. Neurotrophins implicated in SNS
development include nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF),
neurotrophin-3 and neurotrophin-4, and mediate
signalling through the high-affinity TRK receptor
family of tyrosine kinases, and the low-affinity
p75 neurotrophin receptor (p75NTR).
Neurotrophin signalling regulates growth,
development, survival and repair of the
sympathetic nervous system25, 26.
Differential expression of the TRK receptor
kinases is strongly correlated with the biological
and clinical features of neuroblastoma (reviewed
in ref. 27). NTRK1 (TRKA) expression is inversely
related to disease stage and MYCN amplification
status (see further), with high NTRK1 expression
hence being a marker for prognostically favorable
tumors. The presence of NGF results in terminal
differentiation of NTRK1 expressing cells. In
contrast, if NGF is limiting, NTRK1 expressing
cells will enter a programmed cell death.
Full length NTRK2 (TRKB) is expressed
preferentially in advanced stage, MYCN amplified
neuroblastomas. Many of these tumors also
display high BDNF expression, which result in an
autocrine pathway promoting growth and
survival, even in the absence of exogenous
neurotrophins. In favorable tumors, NTRK2 is
expressed as a truncated isoform or in low
amounts of the full length isoform. Lastly, NTRK3
(TRKC) shows a similar expression pattern as
NTRK1.
EUROBLASTOMA GENETICS
In many neoplasms of adulthood, a
multistep process of genetic and epigenetic
alterations has been shown to be implicated in
tumorigenesis, best exemplified for the
progression of colon adenoma to invasive
carcinoma28. In contrast, for many pediatric
tumors, only few or single initiation events, such
as oncogene activation due to a specific
translocation or loss of tumor suppressor function
due to deletion, have been shown to be
responsible for tumorigenesis. For neuroblastoma
however, the observed genetic changes are
heterogeneous, and no single genetic alteration
has been identified which is common to all or
most tumors.
During the last three decades, a complex pattern
of genetic abnormalities has been described in
neuroblastoma (Figure 6), some of which
delineate distinct genetic subgroups with respect
to response to therapy and outcome.
MYCN amplification
The first genetic analyses of neuroblastoma were
cytogenetic characterizations of tumor derived
cell lines in the 1970s. Biedler and colleagues
described double minute chromatin bodies
(dmins) and occasional long, homogeneously
staining regions within chromosomes29. Ten
years later, it was shown that these cytogenetic
abnormalities were the result of MYCN gene
amplification30, a new member of the MYC proto-
oncogene family. Brodeur and colleagues were
the first to report MYCN amplification (MNA) in a
substantial subset of primary untreated
Figure 4: Nervous system development (cross-
section): invagination of the dorsal ectoderm, closure of
the neural tube, neural crest formation at the interface
of the closing neural folds and dorsal ectoderm, and
migration of the pluripotent crest cells (human time
frame).
N
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neuroblastomas, and demonstrated a correlation
with advanced stage of disease31. Subsequently,
it was shown that MNA was strongly associated
with rapid disease progression and a poor
prognosis32. Hence, assessment of MYCN copy
number is an important component of disease
evaluation for newly diagnosed patients (Figure
5).
Overall, around 20% of neuroblastomas show
MNA, all having very high MYCN expression both
at the RNA and protein level. Although there is
some variation in MYCN levels in tumors without
amplification, higher expression in this group is
not correlated with a worse outcome33, 34.
Targeted overexpression of human MYCN in the
neuro-ectoderm of transgenic mice produced
neuroblastoma tumors in a dose-dependent
manner35, firmly demonstrating a role of MYCN in
the development of a subset of neuroblastomas.
MYCN is a proto-oncogene located on
chromosome band 2p24, and is normally
expressed in the developing nervous system as
well as in other tissues. Like all MYC family
proteins, MYCN encodes a transcription factor
with a N-terminal transactivation domain (Myc
box) and a C-terminal basic helix-loop-
helix/leucine zipper (bHLH-LZ) motif. For MYCN
to activate transcription, it must first dimerize to
MAX by means of the bHLH-LZ domain, upon
which the heterodimers bind E-box-related
sequences with high affinity. MAX expression is
relatively constant, and results in the preferential
formation of MAX/MAX homodimers in quiescent
cells, which results in transcriptional repression.
In addition, heterodimerization of MAX with the
MAD family of proteins also represses
transcription36. With increasing MYCN protein
levels (e.g. entrance into the cell cycle, or as a
consequence of genomic amplification),
heterodimerization of MYCN/MAX occurs, which
lead to transcriptional control of -largely
unknown- genes involved in amongst others
growth and proliferation. Indeed, the molecular
mechanism of tumorigenesis caused by
overexpression of MYCN remains largely
unknown.
As the amplicon containing MYCN is large, usually
between 500-1000 kb, it has been postulated
that additional genes located near MYCN could
contribute to the observed aggressive behavior.
High-resolution restriction mapping of the region
around MYCN indicated that a core domain of 130
kb is consistently amplified37. To date, no other
gene besides MYCN has been identified in this
core region38. However, two other genes (DDX1
and NAG) have been reported to be coamplified
in 40-50% of the MYCN amplified tumors39, 40. As
amplification of DDX1 and NAG has never been
observed in MYCN single copy tumors, it seems
that MYCN is primarily responsible for the
formation of the amplicon.
Non-syntenic co-amplification of other genes with
MYCN is rare in neuroblastoma. Amplification of
the CCND1 and EMS1 genes at 11q13 have been
reported in one primary tumor41; amplification of
the SAS, MDM2 and CDK4 genes (12q13-q14),
RSN (12q24), and ZNF133 (20p11) in
neuroblastoma cell line NGP42, 43 (with MDM2
amplification found in two other cell lines and a
tumor44); amplification of the MEIS1 homeobox
gene (2p14) in cell line IMR-3245, 46; and MYCL
(1p34) amplification in cell line GOTO47.
Interestingly, in a MYCN single copy
neuroblastoma cell line SJNB-12, non-syntenic
co-amplification of the ATBF1 gene, located at
16q22-q23, and the MYC proto-oncogene (8q24)
was found48, 49. The biological significance of
these findings in neuroblastoma remains to be
determined.
Ploidy patterns suggest two biological
subtypes
Both cytogenetic and flow-cytometric analyses of
neuroblastoma tumor cells have demonstrated
the existence of two patterns of ploidy with
distinct prognosis for the patient. The majority of
the neuroblastoma cell lines and advanced stage
tumors have a near-diploid or near-tetraploid
chromosome number, whereas favorable
neuroblastomas, especially in infants, usually
have a hyperdiploid or near-triploid DNA content.
Look and colleagues were the first to describe the
association of hyperdiploidy in infants with a
better response to chemotherapy and thus a
more favorable prognosis50. More recent flow-
cytometric studies demonstrated that a
hyperdiploid DNA content primarily provides
important prognostic value in infants, whereas
this variable looses its prognostic significance for
Figure 5: MYCN amplification under the form of double
minute chromatin bodies (red), as evidenced by FISH
analysis for neuroblastoma cell line SMS-KCNR.
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patients over two years of age51, 52. Near-triploid
tumors are characterized by three almost
complete haploid sets of chromosomes, with no
or only few structural abnormalities. In contrast,
the near-diploid or near-tetraploid tumors exhibit
structural abnormalities53, 54.
Recently, comparative genomic hybridization
analysis demonstrated that numerical imbalances
were predominantly found in lower stage
neuroblastoma (1, 2 and 4S), whereas the
advanced stage tumors commonly had partial
chromosome gains and losses41. A subsequent
multicenter study provided an accurate
description of the typical pattern of numerical
imbalances observed in near-triploid
neuroblastomas, with whole chromosome 17 gain
relative to ploidy found in all tumors with only
numerical imbalances55. Based on these findings,
it has been conceived that the near-triploid
tumors have a fundamental defect in mitotic
disjunction, while the near-diploid/tetraploid
neuroblastomas are characterized by genomic
instability leading to various structural
chromosome rearrangements (Figure 6).
Unbalanced gain of distal 17q as adverse
prognostic marker
In a review of Giemsa-banded karyotypes from
35 neuroblastoma cell lines and tumors, Gilbert
and colleagues were the first to report a high
frequency of extra copies of the long arm of
chromosome 1756. These findings however
remained unconfirmed until the advent of the
fluorescent in situ hybridization (FISH) technique
that highlighted the extent and nature of
chromosome 17q rearrangements in
neuroblastoma cell lines57, 58, and subsequently
in two series of primary tumors59, 60. These
studies unequivocally demonstrated that
unbalanced translocations resulting in gain of 17q
and partial loss of the partner chromosome are
the most common genetic abnormalities in
neuroblastoma. The most frequent partner
chromosomes for these translocations are 1p and
11q, with many other partner regions involved,
demonstrating the highly promiscuous nature of
these 17q translocations.
A further study demonstrated that the
chromosome 17 homologue from which the
unbalanced translocation had been derived was
still present and intact in the neuroblastoma
cells. This indicates that the unbalanced 17q
translocations occur in the S/G2 phase of the cell
cycle61.
Extensive breakpoint mapping using FISH
analysis revealed that the breakpoints are
scattered over a large genomic region from
17q11 to 17q23, with a 25 Mb region from
17q23-qter being consistently gained57, 58, 60, 62.
These findings strongly suggest that this region
contains one or multiple genes that -when
present in increased copy number- contribute to
neuroblastoma tumorigenesis through a gene
dosage effect.
More recent comparative genomic hybridization
(CGH) studies on all stages of neuroblastoma
corroborated and extended the results obtained
by FISH41, 59, 63-65. Further analysis in a
multicenter study of 204 both published and new
cases showed that unbalanced 17q gain was
present in 70% of the neuroblastomas without
whole chromosome 17 gain55.
These CGH studies and other molecular
cytogenetic analyses clearly demonstrated that
unbalanced 17q gain is significantly associated
with well established indicators of adverse
prognosis, such as advanced stage of disease,
age at diagnosis over 1 year, 1p deletion (see
further), MNA, and ploidy in the near-diploid or
near-tetraploid range66. To determine the
independent prognostic value of 17q gain, a
multicenter collaborative compilation of 313
cases with known 17q status was studied67.
Overall survival at 5 years was 30.6% for the
cases with 17q gain, whereas 86.0% of the cases
without this feature survived. Furthermore,
multivariate analysis showed that unbalanced
17q gain was the most powerful independent
prognostic factor, followed by the presence of
stage 4 disease and deletion of 1p.
The search for chromosome 1p tumor
suppressor genes
Almost 25 years ago, Brodeur and colleagues first
reported that deletions of the short arm of
chromosome 1 (1p) were a common cytogenetic
finding in neuroblastoma cell lines and advanced
tumors68. Subsequent cytogenetic and molecular
genetic studies have confirmed these findings by
documenting loss of heterozygosity (LOH) in 20-
40% of primary tumors, and until very recently,
this feature was considered to be the most
frequent genetic aberration in neuroblastoma.
It has rapidly been established that 1p deletions
were strongly correlated with high risk factors,
such as age at diagnosis greater than 1 year,
advanced stages of disease, and MNA. However,
there has been ongoing controversy about the
independent prognostic value of 1p deletions. In
a recent large study, Maris and colleagues have
demonstrated that loss of 1p was a significant
independent predictor of decreased event free
survival (EFS), but had no significant effect on
overall survival (OS) probability69. These findings
suggest that diagnostic assessment of the 1p
status may be useful in predicting relapses in
otherwise low risk patients.
The frequent finding of 1p deletions in
neuroblastoma strongly suggests the implication
of a tumor suppressor gene in this region. This
has been reinforced by the description of a
patient with neuroblastoma who was found to
have a constitutional balanced translocation
t(1;17) disrupting the 1p36 region70, and two
patients with a constitutional deletion in the 1p36
region who developed neuroblastoma71, 72.
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Further evidence for the presence of a tumor
suppressor on 1p came from a chromosome
transfer experiment in which the reintroduction of
1p in cell line NGP resulted in morphological
differentiation and cell death73.
Great efforts have been made by many research
groups to narrow down the critical region of LOH
on 1p in order to find the putative neuroblastoma
suppressor gene (reviewed in 74-76). The
observed deletions were generally large,
encompassing the telomere and extending to or
beyond 1p32. Identification of tumors with small
deletions refined the proximal boundary of the
shortest region of overlap (SRO), leading to a
region of consistent loss on 1p36.3 between
markers D1S244 and D1S8077.
Several lines of evidence indicated that there
might be additional 1p neuroblastoma suppressor
genes. Schleiermacher and colleagues reported 3
interstitial deletions of 1p32, suggesting the
existence of a suppressor gene in this proximal
region78. Takeda and colleagues reported that
tumors with large 1p deletions usually exhibited
MNA and poor survival, while tumors with small
terminal 1p deletions generally showed normal
MYCN copy numbers79. A similar finding was
made by Caron and colleagues, who additionally
reported the preferential loss of the maternal
allele in the MYCN single copy tumors with the
smaller deletions80-82. These findings suggest the
presence of at least two neuroblastoma
suppressor genes: an imprinted distal 1p36.3
locus defined by the SRO of all 1p deleted
tumors, and a non-imprinted 1p35-p36.1 locus
that is lost in MYCN amplified aggressive tumors.
Although several genes have been analyzed as
possible candidates for the 1p36 neuroblastoma
suppressor gene (reviewed in 75), no mutations
have been found in the non-deleted allele of any
candidate. However, one has to consider the
possibility that loss of one allele results in
haploinsufficiency of one or more genes with
tumor suppressive function, as shown for the
PTEN and APC gene83, 84.
Recently, the distal SRO was further refined down
to a 1 Mb region between markers D1S2731 and
D1S266685, which may provide an entrance point
for the cloning of candidate genes for
neuroblastoma. Additionally, two different
homozygous deletions of about 500 kb were
identified in two neuroblastoma cell lines, and
might pinpoint 1p36 suppressor genes86, 87.
Chromosome 11q deletions delineate a new
genetic subgroup
Several lines of evidence suggest the localization
of another important neuroblastoma tumor
suppressor gene at chromosome arm 11q.
Deletions of the long arm of chromosome 11
have been described in approximately 15-20% of
tumor karyotypes88, and chromosome 11 transfer
in cell line NGP with 11q LOH resulted in a more
differentiated phenotype73. Furthermore, rare
cases of constitutional abnormalities of this
region in children who developed neuroblastoma
have been reported (reviewed in 76). Molecular
genetic studies demonstrated LOH or loss of 11q
in approximately one third of the neuroblastoma
tumors41, 59, 64, 65, 89. It was first reported by
Vandesompele and colleagues that 11q deletions
were inversely correlated with MNA and loss of
1p. Furthermore, 11q deletions were found
significantly associated with loss of 3p and 14q41.
Figure 6: Top: Overview of frequent gains and losses
in neuroblastoma, with indication of (putatively)
relevant neuroblastoma genes (2q33: CASP8; 2p24:
MYCN; 3p21: RASSF1A; 9p21: CDKN2A; 11q13:
CCND1/EMS1; 16p12-p13: HNB1 (hereditary
neuroblastoma locus 1); 17q22: NME1; 17q25: BIRC5)
(bars to the right represent gains, bars to the left
losses, bold bar indicates amplification; blue: numerical
chromosome changes, each found in more than 40% of
the near-triploid tumors; green: structural aberrations
found in the near-diploid/near-tetraploid tumors).
Bottom: Simplified scheme representing the 4 major
genetic subgroups of neuroblastoma (-: loss, +: gain,
MNA: MYCN amplification).
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A subsequent large multicenter CGH study
confirmed this pattern and delineated a new
genetic subgroup of high stage tumors with 11q
loss in the absence of MNA and 1p deletions55
(Figure 6). Further analysis of this subgroup of
neuroblastomas indicated a very high frequency
of 11q deletions (60%) in stage 4 tumors without
the above mentioned abnormalities90. A recent
large LOH study on 331 neuroblastomas
identified a 2.1 cM consensus region of deletion
in chromosome band 11q23.3, flanked by
markers D11S1340 and D11S129991. However,
further studies are needed to confirm these
observations.
Loss of other chromosomal regions
In addition to ploidy changes, 17q gain, MNA, 1p
and 11q deletions, losses for several other
chromosomal regions were frequently reported,
suggesting the existence of additional tumor
suppressor genes. There have been reports of
frequent LOH at chromosome arms 2q89, 92, 3p89,
93, 4p94, 9p89, 95, 96, 14q89, 97-99, and 18q89, 100.
CGH analyses largely confirmed these PCR based
data (except for 2q and 18q) (Figure 6), and
demonstrated a significant association between
3p and 11q deletions in MYCN single copy
tumors, suggestive for a distinct genetic
subgroup55, 90.
The CASP8 gene has been identified as the
putative neuroblastoma tumor suppressor gene
for the region of frequent allelic loss at 2q33101.
This gene encodes for a cysteine protease
involved in initiation of apoptosis, and was shown
to be preferentially inactivated by deletion or
promoter hypermethylation in MYCN amplified
tumors. As MYCN overexpression sensitizes
neuroblastoma cells to apoptotic signals102, it is
suggested that CASP8 acts as a tumor
suppressor whose loss is required for survival of
MYCN overexpressing cells. However, in a
subsequent study, the correlation between lack of
CASP8 expression and MNA could not be
confirmed92.
Recently, promoter hypermethylation of the
RASSF1A gene located on 3p21.3 has been
reported in half of the neuroblastoma tumors,
and is therefore considered to be a good
candidate for the neuroblastoma 3p tumor
suppressor gene. However, no mutations have
been found as yet. As there was an association
between RASSF1A and CASP8 hypermethylation,
a subset of neuroblastoma might be
characterized by a CpG island methylator
phenotype103.
Mutation status of known tumor suppressor
genes
Several tumor suppressor genes frequently
implicated in other malignancies have been
investigated in neuroblastoma. So far, none of
these seems implicated in neuroblastoma
tumorigenesis, indicating that one or more
hitherto unidentified genetic pathways must play
a role in this tumor.
Although TP53 is inactivated in about half of the
human cancers, very few mutations have been
reported in primary neuroblastomas at
diagnosis104, 105. However, recent reports indicate
that some neuroblastomas acquire TP53
mutations during cytotoxic therapy, which can
confer high-level multidrug resistance (see
further)106, 107. Cytoplasmatic sequestration of
TP53 has been suggested as an alternative
mechanism for accumulation and functional
inactivation of p53 in neuroblastoma. However,
there are conflicting reports about the cellular
localization and functional status of TP53 in
neuroblastoma (overview in 108). In addition,
MDM2 amplification and overexpression
(observed in a few neuroblastomas; cf. supra)
has also been suggested as a mechanism for
TP53 inactivation through ubiquitination and
subsequent degradation.
TP73, the first identified TP53 homolog, was
proposed in 1997 as the long sought-after
neuroblastoma 1p36 tumor suppressor gene109,
but only two mutations have been reported for a
total of 209 tumors from 4 studies110-113. This is
in keeping with a very low mutation rate of TP73
in other human cancers114. In view of the
originally reported monoallelic expression of
TP73, the loss of a single copy would be sufficient
for tumorigenesis. However, more recent studies
showed that TP73 is generally biallelicly
expressed. Interestingly, abnormal splicing
variants of TP73 and increased TP73 expression
have been described in different human cancers
and cancer-derived cell lines, including
neuroblastoma115, 116. The current hypothesis
therefore is that altered TP73 expression, rather
than loss of function, is involved in
tumorigenesis. Further studies need to clarify
whether some TP73 protein isoforms exhibit a
dominant negative gain of function, and if this
gene is involved in neuroblastoma.
Although some studies reported an association
between neuroblastoma and neurofibromatosis
type 1, epidemiological analysis has suggested
that this is coincidental117. Two studies have
documented NF1 gene mutations in a few
neuroblastoma cell lines118, 119. Furthermore, a
homozygous NF1 deletion was described in a
neuroblastoma tumor from a patient with
hereditary neurofibromatosis type 1120. Familial
neuroblastoma was shown not to be linked to the
NF1 locus121.
The consensus deletion region at 9p contains the
tumor suppressor gene CDKN2A, which encodes
two different proteins with overlapping reading
frames (p16INK4A and p19ARF). These cyclin
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dependent kinase inhibitors are mutated in many
human cancers122. Extensive mutation scanning
in 6 studies however revealed only one mutation
in a series of more than 200 neuroblastoma
tumors75. A recent study found 4 homozygous
deletions of the CDKN2A gene in 46 tested
neuroblastoma cell lines, suggesting that biallelic
inactivation may contribute to tumorigenesis123.
In contrast, high expression of p16INK4A has been
reported in NB cell lines and high stage tumors.
Intriguingly, the RB1 protein was nonetheless
phosphorylated and functional. It has therefore
been suggested that neuroblastoma may bypass
the cell cycle block imposed by constitutive
expression of wild-type p16INK4A 124-126. In this
respect, the reported amplification of CCND1 and
CDK4 in a primary tumor and cell line
respectively41, 42, suggest that overexpression of
cyclins or cyclin dependent kinases might be part
of this mechanism.
Hereditary neuroblastoma
Although the majority of neuroblastoma tumors
occur sporadically, 1-2% of patients have a
familial history of the disease127, 128. In these
cases, neuroblastoma is inherited in a autosomal
dominant fashion with incomplete penetrance.
Familial neuroblastoma patients are usually
diagnosed earlier, and have often multiple sites
of primary tumors compared to sporadic cases.
These clinical characteristics are hallmarks of the
two-hit cancer predisposition model first
described for retinoblastoma. Linkage analysis
has excluded all candidate loci of known allelic
loss in neuroblastoma (reviewed in 129), but has
recently identified a putative predisposition locus
for familial neuroblastoma at 16p12-p13130.
LTERED EXPRESSION OF CANCER RELATED
GENES
Multidrug resistance
Half of the patients diagnosed with
neuroblastoma present with disseminated
disease, and have to be treated with
chemotherapeutic agents. Unfortunately, many of
these patients respond only transiently or
incompletely, often due to acquired resistance to
the administered drugs. Furthermore, it appears
that these tumors are concomitantly resistant to
structurally and functionally unrelated agents, a
phenomenon described as multidrug resistance.
Classes of chemotherapeutic drugs commonly
used to treat neuroblastoma patients, and to
which multidrug resistance frequently arises are
the anthracyclins (doxorubicin), vinca alkyloids
(vincristine), epipodophyllotoxins (etoposide),
platinum compounds (cisplatin), and alkylating
agents (cyclophosphamide)131.
The underlying cellular mechanisms that result in
multidrug resistance are increased efflux or
decreased influx of toxic compounds, activation
of detoxification or drug-induced DNA damage
repair systems, and disruption of apoptotic
signalling pathways132. The best characterized
mechanism in neuroblastoma involves increased
expression of two ATP-binding cassette (ABC)
transporters, ABCB1 (MDR1) and ABCC1 (MRP),
that pump hydrophobic toxic compounds out of
the cell. However, the role of MDR1 in
neuroblastoma is controversial (reviewed in133),
mainly due to different methods used for
quantification and the scale of the studies. One
study reported MDR1 overexpression in advanced
stage tumors resulting in poor response to
chemotherapy134. Other studies failed to confirm
this, and even showed preferential expression in
localized and more differentiated tumors of good
clinical prognosis135-137. Furthermore, MDR1
might be transcriptionally activated in response
to differentiation, rather than chemotherapy138.
These results suggest that enhanced MDR1
expression is unlikely to be a major cause of
acquired drug resistance in neuroblastoma.
A more clear picture is available for the other
ABC transporter MRP. It was shown that MRP
expression is strongly correlated with MYCN
expression and poor survival137, 139. Together
with the identification of an E-box sequence in
the MRP promoter region140, and downregulation
of MRP expression in a cell line using MYCN
antisense RNA transcipts141, these data indicate a
mechanistic link between MYCN and MRP,
whereby MYCN amplification can result in
increased drug resistance.
Telomerase activity
Telomeres are short repetitive stretches of DNA
at the end of the chromosomes and are
responsible for the chromosomal integrity. During
each cell division, the telomeres decrease in size,
resulting in cellular senescence and death after
20-80 divisions. Hence, most cancer cells have
developed a mechanism to maintain their
telomeres by aberrantly expressing telomerase,
an RNA dependent DNA polymerase that adds
telomeric repeats to the chromosome ends142.
Telomerase expression is detectable in the
majority of neuroblastoma cells, with high levels
of expression associated with high stage of
disease and poor outcome143, 144. The observed
telomerase activity in favorable neuroblastoma
may reflect the observed expression in
developing normal neuroblasts, while markedly
increased levels in aggressive neuroblastomas
are probably due to reactivation of telomerase in
the tumor cells145.
Metastasis
Two genes that exhibit a differential expression
pattern in many cancer types depending on the
dissemination status, display an opposite pattern
in neuroblastoma. The cell surface glycoprotein
A
Chapter 1 24
CD44 has been postulated to play a role in cell
adhesion and has been shown to be
overexpressed in several cancers. For
neuroblastoma however, CD44 expression is
undetectable in the majority of cell lines and
tumors with dissemination at diagnosis146-148.
CD44 expression is inversely correlated with
MYCN amplification and has been reported as an
independent prognostic marker, especially in
higher stage tumors146, 149.
The NME1 gene encodes a nucleoside
diphosphate kinase, for which reduced expression
has been correlated with metastases of breast
and ovarian carcinomas150, 151. For neuro-
blastoma however, increased expression has
been found in advanced stage primary tumors,
correlating with a decreased survival
probability152-154. Furthermore, missense
mutations in a highly conserved domain were
identified in a subset of these advanced tumors
with NME1 overexpression153, 155. The mutated
protein displays both decreased enzymatic
activity as well as altered protein-binding
interactions, suggesting that overexpression of a
mutated protein might act in a dominant-
negative fashion156. Given the chromosomal
position of NME1 at 17q22, further studies are
required to determine if there is a mechanistic
link between gain of 17q and overexpression of
NME1.
Apoptosis
During normal fetal and neonatal development of
the nervous system, a large number of neuronal
cells die via apoptosis. It has been postulated
that this apoptotic mechanism is somehow
defective in neuroblastoma cells, with the
phenomenon of spontaneous regression of some
neuroblastoma tumors being a delayed process of
naturally occurring apoptosis.
NGF withdrawal is a major signal for apoptosis in
the developing sympathetic nervous system, and
mediates the elimination of redundant cells.
Favorable neuroblastoma tumors usually express
high levels of the high-affinity NGF receptor gene
NTRK1, and differentiate in vitro in response to
NGF (cf. supra). In contrast, deprivation of NGF
results in tumoral cell death157. It was further
shown that high expression of caspases CASP1
and CASP3 are associated with favorable biologic
features (such as MYCN single copy number and
low stage of disease), suggesting that
neuroblastomas prone to undergoing apoptosis
are more likely to regress or respond well to
therapy158, 159. Remarkably, MYCN amplification
and concurrent overexpression seems to sensitize
neuroblastoma cells to apoptotic signals102. A
recent study however demonstrated that CASP8
was preferentially inactivated in these MYCN
amplified tumors, hereby rendering the cells
insensitive to programmed cell death101.
Many cytotoxic agents have been shown in vitro
to induce apoptosis in neuroblastoma cells,
mediated by the TNFRSF6 (FAS,CD95) and
mitochondrial BCL2 pathway. Increased TNFRSF6
expression appears to be a crucial component of
chemotherapy induced apoptosis160, and the
anti-apoptotic BCL2 and BCL2L1 (BCL2-XL)
proteins may play an important role in acquired
resistance to chemotherapy161, 162. BCL2 is
expressed in the majority of cell lines and tumors
(which have neuronal/ganglionic features) where
it is positively correlated to cellular
differentiation. In a small subset of tumors with a
spontaneous neuronal to neuroendocrine-
chromaffin lineage shift, BCL2 expression is high
in the neuroblastic cells, but decreases as the
cells become increasingly more neuroendocrine, a
phenomenon occurring in poorly vascularized
areas, adjacent to necrotic zones. There, BCL2
expression is inversely correlated with
morphological features of apoptosis24, 163-167.
Another anti-apoptotic protein BIRC5 (survivin)
has been associated with a more aggressive and
histologically unfavorable disease168, 169.
Interestingly, this gene is located at 17q25, and
might be the target of consistent gain of 17q in
neuroblastoma. Other proteins involved in
neuroblastoma apoptosis are the members of the
retinoic acid receptor family, which mediate
signalling from different retinoids, resulting in
differentiation or apoptosis of the cell170.
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Comparative genomic hybridization (CGH) analysis was performed on 36 neuroblastomas of both low and high stage of disease.
This study significantly increases the number of neuroblastoma tumors studied by CGH. Analysis of larger series of tumors is
particularly important in view of the different clinical subgroups that are recognized for this tumor. The present data and a
comparison with all published CGH data on neuroblastoma provide further insights into the genetic heterogeneity of
neuroblastoma. Stage 1, 2, and 4S tumors showed predominantly whole chromosome gains and losses. A similar pattern of
whole chromosome imbalances, although less frequent, was observed in stage 3 and 4 tumors, in addition to partial
chromosome gains and losses. An increase in chromosome 17 or 17q copy number was observed in 81% of tumors. The most
frequent losses, either through partial or whole chromosome underrepresentation, were observed for 1p (25%), 3p (25%), 4p
(14%), 9p (19%), 11q (28%), and 14q (31%). The presence of 3p, 11q or 14q deletions defines a genetic subset of neuroblastomas
and contributes to the further genetic characterization of stage 3 and 4 tumors without MYCN amplification (MNA) and 1p
deletion. The present study also provides additional evidence for a possible role of genes at 11q13 in neuroblastoma. In a few
cases, 1p deletion or MNA detected by FISH or Southern blotting was not found by CGH, indicating that the use of a second,
independent technique for evaluation of these genetic parameters is recommended. Genes Chromosomes Cancer 23:141–152,
1998. r 1998 Wiley-Liss, Inc.
INTRODUCTION
Neuroblastoma is the most common extracranial
solid tumor in children (Brodeur and Castleberry,
1993). The tumor cells are thought to arise from
neuroectodermal stem cells (Ross et al., 1995).
Neuroblastoma is a heterogeneous disorder both
clinically and genetically. Three subgroups can be
distinguished based on the clinical behavior and
genetic abnormalities of the tumors. A first group of
neuroblastomas with a low stage of disease, most
often occurring in children younger than one year of
age, shows a hyperdiploid or near-triploid nuclear
DNA content with no 1p deletion or MYCN amplifi-
cation (MNA). These patients have a good progno-
sis. In contrast, older children with disseminated
disease and tumors exhibiting 1p deletions and
MNA have a poor survival. These neuroblastomas
are typically diploid or near-tetraploid. A third
group with a so-called intermediate prognosis con-
sists of near-diploid tumors without MNA (Brodeur
and Castleberry, 1993).
The variety in the clinical behavior of neuroblas-
tomas and the current knowledge of genetic aberra-
tions occurring in these tumors suggest that disrup-
tion or activation of multiple genes that control cell
division, differentiation, or apoptosis of neuroblasts
is implicated in neuroblastomas. The direct role of
MYCN in the development of neuroblastoma was
recently shown by the occurrence of neuroblasto-
mas in transgenic mice overexpressing the MYCN
gene in neuroectodermal cells (Weiss et al., 1997).
Furthermore, multiple genes on 1p are thought to
be involved in the development of neuroblastoma.
A strong candidate gene for the imprinted neuroblas-
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toma suppressor locus, called p73, has been identi-
fied (Kaghad et al., 1997).
In contrast to the overwhelming data suggesting
the involvement of genes on 1p in neuroblastoma,
familial predisposition of neuroblastoma was shown
not to map to 1p36 (Maris et al., 1996) and thus
other regions must also play an important role in
neuroblastoma. A number of these chromosomal
regions have been identified by their recurrent loss
in neuroblastoma, including 3p, 4p, 11q, and 14q
(Suzuki et al., 1989, 1991; Fong et al., 1992;
Takayama et al., 1992; Srivatsan et al., 1993; Caron
et al., 1996; Hallstensson et al., 1997). An allelotype
study revealed 2q, 9p, and 18q as additional chromo-
somal regions exhibiting preferential loss in neuro-
blastomas (Takita et al., 1995). Extra copies of 17q
were observed in most of the investigated neuroblas-
toma cell lines and disseminated tumors (Caron et
al., 1994; Savelyeva et al., 1994; Van Roy et al., 1994,
1995a; Meddeb et al., 1996; Lastowska et al.,
1997c). Despite progress in the genetic dissection
of neuroblastoma, the genes that play a key role in
the development of neuroblastoma remain to be
identified and thus alternative approaches for fur-
ther genetic characterization are needed.
Comparative genomic hybridization (CGH) has
been useful in whole tumor genome screening,
allowing identification of those chromosome re-
gions that are preferentially lost, overrepresented,
or amplified (Kallioniemi et al., 1992; du Manoir et
al., 1993). We have previously shown by analyzing
genetically well-characterized neuroblastoma cell
lines that CGH can reliably detect chromosomal
imbalances, including a small interstitial deletion
approximately 10 Mb in size (Van Gele et al., 1997;
Van Roy et al., 1997). Nevertheless, due to intrinsic
limitations of CGH, it is recommended that a
second approach should always be used to detect
small 1p deletions or low-level/small amplicon
MNA.
Only five CGH studies on neuroblastoma tumors
have been reported so far (Altura et al., 1997;
Brinkschmidt et al., 1997; Lastowska et al., 1997b;
Plantaz et al., 1997; Van Gele et al., 1997), one of
which involves a small series of familial neuroblas-
tomas (Altura et al., 1997). The number of tumors
of each stage that has been analyzed so far is still
relatively small. Our aim in this study was to extend
the present series of neuroblastomas studied by
CGH and to compare our data with those published
in order to further characterize genetic subgroups,
to gain more information on imbalances that have
not been extensively studied so far, and to identify
new chromosomal regions involved in neuroblas-
toma.
MATERIALS AND METHODS
Patients
Thirty-six tumors were analyzed, including 10
tumors for which preliminary CGH data were
reported previously (cases 4, 5, 12, 14, 21, 22, 25, 26,
28, and 29) (Van Gele et al., 1997). Clinical and
genetic data are summarized in Table 1. Staging
was done according to the International Neuroblas-
toma Staging System (INSS, Brodeur and Castle-
berry, 1993). Twenty-six unselected tumor samples
from which enough tumor material was available
(cases 1–12, 14–16, 20–30) were collected from five
different Belgian pediatric oncology centers. Ten
tumors (cases 13, 17–19, 31–36) were obtained from
the Children’s Cancer Research Institute (Vienna,
Austria).
Comparative Genomic Hybridization (CGH)
Metaphase spreads were prepared from phytohe-
magglutinin-stimulated lymphocytes from healthy
individuals according to standard procedures. Each
batch of chromosome preparations was tested by
hybridization (reverse painting) with DNA from
the neuroblastoma cell line IMR32 with known
DNA gains and losses (Van Roy et al., 1997) in order
to assess the quality of the slides for CGH. Batches
with poor hybridization (e.g., strong contour stain-
ing of sister chromatids, heterogeneous or granular
staining, etc.) were discarded. Slides were stored in
plastic boxes with silica gel at -20°C before use.
Control DNA was extracted from peripheral
blood cells from a healthy male individual as
described (Sambrook et al., 1989). Primary tumor
DNA was extracted from 50 µm cryosections from
biopsy specimens stored at -80°C. Evaluation of the
tumor percentage was done on H&E-stained 5 µm
cryosections. Tumor samples containing less than
60% of tumor material were excluded from further
analysis. Labeling of DNA, in situ hybridization,
fluorescence microscopy, and digital image acquisi-
tion and processing were done according to du
Manoir et al. (1993, 1995), with minor modifications
(Van Roy et al., 1997). DAPI images of metaphases
were recorded prior to hybridization using a Leitz
DM microscope, a high-sensitivity integrated mono-
chrome CCD camera (Sony IMAC-CCD S30), and
dedicated software (ISIS, MetaSystems, Germany).
Further processing of these images for CGH analy-
sis was performed with the ISIS-CGH software
(MetaSystems, Altlussheim, Germany). For each
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case, 10 to 20 metaphase cells were analyzed. For
evaluation of CGH data, average ratio profiles with
fixed limits at 1.25 and 0.75 and standard deviation
limits (the width of the confidence interval being
three times the standard deviation), as well as
individual ratio profiles, were analyzed. A chromo-
somal region was considered to be overrepresented
(gain) or underrepresented (loss) if the average ratio
profile crossed the standard deviation limit. The
reliability of the CGH procedure and software
analysis was previously tested on well-character-
ized neuroblastoma cell lines. Particular attention
was given in that study to the accuracy for detection
of small distal 1p deletions and MYCN amplification
(Van Roy et al., 1997). As a control, normal-to-
normal hybridizations were performed.
Fluorescence In Situ Hybridization (FISH)
and Southern Blot Analysis
For cases 1–4, 7–12, 14–16, 20, 22–27, and 29,
FISH analysis for the detection of 1p deletion and
MNA was performed on tumor cell interphase
nuclei on standard unfixed touch slides or by
collagenase disaggregation of tumor tissue (1000
U/ml for 1 hr at 37°C). For the latter method, cell
clumps were removed by filtering through a 70 µm
TABLE 1. Clinical and Genetic Data of 36 Primary Neuroblastomas
Case Stagea MNAb
Chromosome 1
statusc
DNA
index
Age at
diagnosisd Deade EFSf Sg
1 1 2 2 (3/3; 5/5) 1.43 17 — — 70
2 1 2 2 (3/3) nd 10 — — 13
3 1 2 2 (3/3) 1.54 36 — — 20
4 1 2 2 (2/2) 1 12 — — 24
5 1 nd nd nd 7 — 6 61
6 1 2 nd nd 2 days — — 72
7 2 2 2 (2/2) 1 185 — — 45
8 2 2 2 (3/3) 1.28 11 — — 41
9 2 nd 2 (3/3) nd 3 — — 7
10 2 2 2 (3/3; 4/4; 5/5) nd 1 — — 80
11 4S 2 1 (2/3) 1.74 3 — — 61
12 4S 2 1 (2/3) 1.6/1.29 3 — — 42
13 4S nd 1 (3/4) 1.0/2.0 2 1.5 — —
14 3 – – (1/2) nd 20 21 19 —
15 3 2 2 (3/3) nd 36 — — 84
16 3 2 2 (3/3) 1.51 8 — — 19
17 3 1 1 (1/2) 1 25 — — 25
18 3 2 2 (2/2) nd 10 — 20 114
19 3 1 1 (2/3) 1.0/1.84 20 — — 46
20 4 2 2 (2/2) nd 101 19 — —
21 4 nd nd nd 31 2 8 64
22 4 2 2 (2/2) nd 65 — — 40
23 4 nd nd nd 32 38 14 —
24 4 2 2 (2/2) nd 47 36 24 —
25 4 1 1 (1/2) 1.13 57 25 24 —
26 4 — 1 (1/2) nd 63 3 — —
27 4 2 2 (2/2) 1.09 57 21 13 —
28 4 2 nd nd 49 20 15 —
29 4 2 2 (2/2) 1.09 41 — — 43
30 4 1 nd nd 32 24 18 —
31 4 1 1 (2/4) 2.01 18 — — 78
32 4 1 1 (3/4) 1.0/1.93 35 — — 38
33 4 2 2 (2/2) nd 32 — — 67
34 4 1 1 (1/2) 1 178 — — 25
35 4 1 1 (1/2) 1 19 — — 52
36 4 1 1 (2/3) 1.17 34 — — 42
aAccording to the International Neuroblastoma Staging System (INSS, Brodeur and Castleberry, 1993).
bMYCN amplification (1); normal (2); not done (nd).
c1p depletion (1); normal (2); not done (nd); (ratio p1–79/pUC1.77 FISH signals).
dMonths.
eMonths between first diagnosis and death of patient; still alive (2).
fEvent free survival, months between first diagnosis and relapse or tumor progression; no relapse or progression (2).
gSurvival, months between first diagnosis and present time if patient is still alive; patient is dead (2).
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nylon membrane, followed by hypotonic treatment
in 0.95% Na citrate for 20 min and subsequent
fixation in a 3:1 methanol:acetic acid solution.
Probes used for in situ hybridization were Cy3
direct-labeled pUC1.77 (1q12, D1Z1), biotinylated
p1–79 (1p36.33, D1Z2), and pNB-9 (MYCN). Probe
labeling, slide pretreatment, in situ hybridization,
and immunocytochemical detection for pNB-9 were
performed as described (Van Roy et al., 1994).
Probes pUC1.77 and p1–79 were cohybridized for
detection of distal 1p deletions and determination
of chromosome 1 copy number.
After hybridization, p1–79 was detected using
the Blast-HRP kit (NEN-117, Dupont), which
allowed a more sensitive detection than conven-
tional biotin-avidin detection and unequivocal inter-
pretation of the presence or absence of the D1Z2
sequence (Fig. 1). Slides were incubated with
streptavidin-HRP (diluted 1:500 in 0.5% Blocking
Reagent, Boehringer-Mannheim, Mannheim, Ger-
many) for 5 min in a moist chamber at room
temperature. Subsequently, slides were rinsed for
3 3 5 min with 0.1 M Tris-HCl/0.15 M NaCl/0.05%
Tween-20 and incubated with biotinyl tyramide
(diluted 1:1,000 in amplification diluent concen-
trate and H2O) for 1 min. Slides were washed with
0.1 M Tris-HCl/0.15 M NaCl/0.05% Tween-20 for
3 3 5 min. Finally, slides were incubated with
Neutralite-avidin-FITC (Eurogentec) (diluted 1:200
in 0.5% Blocking Reagent) for 5 min. Slides were
rinsed for 2 3 5 min with 0.1 M Tris-HCl/0.15 M
NaCl/0.05% Tween-20, 1 3 5 min in 1 3 PBS, and
dehydrated through an ethanol series. Slides were
embedded in Vectashield (Vector Labs, Burlin-
game, CA) containing 4,6-diamidino-2-phenylin-
dole (DAPI) for counterstaining. Streptavidin-HRP,
biotinyl tyramide, and amplification diluent concen-
trate were supplied in the Blast-HRP kit (NEN-
117, Dupont). For cases 13, 17–19, and 31–36,
FISH analysis for chromosome 1 status and MYCN
copy number was done according to Strehl and
Ambros (1993). Detection of MYCN amplification
by Southern blot analysis for cases 6, 28, and 30 was
done according to standard procedures.
Statistical Analysis
Fisher’s Exact Test was used to look for signifi-
cant differences in the frequency of a specific
chromosome abnormality between the two groups
of neuroblastoma tumors (stages 1, 2, and 4S versus
stages 3 and 4). This test was also performed in
order to investigate whether two different chromo-
somal abnormalities occur independently of each
other over all the cases. Statistical significance was
always defined as P # 0.05.
RESULTS
To evaluate the presence of genetic abnormali-
ties in neuroblastoma, we performed CGH on 36
primary neuroblastomas. Chromosomal imbalances
were found in 34/36 tumors analyzed. The results
are summarized in Figure 2. The results for tumors
with a low stage of disease (stages 1, 2, and 4S)
versus a high stage of disease (stages 3 and 4) are
represented on separate ideograms in order to
facilitate comparison. Examples of average ratio
profiles for specific chromosomes are given in
Figure 3.
A total of 237 imbalances were observed (122
partial and 115 whole chromosome abnormalities).
DNA copy number abnormalities varied from 1 to
18 per tumor. Although the average number of
chromosomal imbalances in stage 1, 2, and 4S
versus stage 3 and 4 neuroblastomas is approxi-
mately the same (7 vs. 6.3), stage 1, 2, and 4S
tumors show highly significantly (P 5 5.48 3 10-6)
more whole and less partial gains and losses com-
pared to stage 3 and 4 neuroblastomas (4.7 vs. 2.3
average whole abnormalities; 2.3 vs. 4 average
partial abnormalities). Most of the partial imbal-
ances in stage 1, 2, and 4S tumors were accounted
for by only three tumors (cases 3, 11, and 13).
Figure 1. Comparison of interphase nuclei hybridized with biotin-
labeled p1–79 (D1Z2) (white) and direct Cy3-labeled pUC1.77 (D1Z1)
(black) by use of standard immunocytochemical detection (a) versus
ultrasensitive detection with the Blast-HRP kit (b–d) (see text). a and b:
Normal diploid nuclei; c: a nucleus of a triploid neuroblastoma cell
without 1p deletion; d: a near-diploid neuroblastoma cell with 1p
deletion.
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Figure 2. Ideograms of DNA copy number changes in 36 samples of neuroblastoma tumors. Lines on the left side of the ideograms indicate
underrepresentations, lines on the right side show overrepresentations, bars on the right side represent high copy number amplification. A: 13 stage 1, 2,
and 4S neuroblastomas; B: 23 stage 3 and 4 neuroblastomas.
Whole Chromosome Gains and Losses
Of the 12 stage 1, 2, or 4S neuroblastomas with
imbalances, seven tumors (58%) showed only whole
chromosome abnormalities. The pattern of imbal-
ances is clearly nonrandom and predominantly
consists of gains of chromosomes 17 (10/13, 77%), 7
(8/13, 61%), 6 (6/13, 46%), and 18 (5/13, 38%). The
same pattern of whole chromosome gains and losses
was apparent in stage 3 and 4 neuroblastomas,
although the average number of whole chromo-
some gains or losses was significantly lower.
Partial Chromosome Gains
Partial chromosome gains were most frequently
observed for 17q (12/36, 33%). Extra 17q material
was found exclusively in stage 3 and 4 tumors
(11/23, 48%) and one stage 4S neuroblastoma. The
distal part of 17q was always implicated, with the
smallest overrepresented segment being 17q23–
qter. Taken together for all stages, overrepresenta-
tion of 17q either through 17q gain or whole
chromosome 17 gain was observed in 81% of the
tumors (29/36). We compared the results of this
study with the data reported by Plantaz et al. (1997)
on the occurrence of extra chromosome 17 or 17q
with respect to the presence or absence of 1p
deletion and/or MNA. In both studies, (1) .70% of
the neuroblastomas showed an extra chromosome
arm 17q or 17 material; (2) the majority of whole
chromosome 17 overrepresentations were found in
tumors without 1p deletion and/or MNA and was
never associated with MNA and 1p deletion; (3)
17q gain was frequently associated with 1p deletion
and MNA; and (4) MNA and 1p deletion also
occurred in stage 3 and 4 tumors without chromo-
some 17 abnormalities. A difference between the
two studies is the high frequency of extra 17q in
stage 1, 2, and 4S tumors reported by Plantaz et al.
(1997) (6/17, 35%).
Partial or complete gain of 1q was observed in
one stage 1, one stage 3, and six stage 4 tumors. The
consensus region for 1q overrepresentation was
1q31.2–32.3. Partial gains were also observed for
other chromosomal regions, including 2p (7/36,
19%, consensus region 2p23–pter) and 18q (5/36,
14%, consensus region 18q11.2–12.3).
Partial Chromosome Losses
DNA losses were most frequently observed for
1p (9/36, 25%), 3p (8/36, 22%), 11q (8/36, 22%), 14q
(6/36, 17%), and 9p (3/36, 8%). Underrepresenta-
tion of 1p involved at least 1p35–36 in all cases. For
five neuroblastoma biopsy specimens with a suffi-
cient percentage of tumor cells (cases 11, 12, 14, 26,
and 36), a normal ratio profile was observed for 1p,
although loss of 1p36.33 was revealed by FISH
analysis with probe p1–79. Karyotyping of case 14
revealed the presence of a der(1)t(1;1)(p36;q11),
which leads us to assume that, at least in this case,
the size of the lost segment was too small to be
detected by CGH.
Partial 3p underrepresentation was found in six
stage 3 and 4 and two stage 1, 2, and 4S neuroblasto-
mas (Table 2). Four tumors with partial 3p loss and
one tumor with whole chromosome 3 loss were
found in association with 11q loss (P 5 0.030).
Three of these tumors and two tumors without 11q
loss also showed 14q loss. Two tumors with 3p loss
had a 1p deletion and MNA. With one exception,
all tumors with 3p loss showed chromosome 17 or
17q overrepresentation. For all stages together, 3p
loss either through distal 3p underrepresentation or
whole chromosome loss (only 1 case) was observed
in 25% of the tumors (9 cases).
Figure 3. Examples of average ratio profiles with 99% confidence limits and fixed limits (0.75–1.25). a:
Distal 1p deletion; b: MYCN amplification at 2p23–24; c: 3p deletion; d: 11q deletion; e: high-level DNA
copy number amplification at 11q13. The strong white staining corresponds to increased fluorescence
intensity of tumor DNA detected by FITC.
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Loss of 11q was found in eight tumors (22%): one
stage 1, one stage 4S, and six stage 4 tumors.
Underrepresentations of 11q were found in associa-
tion with 1p deletion in only two tumors, one of
which was MYCN-amplified (Table 2). Four of six
14q losses were found in tumors exhibiting 11q
loss, which results in a significant positive associa-
tion (P 5 0.014). All cases with 11q loss showed 17q
overrepresentation, either through 17q gain only or
through whole chromosome 17 gain. Besides eight
partial chromosome 11 losses, two additional whole
chromosome 11 losses were observed, which brings
the total percentage of 11q underrepresentation to
28% of all cases.
Underrepresentation of a small distal segment of
chromosome 14 (14q31–qter) was found in a stage
1, 4S, and 4 tumor. Loss of larger distal 14q
segments was found in two stage 4 and one stage 4S
tumor. The occurrence of 14q loss with or without
1p loss, 3p loss, 11q loss, and MNA is also shown in
Table 2. Besides the six partial 14q losses, five
additional whole chromosome 14 losses were found
(one stage 1, three stage 3, and one stage 4 tumor).
This means that 31% of all cases had 14q losses,
either through partial or whole chromosome 14
underrepresentation.
Loss of 9p was observed in one stage 1 neuroblas-
toma and two stage 4 tumors. The two stage 4
tumors also showed 1p deletions and MNA. Be-
sides these three partial losses, four whole chromo-
some 9 underrepresentations were observed (one
stage 2, one stage 4S, and two stage 4 tumors).
Among these four cases, one stage 4 tumor was
associated with a large 1p deletion and with MNA
(case 30), and two tumors showed a 1p deletion
(case 13 and 26) without MNA.
DNA Amplification
DNA amplification for the 2p23–24 region de-
tected by CGH was found exclusively in stage 3
and 4 tumors (6/36, 17%) and correlated with the
presence of MNA as analyzed by FISH or Southern
blot analysis. In three tumors with MNA as deter-
mined by Southern blot analysis (cases 19, 30, and
36), gain of 2p was observed by CGH, but there was
no DNA amplification at 2p23–24. In two of these
three tumors, a large 1p deletion was also found.
Repeated independent experiments yielded simi-
lar results. We are currently investigating the ampli-
con size and copy number in order to explain this
discrepancy.
As reported (Van Gele et al., 1997), in one stage 4
tumor (case 26), DNA amplification at 11q13 was
observed in the absence of MNA. Southern blot
analysis using probes for the EMS1/cortactin and
cyclin D1 genes located at 11q13 showed significant
amplification of both genes (approximately 10-
fold), thus confirming the CGH observation.
TABLE 2. Presence (1) or Absence (2) of Chromosome Arm 1p, 3p, 11q, and 14q Deletions, Chromosome 17q Gain, and MYCN
Amplification in Tumors with 3p, 11q, or 14q Lossa
Case Stageb 3pc 11q2c 14q2c 1p2d MNAe 17q1f
2 1 2 1 WCL 1 WCL 2 2 1 WCG
3 1 1 1 1 2 2 1 WCG
10 2 1 2 2 2 2 1 WCG
15 3 1 2 1 WCL 2 2 1 WCG
16 3 2 2 1 WCL 2 2 1 WCG
18 3 2 2 1 WCL 2 2 2
20 4 2 1 2 2 2 1 WCG
33 4 2 1 2 2 2 1
26 4 2 1 WCL 1 WCL 1 F 2 1 WCG
21 4 1 1 1 2 2 1
27 4 1 1 1 2 2 1
22 4 1 1 2 2 2 1 WCG
25 4 1 WCL 1 2 1 1 1
30 4 1 2 1 1 1 S 1
34 4 1 2 2 1 1 2
11 4S 2 1 1 1 F 2p1 1 WCG
13 4S 2 2 1 1 2p1 1
aGray boxes are used to facilitate visual inspection of different subgroups of tumors.
bAccording to the International Neuroblastoma Staging System (Brodeur and Castleberry, 1993).
cWCL, whole chromosome loss.
dF, detected by FISH, but not by CGH.
eMYCN amplification; 2p1, partial gain for 2p, including 2p23–24; S, detected by Southern blot, but not by CGH.
fWCG, whole chromosome gain.
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Comparison of Present and Published
Neuroblastoma CGH Data
Figure 4 shows the cumulative percentage of
whole and partial imbalances for each chromosome
in the present study and in other CGH analyses
reported by Brinkschmidt et al. (1997), Lastowska
et al. (1997b), and Plantaz et al. (1997). The figure
shows that, although the overall pattern of gains
and losses is quite similar, there are a number of
differences between the individual studies, either
in the proportion of whole versus partial gains and
losses for certain chromosomes or in the frequency
of specific imbalances. The study by Plantaz et al.
(1997) showed a higher proportion of whole chromo-
some losses as compared to the other studies. In the
former study, a very high percentage of whole
chromosome 11 losses was observed, whereas in
this study a high proportion of 11q loss was de-
tected. Furthermore, in this study, chromosome 4
loss was found in only 16% of tumors, versus nearly
30% in the other studies. Imbalances for whole
chromosomes 6, 14, and X were much more fre-
quently observed by Plantaz et al. (1997) than in
the other studies. Similarly, Brinkschmidt et al.
(1997) found a higher percentage of chromosome
15 loss. Lastowska et al. (1997b) showed few
chromosome 7 gains and no chromosome 18 gains,
both of them imbalances that were observed fre-
quently in the other studies. The same authors also
more frequently detected partial chromosome 13
losses, 11q13 gain, and chromosome 12 gain.
DISCUSSION
In this study, chromosomal imbalances were
observed in 34/36 tumors, confirming the presence
of DNA gains and losses in the majority of neuro-
blastomas (Altura et al., 1997; Brinkschmidt et al.,
1997; Lastowska et al., 1997b; Plantaz et al., 1997).
Predominantly gains of whole chromosomes 17, 7,
6, and 18 (in order of frequency) and losses of whole
chromosomes 14, 9, and 4 were observed in tumors
in a low stage of disease. This pattern of whole
chromosome gains and losses correlated with a
DNA content in the triploid range for most tumors
on which this information was available. Most of
these patients were diagnosed when they were
younger than one year and are still alive, except one
patient with a stage 4S tumor bearing a 1p deletion
(case 13). A favorable outcome for hyperploid
neuroblastomas was previously demonstrated by
DNA content analysis (Look et al., 1991) and
cytogenetic investigation (Hayashi et al., 1988). A
similar pattern of whole chromosome imbalances
was observed for stage 3 and 4 tumors, but in a
significantly lower number as compared to low
stages of disease, and associated with partial gains
and losses.
In the present study, gain of chromosome 17 or
17q was found in 81% of tumors, confirming that
this is the most frequent imbalance observed by
CGH in neuroblastoma (Brinkschmidt et al., 1997;
Lastowska et al., 1997b; Plantaz et al., 1997). In
stage 1, 2, and 4S tumors, only whole chromosome
17 gains were found except for one 4S tumor,
whereas in stages 3 and 4 both chromosome 17 and
17q gain were frequently observed. Like CGH
analysis, karyotyping of near-triploid neuroblasto-
mas (Hayashi et al., 1988) revealed that additional
copies (more than three) are found most frequently
for chromosome 17. The distribution for the other
chromosomes was different, however. This discrep-
ancy could be related to the fact that the karyo-
typed tumors were identified by vanillylmandelic
acid (VMA) mass screening. CGH analysis of this
particular group of tumors should be performed in
order to validate whether differences in patterns of
whole chromosome imbalances exist in clinically
diagnosed low stage tumors versus those identified
by mass screening programs.
The occurrence of chromosome 17 abnormalities
in neuroblastomas was first described by Gilbert et
al. (1984) and confirmed by FISH and molecular
studies by Caron et al. (1994), Savelyeva et al.
(1994), Van Roy et al. (1994), Meddeb et al. (1996),
and Lastowska et al. (1997c). The present data and
those published by Plantaz et al. (1997) showed
that 83% of tumors with 17q gain also had 1p loss,
11q loss, or 1p loss and MNA. It is of interest that
the remaining 17% of tumors with 17q gain showed
only one (2 cases) or no additional partial imbal-
ances (2 cases). Of these patients, 3/4 are alive
without disease and one has died (case 28, in whom
17q gain was the only detectable abnormality). This
analysis shows that 17q gain can be found in tumors
with a favorable prognosis, without 1p loss, 11q loss,
or MNA, although a recent study by Lastowska et
al. (1997a) indicated that patients who had a tumor
with partial 17q gain had an unfavorable prognosis.
The high incidence of chromosome arm 17q gain in
all stages of neuroblastoma suggests that a dosage
effect of genes located in this region could play a
role in the development of this tumor. Possible
candidate genes on 17q include NME2 and sur-
vivine (Leone et al., 1993; Ambrosini et al., 1997).
One of the major challenges in the genetic
analysis of neuroblastoma is the identification of
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particular gains and losses in stage 3 and 4 tumors
without 1p deletion and/or MNA. In this study, loss
of 11q was found in 28% of predominantly stage 3
and 4 tumors without 1p deletion and/or MNA
(consensus region 11q22–q24). In addition, statisti-
cal analysis showed a significant positive association
between losses of 11q and 14q or 11q and 3p. This
pattern of imbalances is found in a large proportion
of stage 3 and 4 tumors without 1p and/or MNA,
thus possibly defining a distinct genetic subgroup.
Figure 4. Cumulative percentages of whole (gray) and partial (black) chromosome abnormalities versus
chromosome number: Plantaz et al. (1997) (top right); Brinkschmidt et al. (1997) (bottom right); this
study (top left); and Lastowska et al. (1997b) (bottom left).
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As was the case for 1p, the observed recurrent losses
of 3p, 11q, and 14q material suggest that tumor
suppressor genes located in these regions play a role
in neuroblastoma.
Previous CGH studies revealed loss of 11q in
17%, 10%, and 10% in the studies by Brinkschmidt
et al. (1997), Lastowska et al. (1997b), and Plantaz
et al. (1997), respectively. Loss of 11q has previ-
ously been studied in neuroblastoma by LOH
(Srivatsan et al., 1991, 1993; Fong et al., 1992). The
incidence of 11q loss as studied by LOH varied
considerably. Srivatsan et al. (1993) found 11q loss
in as many as 26% of tumors, whereas in the study
of Fong et al. (1992) only 5% of tumors showed 11q
loss (one tumor in a series of 20 informative cases).
Although the data by Srivatsan et al. (1993), Brink-
schmidt et al. (1997), and Plantaz et al. (1997)
suggest that 11q loss occurs in prognostically unfa-
vorable tumors, we found $ 3-year survival of more
than 60% of patients with 11q deletion.
Involvement of 3p deletions is a relatively new
finding in neuroblastoma. Using LOH analysis,
Hallstensson et al. (1997) found 3p deletions in 9 of
58 low-stage neuroblastomas and in 8 of 43 addi-
tional tumors of varying stages. In their CGH
studies, Brinkschmidt et al. (1997) and Plantaz et al.
(1997) could only detect one tumor each with 3p
loss, whereas Altura et al. (1997) found 3p deletions
in three of six tumors in patients with familial
neuroblastoma and Lastowska et al. (1997b) found
four cases (20%) of 3p loss. In the present study, we
identified 8/36 (22%) tumors of both high and low
stage of disease with 3p deletion. Underrepresenta-
tion of the entire chromosome 14 or the distal part
of arm 14q was found in 31% of stage 1, 2, and 4S
tumors and 30% of stage 3 and 4 tumors. Previous
LOH studies revealed a similar incidence of chro-
mosome 14 deletions in advanced stages, predomi-
nantly without 1p deletion or MNA (Suzuki et al.,
1989, 1991; Fong et al., 1992).
By using reverse painting and CGH, we have
previously shown that regions other than 2p24 can
be amplified in neuroblastoma. This was shown to
be the case for regions 12q13–15 (implicating the
SAS and MDM2 oncogenes) and 12q24 in cell line
NGP and regions 2p23 and 2p13 in IMR32 (Van
Roy et al., 1995b, 1997). Other CGH studies have
also identified new regions of amplification in
neuroblastoma, including 3q24–26, 4q33–35, and
6p11–12 (Brinkschmidt et al., 1997; Plantaz et al.,
1997).
In one particular tumor included in this study, we
previously reported for the first time in neuroblas-
toma the presence of DNA amplification of the
11q13 region. Southern blot analysis using probes
for the EMS1/cortactin and cyclin D1 genes located at
11q13 showed significant amplification for both
genes (approximately 10-fold), thus confirming the
CGH observation (Van Gele et al., 1997). In the
present study, gain of 11q13 was observed in three
additional tumors. A similar observation was previ-
ously made by Lastowska et al. (1997b) in six
tumors. Amplification of the EMS1/cortactin, cyclin
D1, HST1/FGF4, and INT2/FGF3 genes located at
11q13 has been reported frequently (13–30% of the
cases) in carcinomas of the breast, head and neck,
bladder, and lung (Schuuring et al., 1995), but,
interestingly, only low-copy DNA amplification
(,10 copies) has been observed in these tumors.
Therefore, a modest increase in the copy number of
genes located at 11q13 may play a role in the
biology and clinical behavior of subsets of neuroblas-
tomas. We are currently investigating the incidence
of low-level DNA amplification of 11q13 genes in
more detail by using more sensitive methods for
detection.
DNA amplification for the 2p23–24 region harbor-
ing the MYCN gene was observed in 6/36 (17%)
tumors. All tumors typically displayed large 1p
deletions with breakpoints ranging from 1p12 to
1p32. In three tumors, with MNA demonstrated by
Southern blot analysis, gain of 2p (always including
the MYCN region) was demonstrated by CGH,
instead of DNA amplification. Thus, as for detec-
tion of 1p deletions, a second independent method
in addition to CGH should be used for detection of
MNA.
Survival of patients in this study of MYCN-
amplified tumors is remarkably high and may
reflect the use of improved treatment protocols. A
similar observation was made by Lastowska et al.
(1997a), who found no significant difference in
survival between patients with MYCN-amplified vs.
MYCN-nonamplified tumors.
In this study, DNA loss of the chromosome 1
short arm was seen in 25% of tumors, and always in
association with MNA, except in one tumor. In five
tumors with normal 1p ratio profiles, 1p deletions
were detected by FISH. In one case, a patient who
died 21 months after diagnosis, karyotypic analysis
revealed an unbalanced translocation, der(1)t(1;
1)(p36;q21). CGH analysis revealed the expected
1q gain in addition to gains for chromosomes 12, 17,
and 19, but no 1p loss. In view of the distal
localization of the 1p breakpoint, it is possible that
the segment lost upon translocation was too small to
be detected by CGH. This case illustrates that
small distal 1p deletions can be missed by CGH
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and thus a second independent technique, like
FISH or LOH analysis, should be performed. In
this study, we employed a recently developed
method for ultrasensitive FISH by using peroxidase-
mediated deposition of biotin tyramides for the
detection of 1p deletions in interphase nuclei.
Instead of clusters of small, distinct spots, the
signals for the 1p36 DNA probe for locus D1Z2
appear as large, strong hybridization spots, which
greatly facilitated the scoring of interphase nuclei.
Comparison of the present with previously pub-
lished CGH data on neuroblastoma reveals a similar
overall pattern of gains and losses. At the same
time, differences are found in either the frequency
of certain chromosome imbalances or the propor-
tion of whole and partial imbalances for a specific
chromosome. A number of explanations can ac-
count for this observation. The high frequency of
whole chromosome abnormalities in the study by
Plantaz et al. (1997), where 59% of the tumors were
stage 1, 2, or 4S, compared to 36–40% in the other
studies, can be explained by the higher relative
number of tumors in a low stage of disease. The
relatively small sampling size and the genetic
heterogeneity of neuroblastoma tumors can also
account for some discrepancies. Finally, subtle
differences in the CGH procedure and the interpre-
tation of gain and loss may explain some of the
observed discrepancies.
In conclusion, the present study provides further
support for the heterogeneity of neuroblastoma. In
tumors in a low stage of disease, whole chromosome
imbalances predominate, whereas partial gains and
losses are more frequent in stage 3 and 4 tumors.
The high incidence of chromosome 17 overrepresen-
tation in both high- and low-stage neuroblastomas
is now firmly established. Tumors with 11q and/or
14q and/or 3p loss may identify a genetic subgroup
of neuroblastomas that contributes to a further
genetic characterization of stage 3 and 4 tumors
without MNA or 1p deletion. This study adds
11q13 to the list of regions that may be amplified in
neuroblastoma. Although the results of the CGH
studies on neuroblastomas performed so far are
generally comparable, our data also reveal a number
of discrepancies. The study of additional tumors
with well-documented molecular and clinical data
will be necessary for further characterization of
discrete subgroups of neuroblastoma such as those
carrying 3p, 11q, or 14q deletions.
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Multicentre Analysis of Patterns of DNA Gains and Losses in 204
Neuroblastoma Tumors: How Many Genetic Subgroups Are There?
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Procedure. Analysis of comparative geno-
mic hybridization (CGH) data of 120 tumors
from four different studies, and data of 84 pre-
viously unpublished tumors, allowed delinea-
tion of at least six different genetic subsets of
neuroblastomas. Results and Conclusions. A
small number of tumors show no detectable im-
balances. A second group of tumors presents
with gains and losses of whole chromosomes
and is found predominantly in prognostically
favorable stage 1 and 2 tumors. The remaining
groups are characterized by the presence of
partial chromosome imbalances, and are found
mostly in stage 3, 4, and 4S tumors. The third
group shows 17q gain without 11q loss, 1p
loss, or MYCN amplification (MNA). The fourth
group has 1p deletion or MNA, and finally, a
fifth group shows 11q loss without 1p deletion
or MNA, and is found mainly in stage 4 tumors.
The latter group is significantly associated with
losses of 3p, 4p, and 14q. Med. Pediatr. Oncol.
36: 5–10, 2001. © 2001 Wiley-Liss, Inc.
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INTRODUCTION
The genetic study of neuroblastoma was initiated in
the early seventies. Cytogenetic data were mainly ob-
tained for a subset of tumors which typically presented
with MYCN-amplification (MNA) and/or 1p-deletions
[1]. Analysis of tumor DNA ploidy identified tumors
with a near triploid DNA content, predominantly in
young children (age <1 year) with lower stages of dis-
ease and good prognosis [2]. In contrast, near diploid
or near tetraploid DNA was found most often in stage
3 and 4 tumors. Molecular studies defined the critical
regions on the short arm of chromosome 1, which are
lost in subsets of neuroblastomas [3,4]. In addition to
1p36, other genomic regions were shown to be involved
in neuroblastoma. Recurrent losses were observed for
3p, 4p, 9p, 11q, and 14q [5–12], as well as frequent gain
of chromosome 17 or the chromosome 17q arm [13–20].
A drawback of many molecular and molecular cyto-
genetic studies is that they do not provide a complete
overview of all genomic imbalances occurring in tu-
mors. CGH can circumvent this problem. It allows the
detection of DNA gains and losses for the entire tumor
genome within one experiment, and thus provides in-
formation of all, albeit large (>10 Mb), genomic im-
balances, which are present in each investigated tumor
[21]. This technique has been successfully applied
for genome-wide screening of neuroblastomas by se-
veral investigators [22–28]. The aim of these studies
was:
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1. To identify previously unrecognised gains, losses,
or amplifications, and thus new regions which could har-
bour genes implicated in neuroblastoma.
2. To look for associations between frequently occur-
ring imbalances, and thus identify new genetic sub-
groups.
3. To study the response to therapy and survival for
these subgroups.
As it was not possible to evaluate genomic imbalances
for individual tumors for all published CGH data, we
decided to collect all data on these 120 tumors and re-
evaluate them in one single study. Moreover, data from
84 unpublished cases are included in this study. This
multicentre study thus yielded an unprecedented over-
view of the pattern of genomic imbalances occurring in
36 stage 1, 30 stage 2, 31 stage 3, 68 stage 4, and 39 stage
4S tumors.
MATERIALS AND METHODS
Patients
In total, 204 different tumors were studied by five
different centres (Department of Medical Genetics and
Paediatric Oncology, Ghent University Hospital, Bel-
gium, 36 cases; Department of Paediatrics, University
Hospital Centre of Grenoble, France, 82 cases; Gerhard-
Domagk-Institute of Pathology, University of Mu¨nster
and Department of Paediatrics, University of Marburg,
Germany, 51 cases; Department of Human Genetics,
University of Newcastle upon Tyne, UK, 22 cases; Wes-
sex Regional Genetics Laboratory, Salisbury District
Hospital, UK, 13 cases). Detailed survival data have been
published or will be published elsewhere.
CGH
CGH was performed according to du Manoir et al.
[29], or Kallioniemi et al. [30]. For digital image analy-
sis, different image acquisition equipment and software
programs were used [23,24,27,28]. For data analysis,
DNA copy number changes for individual cases were
represented on separate ideogram charts.
RESULTS
Chromosomal imbalances were observed in most tu-
mors (92%). Figure1 shows the cumulative percentages
of whole and partial imbalances for each chromosome for
the 204 analysed tumors. Detailed data on the gains and
losses observed for each individual tumor and survival
data can be found at http://allserv.rug.ac.be/neubla/
cgh.htm.
Whole Chromosome Gains and Losses
Most tumors with lower stages of disease showed ex-
clusively whole chromosome gains and losses. Pooling
of all data from 51 tumors with only numerical imbal-
ances revealed a nonrandom pattern of gains for chro-
mosomes 1, 2, 6, 7, 8, 12, 13, 17, 18, and 22, and losses
for chromosomes 3, 4, 9, 11, 14, and X (Fig. 2). This
pattern was observed in the majority of all stage 1 and 2
tumors (50 and 60%, respectively), in a small portion of
stage 3 and 4S tumors (16 and 15%, respectively), and in
a few cases of stage 4 tumors (6%) (Fig. 3). This char-
Fig. 1. Cumulative percent of
whole (gray) and partial (black)
chromosome imbalances detected
by CGH in 204 neuroblastomas
(bars above horizontal axis indicate
gains, bars below indicate losses).
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acteristic pattern of whole chromosome imbalances was
typically observed in infants (61% # 1 year of age at
diagnosis), with high survival rates (only 3 of 51 patients
died). Seventy percent of these tumors for which infor-
mation on DNA index was available showed a DNA
content in the near triploid range. The highest incidence
of whole chromosomal imbalance taken together for all
stages was observed for chromosome 17 gain (89/204,
44%; Fig.1).
Partial Chromosomal Imbalances
Partial chromosome gains were most frequently ob-
served for 17q (80/204, 39%). Gain of 17q either through
over-representation of a complete chromosome 17 or
(partial) gain of the long arm only, thus occured in 83%
of all examined tumors. Seventeen-q gain was exclu-
sively found in tumors with 1p loss and/or MNA or 11q
loss in stage 2 (P 4 2.10−6) and 3 (P 4 2.10−7) and was
significantly associated with 1p loss and/or MNA or 11q
loss in stage 4 (P 4 0.01). The majority of stage 3
tumors with partial chromosomal imbalance showed
MNA, and most often but not exclusively 1p-deletion
and 17q over-representation. The same pattern emerged
in stage 2 tumors but in a much smaller proportion. Most
stage 4 tumors showed 17q over-representation in com-
bination with 1p-deletion, 1p-deletion and MNA, 11q-
deletion with or without 3p- and/or 14q-deletion, or with-
out any of these aforementioned additional changes.
Survival analysis for patients with or without 17q gain is
described in an accompanying paper (Bown et al., this
issue).
Although indicative from data of some individual
studies, pooling of all data clearly defines a subset of
tumors with 11q-deletion (Fig. 3). Loss of 11q was found
in a few cases of stage 1(2 of 36), 2 (2 of 30), 3 (3of 31),
and 4S (3 of 39) tumors and in 19 out of 68 stage 4
tumors. These 11q losses typically occurred in stage 4
tumors without 1p deletion or MNA. Within this sub-
group of tumors (15 cases), losses of 3p, 4p, 14q, and 9p
were frequently observed (53%, 27%, 27%, and 13%,
respectively).
Loss of 1p was observed in 59 tumors (29%). No 1p
loss was found in stage 1 tumors. Only three cases were
observed in stage 2 tumors, two of which had MNA.
Seventy-three percent of tumors with 1p loss also
showed MNA.
Other regions for which loss was observed included
3p, 4p, 9p, and 14q. Losses of 3p, 4p, and 14q showed a
highly significant association with 11q loss (P 4 1.10−6,
P 4 0.016, and P 4 4.10−4, respectively). Loss of 3p (18
cases, 9%) was found in all stages, but most frequently in
stage 4 tumors with 11q loss (see above). Loss of 4p was
observed in eight tumors (four of which were stage 4
tumors with 11q loss). Loss of 9p material was observed
in 12 cases (6%), three of which were stage 1 tumors
with otherwise good prognostic features.
Partial loss for chromosome arm 14q was found in
10% of tumors (20 cases), mainly stage 4 and 4S. Partial
14q loss was found in only 1 out of 25 stage 4 tumors
with 1p deletion and MNA and in 4 out of 15 (27%) stage
4 tumors with 11q loss without 1p deletion or MNA.
MNA was observed in 49 tumors (24%). Additionally,
the five different CGH studies identified seven new re-
gions of amplification: 2p23, 3q24-26, 4q33-35, 6p11-
12, 10p13, 10q25, and 11q13. For each of these chromo-
somal regions, high level DNA amplification was
observed only once, indicating that amplifications of
these sites in neuroblastoma are rare events. One excep-
tion may be the 11q13 region, for which over-
representation (but not amplification) was observed in 11
additional cases. In the tumor with 11q13 amplification,
copy number increase of CCND1 and EMS1 was con-
firmed by Southern blot analysis.
DISCUSSION
As cytogenetic analysis is often unsuccessful in the
analysis of neuroblastoma, CGH is a valuable alternative
for genome-wide screening of whole or partial chromo-
somal gains and losses and gene amplification. Recently,
several investigators have successfully applied CGH to
the genetic study of neuroblastoma [22–27]. In Vande-
sompele et al. [28], the authors compared the published
data with their own series of analysed tumors. The major
Fig. 2. Characteristic pattern of whole chromosome gains (bars to
the right, in percentage) and losses (bars to the left) in 51 neuroblas-
tomas with only numerical imbalances (chromosomes that show ab-
normalities in less than 20% in this subgroup are not included).
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findings in all individual studies were concordant, but
from this analysis it was apparent that, although signifi-
cant numbers of tumors were studied, the total number of
tumors of clinical and genetic subgroups was relatively
small in the individual studies. Moreover, simultaneous
occurrence of particular imbalances in individual tumors
could not be analysed from published data in all cases.
For this reason, we decided to collect and re-evaluate all
individual tumor CGH data. In addition, a significant
number of previously unpublished data was included in
this analysis. Many of the previously observed charac-
teristic CGH findings from individual studies were con-
firmed and strengthened by pooling of all data. This in-
cludes the typical pattern of gains for chromosomes 1, 2,
6, 7, 8, 12, 13, 17, 18, and 22, and losses for chromo-
somes 3, 4, 9, 11, 14, and X. These tumors are typically
triploid and occur in children with favorable prognosis
and age less than one year. Particular patterns of whole
chromosome gains and losses have also been observed in
other pediatric tumors with good prognosis, including
acute lymphoblastic leukemia [31]. The biological sig-
nificance of these numerical chromosome changes is un-
known, and it is puzzling that most of the chromosomes
that are underrepresented in low stage tumors also show
partial losses in high stage tumors. Similarly, gain of
chromosome 17 and extra 17q are the most frequently
observed chromosomal imbalances in low and high stage
tumors, respectively.
The frequent finding of chromosome 17q gain in neu-
roblastoma is an interesting observation that is receiving
increasing attention. In early cytogenetic studies prefer-
ential involvement of 17q was noted [13], but these ini-
tial findings were not further explored until the introduc-
tion of FISH analysis [14–16]. Using this approach, it
became clear that unbalanced translocations result in ex-
tra 17q copies and loss of chromosomal material in the
partner chromosome. The observation that chromosomes
1 and 11 were frequently implicated as partner chromo-
somes with resulting 1p and 11q loss led to the sugges-
tion that these translocations could act as a mechanism
which lead to simultaneous loss of tumor suppressor
genes on 1p and 11q and extra copies of genes on 17q,
controlling growth, differentiation, or apoptosis [16,20].
An accompanying paper shows that 17q gain is a pow-
erful prognostic predictor of adverse outcome (Bown et
al., this issue). Whether genes on 17q, and in particular
an imbalance of 17p versus 17q genes, is responsible for
a more aggressive tumor phenotype, or whether 17q is an
innocent bystander in association with known or possibly
prognostically unfavorable genetic parameters such as
MNA and 1p and 11q deletion, remains to be determined.
The present analysis of a large set of tumors showed
that 11q loss defines a distinct genetic subgroup of stage
4 tumors. Eleven-q loss was found in almost half of stage
4 tumors without 1p deletion and/or MNA. A high pro-
portion of 3p, 4p, and 14q losses was observed within
this newly defined genetic subgroup, and furthermore
17q gain was consistently present. Literature on inci-
dences of 11q loss in neuroblastoma is scarce and con-
flicting. Srivatsan et al. [8], Takita et al. [10], and Takeda
et al. [32] found 11q loss in 26%, 24%, and 19% of
analysed tumors, respectively, whereas Fong et al. [6]
reported 11q loss in only 5% of tumors (one tumor in a
series of 20 informative cases). Recently, a LOH study
Fig. 3. Normalised distribution (in percent) of clinical stages for each genetic subgroup of neuroblastoma as defined by CGH. 1: No detectable
abnormalities; 2: Only numerical imbalances; 3: 1p loss and/or MNA; 4: 11q loss (no 1p loss or MNA); 5: 17q gain (no 1p loss or MNA or
11q loss); 6: Others (mainly tumors with numerical imbalances and few structural changes).
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with 11q markers on a series of 267 neuroblastomas was
conducted by Maris et al. (this issue). These authors
found 11q loss in 43% of tumors, a frequency that is
much higher than that observed by CGH. If we assume
that their tumors could also represent near-triploid tu-
mors with whole chromosome 11 loss (61 cases), partial
11q-loss occurred in only 20% of tumors, a figure that is
in keeping with our findings. Inclusion of near-triploid
tumors in the series of Maris et al. may also explain why
no correlation with clinical stage was found.
The present study and previous 11q LOH studies
strongly suggest that one or more tumor suppressor genes
on 11q play an important role in the development of this
subgroup of neuroblastomas. An essential first step to-
wards the identification of this gene is the delineation of
a shortest region of overlap for 11q deletions. Based
upon the ratio-profiles of cases with partial 11q loss, an
SRO was assigned to 11q21 fi q22. Caution is needed,
however, in the positioning of breakpoints based upon
CGH profiles, and further molecular analysis of the cases
with small 11q deletions is warranted to verify the exact
chromosomal localization of these deletions. Interphase
FISH-, CGH- and LOH-analyses on larger series of stage
4 tumors without 1p-deletion and/or MNA could allow
further refinement of this SRO, which should facilitate
the selection of positional and functional candidate tumor
suppressor genes within this region for further analysis.
Eight out of the 15 patients with tumors with 11q dele-
tions described in this study died and one patient re-
lapsed, thus indicating a poor survival for patients with
tumors belonging to this genetic subgroup. Additional
patients need to be studied in order to obtain more reli-
able survival estimate figures.
CGH is a technique that is particularly suited for iden-
tification of new amplicons in tumors. The CGH studies
that have been performed so far on neuroblastoma show
that amplification of chromosomal regions other than
2p23-24 is a rare event. Several additional regions for
which high level DNA amplification was noted were
identified by CGH. One region, 11q13 is particularly
interesting, as it is known to be implicated in many other
malignancies, including carcinoma of the breast, head,
neck, bladder, lung [33]. The observation of 11q13 gain
(not amplification) in additional neuroblastomas, and the
fact that low-copy 11q13 DNA amplification (<10 cop-
ies) occurs in other tumors opens the possibility that
11q13 gain or amplification plays a role in a subset of
neuroblastomas.
In conclusion, this study further illustrates the signifi-
cance of CGH in the characterization of genetics sub-
groups in neuroblastoma. We were able to define the
pattern of whole chromosome gains and losses in the
genetic subgroup of tumors with whole chromosome im-
balances only. Furthermore, we defined a new genetic
subgroup of tumors with 11q loss within the subset of
stage 4 tumors without 1p deletion or MNA. As this
group represents almost one-third of all stage 4 tumors, a
search for a tumor suppressor gene on 11q is warranted,
as the identification of this gene may improve our un-
derstanding of the behavior of this subgroup of tumors,
and may ultimately lead to new therapeutic approaches
and increased survival for these patients.
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NEUROBLASTOMA REVEALS HIGH FREQUENCY OF 11Q DELETION IN
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We have studied the occurrence and association of 11q
deletions with other chromosomal imbalances in Stage 4
neuroblastomas. To this purpose we have performed com-
parative genomic hybridization (CGH) analysis on 50 Stage 4
neuroblastomas and these data were analyzed together with
those from 33 previously published cases. We observed a
high incidence of 11q deletion in Stage 4 neuroblastoma
without MYCN amplification (59%) whereas 11q loss was only
observed in 15% of neuroblastomas with MYCN-amplification
(p 5 0.0002) or 11% of cases with 1p deletion detected by
CGH (p 5 0.0001). In addition, 11q loss showed significant
positive correlation with 3p loss (p 5 0.0002). Event-free
survival was poor and not significantly different for patients
with or without 11q deletion. Our study provides further
evidence that Stage 4 neuroblastomas with 11q deletions
represent a distinct genetic subgroup that typically shows no
MYCN-amplification nor 1p deletion. Moreover, it shows that
neuroblastomas with 11q deletion also often present 3p de-
letion. This genetic subgroup shows a similar poor prognosis
as MYCN amplified 4 neuroblastomas.
© 2001 Wiley-Liss, Inc.
Key words: Stage 4 neuroblastoma; comparative genomic hybrid-
ization; 11q deletion; MYCN; 1p deletion; genetic subgroup
Neuroblastoma (NB) is an embryonal solid tumour of childhood
believed to originate from immature neural crest cells.1 The dis-
ease has a variable clinical course, ranging from spontaneous
regression to malignant progression with complete resistance to
therapy. Genetic investigations further supported the heteroge-
neous nature of this tumour. Based upon these clinical and genetic
findings, three prognostically distinct groups were recognized.2
One group includes hyperdiploid tumors that lack 1p deletion and
MYCN-amplification (MNA). These patients are often infants with
less advanced disease, and prognosis is usually excellent. A second
group includes near-diploid or near-tetraploid tumors that lack
MNA. These patients are usually over 1 year of age and present
with advanced stage disease. Although their overall outcome is
poor, these patients tend initially to respond to treatment. The third
group is also near-diploid or near-tetraploid, but with both MNA
and 1p deletion. These patients tend to respond poorly to therapy,
and die within months.
Recent studies have illustrated the power of CGH in whole
genome screening for partial and whole chromosome imbalances
in NB, in particular for the analysis of low stage NB for which
little genetic information was available apart from ploidy, 1p and
MYCN status. One of the striking findings of CGH analyses was
the occurrence of whole chromosome 17 or 17q gain as the most
frequent chromosome abnormality in low and high stage NB,
respectively.3–6 Gain of 17q was subsequently shown to be a
strong indicator for unfavorable prognosis.7
Genetically, the subgroup of Stage 4 NB lacking MYCN ampli-
fication has remained poorly defined. CGH studies revealed 11q
loss in these tumors, but the number of cases in the individual
studies was too small to draw significant conclusions.5,6 In a larger
multicenter study on 204 NB, preferential occurrence of 11q
deletion in Stage 4 NB without MNA was observed, but the latter
group of tumors was still relatively small (33 Stage 4 tumors). In
a recent loss of heterozygosity (LOH) study, Guo et al.8 found a
high incidence of 11q loss in all NB stages. To further evaluate the
occurrence of 11q deletions in MYCN non-amplified Stage 4
neuroblastomas and its correlation with other chromosomal imbal-
ances in MYCN amplified or non-amplified Stage 4 neuroblasto-
mas, we performed CGH analysis on 50 additional Stage 4 tumors.
These data were compiled with data from 33 previously published
unselected Stage 4 NB (for details see Material and Methods). A
second objective was to assess the prognostic value of 11q deletion
in metastatic neuroblastomas.
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MATERIAL AND METHODS
Data from 50 unpublished Stage 4 neuroblastomas (23 un-
selected, 27 selected for absence of MYCN-amplification) were
included in our study as well as data on 33 unselected Stage 4 NB
from previously published CGH studies.3–6 Indeed, as genetic
imbalances are now well known in tumors with MNA, we ex-
tended the series of Stage 4 tumors with a selection of 27 non-
amplified Stage 4 tumors, to better define genetic abnormalities in
this putative subgroup; Table I gives an overview of clinical,
genetic and CGH data on all cases. In total 83 Stage 4 tumors were
studied by 6 different research laboratories from the following
institutions: University of Grenoble, France (27 cases); University
of California San Francisco, USA (20 cases); University of Ghent,
Belgium (16 cases); University of Newcastle upon Tyne, UK (8
cases); Salisbury District Hospital, UK (7 cases); University of
Munster, Germany (5 cases).
The median age of the 83 patients was 39 months (range 1–216).
Clinical follow-up data were available from 77 patients. Forty-
seven of them relapsed and 43 died with a median follow-up of 20
months (range 3–80).
Genetic data including at least the MYCN status were available
for 80 patients. Twenty-six of these 80 tumors (33%) showed
MNA as determined by FISH, Southern blot or PCR analysis.
CGH was performed according to Kallioniemi et al.9 or du
Manoir et al.10 techniques with minor modifications. For digital
image analysis, each group used particular image acquisition
equipment and software programs, that have been individually
validated.3–6 For data analysis, DNA copy number changes for all
individual cases were represented on ideogram charts. We chose
upper (indicating gains) and lower (indicating loss) fluorescence
ratio thresholds of 1.2 and 0.8 respectively. Amplifications were
defined by a ratio .1.5 in a subchromosomal region.
RESULTS
Seventy-eight (94%) cases had partial chromosome gains or
losses. Forty-seven of these 78 (60%) cases with partial imbal-
ances also had whole chromosome gains or losses. Five out of 83
cases (6%) solely exhibited whole chromosome abnormalities. The
modal number of partial imbalances was 4 per tumour (range
0–11).
Partial chromosomal gains were most often detected for chro-
mosomes 17q (65/83) (78%), 2p (34/83) (41%) (24 cases of
2p23–25 amplification and 10 cases of 2p16–25 simple gain) and
1q (23/83) (28%). Partial chromosomal losses were observed for
chromosomes 11q (36/83) (43%), 1p (32/83) (39%), 3p (18/83)
(22%), 4p (13/83) (16%), 9p (8/83) (10%), and 14q (9/83) (11%).
Figure 1 shows the relative percentage of partial gains of chromo-
some 1q, 2p and 17q and partial losses of chromosome 1p, 3p and
11q, with the distinction according to the MYCN status of the
tumour. The interrelationship between MNA and deletion of 1p
and 11q is illustrated in Figure 2. The majority of the 65 tumors
with 17q gain (54/65, 83%) had either 1p deletion or 11q deletion.
DNA losses
CGH identified 36 tumors with 11q deletion. These deletions
were found in 32 of 54 (59%) tumors without MNA and only in 4
of 26 (15%) tumors with MNA determined by Southern blot
analysis(p 5 0.0002). Thirty-one (86%) of these 36 tumors also
had a 17q gain. Only 4 of these 36 tumors (11%) presented with a
1p deletion by CGH. In 9 of these 36 (25%) tumors 1q gain was
noted. Within this subgroup defined by 11q deletion, losses of 3p,
4p, 9p, or 14q were frequently observed [14/36 (39%), 7/36 (19%),
4/36 (11%) and 6/36 (17%) respectively]. Fisher’s exact test re-
vealed a significant positive correlation between deletion of 11q
and 3p (p 5 0.0002). A significant inverse correlation was found
between 11q deletion and MNA (p 5 0.0002) and between dele-
tions of 1p and 11q (p 5 0.0001). Figure 3 gives an overview of
all CGH results for chromosome arms 3p and 11q. The 11q
deletions were generally large with breakpoints being most fre-
quently located at chromosome bands 11q14 to 11q22, except for
a single case that showed an interstitial deletion 11q14–q21.
CGH identified 32 tumors deleted at 1p with breakpoints in the
1p12–p36 region. Twenty-seven of these 32 (83%) tumors with 1p
deletion had a 17q gain. Twenty-two of these 32 (69%) had
evidence for MNA. Nineteen of these 32 (59%) tumors with 1p
deletion had both 17q gain and MNA. CGH detected a gain
involving chromosome 1q in 23 cases. These 1q gains were asso-
ciated with a 1p deletion in 13 cases (56%) and with an 11q
deletion in 8 different cases (35%). The 1q gains usually involved
the whole q arm.
The third most frequent deletion found was a 3p deletion,
occurring in 18 cases. Fifteen of these 18 cases (83%) also had an
11q deletion, whereas only 4 of these 18 cases (22%) presented
with a 1p deletion (p 5 0.04).
Nine tumors had a 14q deletion; 6 of them also had an 11q
deletion. Only 1 of the 9 tumors with 14q deletion had MNA (not
statistically different).
Gene amplification and gains
High level amplifications at 2p23–25, corresponding to MNA
were found in 24 cases (29%); 22 of these 24 (92%) tumors had a
1p loss and 20/24 (83%) a 17q gain. Nineteen of the 24 (79%)
tumors with MNA had both 1p deletion and 17q gain. In 10 other
cases (12%), CGH detected an apparently simple gain (duplica-
tion) of the 2p distal region (2p16–25) clearly distinct from the
typical pattern that emerges in MNA tumors. Eight of these 10
tumors with a simple 2p gain had a 17q gain, 3/10 had a 1p
deletion and 6/10 had an 11q deletion.
Among the 83 cases, 5 regions of high level amplification at
another locus than 2p23–25 were identified by CGH: 4q33–35 (2
cases), 10p13 (1 case), 10q25 (1 case), 11q13 (1 case) and
14q12–13 (1 case). Except for the 10p13 and 10q25 amplification,
these tumors showed no MNA. It is interesting to note that besides
11q13 amplification found in 1 case, 6 tumors show local gain at
11q13 and 2 tumors have 11q gain encompassing the 11q13 locus
(see also Fig. 3).
Other chromosomal imbalances
Twenty tumors among the 83 (24%) cases with chromosomal
imbalances at one or more loci had neither 1p nor 11q deletion.
Five of these 20 had only whole chromosome copy number
changes and triploid DNA content. Fourteen of the 15 remaining
tumors had a 17q gain. Three of these 15 had MNA. MNA was the
sole imbalance detected by CGH in only 1 case.
Survival
The 3-year event-free survival (EFS) (Kaplan–Meier) for the 77
patients with a known follow-up was 31% (67%). EFS was not
significantly different between patients whose tumour had an 11q
deletion (36%) (66%) and patients whose tumour showed no 11q
deletion (29%, 67%) (p 5 0.9). Among 54 patients with a known
follow-up and whose tumour was not amplified for MYCN, EFS
was 37% (66%) for patients whose tumour showed an 11q dele-
tion and 33% (67%) (p 5 0.9) for patients whose tumour had no
11q deletion.
DISCUSSION
Our study presents the largest genome wide screening of gains
and losses by comparative genomic hybridization in Stage 4 neu-
roblastomas. CGH is now well recognized as a valuable and
powerful method for genetic analysis of this tumour. Thus far,
however, each individual published CGH study of NB included
only a limited number of Stage 4 cases (6 to 17 cases per study)3–6,11
and thus particular genetic subgroups may have remained unno-
ticed or poorly defined.
In the present study, we compared the pattern of chromosomal
imbalances between Stage 4 NB with MNA and those without this
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TABLE I – CLINICAL DATA AND OVERVIEW OF CGH ABNORMALITIES ON 83 STAGE 4 NEUROBLASTOMA TUMOURS
No. Age1 MNA2 Event3 Fol-up
event1 Death
4 Fol-up
death4 Overview CGH abnormalities
5
1 61 0 1 5 1 10 211q21-25, 117q21-25
2 34 0 1 3 1 5 21p11-36, 11q11-44, 24p11-16//17, 113, 23, 28, 29, 210, 211,
216
3 36 1 6 1 7 21p34-36, 24p15-16
4 54 0 1 7 1 20 12p14-25, 29p12-24, 211q14-25, 117q11-25//113
5 29 0 1 14 1 16 211q14-25, 117q22-25
6 12 0 1 8 1 8 211q14-25, 117q11-25
7 88 0 1 2 1 4 23p11-26, 211q21-25, 217p11-13
8 27 0 1 10 1 10 117q11-25//12, 17, 28, 29, 211
9 38 0 1 11 1 11 23p11-26, 24p14-16, 16q23-37, 28p11-23, 111p11-15, 211q14-25,
117q11-25
10 64 0 0 6 0 6 12p22-25, 23p21-26, 24p15-16, 211q14-25, 113q21-34, 117q22-25
11 57 0 0 8 0 8 17q21-36, 211q14-25, 117q21-25//118
12 41 0 1 19 1 20 23p11-26, 211q14-25, 214q24-32, 217p11-13, 117q11-25//113,
118, 210
13 38 0 0 9 0 9 24q31-35, 16p22-25, 17p11-14, 17q11-36, 117q11-25//113
14 9 0 0 51 0 51 211q14-25
15 2 0 ND ND ND ND 16, 17, 113, 117, 23, 24, 25, 29, 211, 214, 215
16 6 0 ND ND ND ND 17, 117, 23, 24, 29, 211, 216, 2X
17 29 0 1 12 1 12 21p35-36, 11q11-44, 16p11-25, 26q11-27, 117q22-25//17, 118,
122, 2X
18 61 1 0 26 0 26 21p35-36, 11q11-44, 112p24-25, 117q21-25//17, 1X, 23, 25,
210, 215
19 20 0 1 10 1 15 21p11-36, 11q11-44, 114q34-35, 18q22-24, 28q24, 29p21-24
20 45 1 1 14 1 19 21p35-36, 112p24-25, 16p11-25, 26q21-27, 111q21-25, 117q23-
25
21 31 ND 1 8 0 64 11p35-36, 11q11-44, 23p22-26, 15p31-35, 211q14-25, 111q13,
214q22-32, 117q11-25//113
22 32 0 0 67 0 67 11q43-44, 25p11-15, 17q21-36, 28p11-23, 210p11-15, 211q14-25,
117q22-25
23 32 1 1 18 1 24 21p32-36, 12p11-25, 23p13-26, 217p11-13, 117q22-25, 218q21-
23//29
24 57 1 1 24 1 25 21p11-36, 11q11-44, 112p24-25, 211q14-25, 111q13, 117q11-25//
17, 112, 23, 210, 215
25 49 0 1 15 1 20 21q42-44, 117q22-25
26 34 1 0 42 0 42 12p22-25, 12q23-37, 15q14-23, 117q21-25, 118q11-23//17, 112,
122
27 57 0 1 13 1 21 11q11-44, 22p24-25, 23p21-26, 17p15-22, 211q13-25, 214q24-32,
117q21-25
28 63 0 1 1 1 3 12p11-15, 15p11-15, 1111q13, 112q22-24//16, 17, 115, 116,
117, 118, 24, 28, 29, 211, 214, 221, 2X
29 178 1 0 25 0 25 21p13-36, 11q31-44, 112p24-25, 23p22-26, 111q13-25//122
30 19 1 0 52 0 52 21p22-36, 112p24-25, 117q22-25
31 101 0 1 1 1 19 11q11-44, 12p22-25, 15p31-35, 111p11-15, 211q21-25, 116p11-
13//16, 17, 113, 117, 118, 120
32 47 0 1 24 1 36 117, 119, 2X
33 65 0 0 40 0 40 23p13-26, 24p11-16, 211q14-25, 111q13, 220p11-13//17, 117,
118
34 18 1 0 78 0 78 21p33-36, 112p24-25, 29p21-24, 117q21-25
35 35 1 0 38 0 38 21p32-36, 112p24-25, 29p22-24
36 41 0 0 43 0 43 117q21-25
37 39 0 1 6 1 6 211q14-25, 117q21-25//17, 118
38 60 0 1 32 1 40 11q11-44, 210q23-26, 211q21-25, 117q11-25//17, 18, 118, 29,
2Y
39 9 0 0 68 0 68 117q22-25//16, 17, 112, 113
40 60 0 0 54 0 54 23p21-26, 24p15-16, 211q14-25, 111q13, 117q21-25//17, 119,
221
41 28 0 0 14 0 14 21p32-36, 12p22-25, 24p12-16, 17q21-36, 210p11-15, 214q22-34,
117q21-25
42 19 0 0 16 0 16 24p14-16, 14q11-35, 15q11-23, 113q14-34, 217p11-13//216, 219,
220, 222
43 65 0 1 10 0 22 26q24-27, 112q21-24, 217p11-13, 117q11-25
44 44 0 1 22 0 22 11q11-44, 29p11-24, 211q14-25, 113q33-34, 216q11-24, 117q11-
25
45 36 0 0 8 0 8 12p15-25, 17q21-26, 211q14-25, 117q11-25
46 156 0 0 67 0 67 12p21-25, 23q11-29, 26p11-25, 110p11-15, 211q14-25, 1114q12-
13, 117q11-25, 1Xp11-22//117, 118
47 84 0 0 22 0 22 12p16-25, 17q22-26, 211q21-25, 214q22-32//23
48 96 0 0 41 0 41 214q22-32, 117q21-25
49 84 0 0 6 0 6 23p14-26, 117q21-25, 1Xp11-22//118
50 47 0 1 1 1 4 211q14-25, 117q21-25//113
51 12 0 ND ND ND ND 23p21-26, 211q13-25, 117q21-25
52 67 0 0 10 0 10 21p32-36, 112p24-25, 24p11-16, 17q11-26, 116q22-24, 217p11-
13, 117q11-25//112, 211
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genetic change. This analysis revealed a remarkably high inci-
dence of 11q deletions in tumors without MNA (59%) whereas in
Stage 4 NB with MNA, 11q deletion was observed in only 15% of
cases. All except one of the 11q deletions were large, encompass-
ing more than half of the distal end of 11q. The subgroup defined
by the 11q deletion was also characterized by the infrequent 1p
deletion by CGH. In addition to typical absence of MNA and 1p
deletion, Stage 4 NB with 11q deletions were significantly asso-
ciated with 3p deletion. The present data therefore strongly suggest
that 11q deletions identify a distinct genetic subgroup of Stage 4
NB. In two previous, studies an association between 11q and 14q
loss was reported, albeit less stronger than the association between
11q and 3p.6,11 In our study on a larger series of tumors with 11q
deletion the association between 11q and 14q loss was not statis-
tically significant.
Standard cytogenetic studies of neuroblastoma did not reveal
11q deletion as a recurrent cytogenetic abnormality.12 More re-
cently, a compilation of reported neuroblastoma karyotypes how-
ever showed a rate of 11q deletion in approximately 15% of
cases.13 Initial studies analyzing loss of 11q by LOH were con-
flicting.14–17 In some LOH studies 11q loss was found in up to 19
to 26% of cases, whereas others found only 5% of tumors with 11q
loss (1 case in a series of 20 informative cases). Recently, in a
large LOH study on a series of 310 primary neuroblastomas LOH
was found for multiple 11q loci in as much as 43% of cases,8 with
a smallest region of overlap (SRO) in the 11q23.3 chromosomal
region. As in our study, there was a strong inverse relationship of
11q LOH and MNA. The authors did not find a negative correla-
tion with 1p deletion. The highest percentage of 11q allelic loss
was observed in Stage 4 tumors (48%) but surprisingly, a high
proportion of Stage 1, 2 and 3 tumors also showed 11q loss (30%,
45% and 45%, respectively). In previous CGH studies a much
lower incidence of 11q deletion was observed but whole loss of
chromosome 11 was a frequent finding in near triploid low stage
NB.3–6 Further studies by Guo et al.,8 including microsatellite loci
from the short arm of 11p confirmed (as CGH) difference between
whole chromosome 11 losses in the low stage tumors and chro-
mosome 11q losses in high stage tumors.
The frequent occurrence of 11q deletions in this subset of Stage
4 NB, strongly suggests that one or more tumour suppressor genes
residing on 11q are implicated in the biology of these tumors. This
was previously suggested by chromosome 11 transfer experiments
that resulted in induction of differentiation of neuroblastoma
cells.19 Guo et al.8 defined an SRO on 11q23.3. Interestingly, this
region falls within a constitutional 11q23–qter deletion reported in
a patient with NB.21 Deletions found in our study were large and
TABLE I – CLINICAL DATA AND OVERVIEW OF CGH ABNORMALITIES ON 83 STAGE 4 NEUROBLASTOMA TUMOURS (CONTINUED)
No. Age1 MNA2 Event3 Fol-up
event1 Death
4 Fol-up
death4 Overview CGH abnormalities
5
53 33 1 1 9 1 17 21p11-36, 11q11-44, 112p24-25, 117q21-25//28, 211
54 38 1 1 1 1 10 21p32-36, 11q11-44, 112p24-25, 117q21-25, 218p11.1-11.3,
118q22-23//13, 15
55 57 1 1 22 1 34 21p11-36, 11q11-44, 112p24-25, 113q21-31, 117q11-25//12, 17,
23, 28, 29, 211, 214, 215, 218, 2X
56 9 1 1 12 1 16 21p11-36, 112p24-25, 117q11-25
57 41 1 1 1 1 15 21p34-36, 11q11-44, 112p24-25, 118q11-23
58 19 0 1 6 1 9 11q11-44, 117q21-25, 118q11-23//12, 116
59 47 0 0 79 0 79 24q31-35, 211q14-25, 117q11-25//122
60 38 0 1 8 1 8 23p21-26, 111p11-15, 211q11-25, 116q21-24, 117q21-25
61 51 1 0 4 0 4 21p32-36, 112p24-25, 13q25-29, 14q11-35, 17q11-36, 211q22-25,
113q14-34, 216q23-24, 217p11-13, 117q21-25//210, 219
62 12 1 ND ND ND ND 21p36, 112p24-25, 211q11-25, 113q11-21, 214q22-34, 117q21-
25//17, 218, 219
63 66 0 0 28 0 28 25q11-35, 16q11-27, 17q21-36, 211q22-25, 212q23-24, 117q21-
25//118, 23
64 3 0 0 19 0 19 117, 23, 211, 214, 215
65 30 1 1 1 1 11 21p35-36, 112p24-25, 111q12-14, 117q11-25//119
66 24 ND 1 11 1 11 21p11-34, 12q22-37, 23p21-26, 25p11-15, 15q32-35, 16p21-22,
29p21-24, 211q14-25, 112q23-24, 113q21-34,
1117q12-21//117, 119, 122
67 24 1 1 1 1 9 21p21-36, 112p24-25, 117q21-25//2X
68 42 0 1 10 1 15 11p32-36, 11q11-44, 29p13-24, 117q11-25//17, 119, 214, 221
69 12 0 1 30 1 30 21p34-36, 12p22-25, 23p11-26, 24p11-16, 117q22-25, 218q22-23//
16, 112, 214, 22
70 90 1 1 1 1 29 21p11-36, 112p24-25, 210q11-26, 117q21-25, 118p21-25//17, 2X
71 156 0 1 1 1 3 23p24-26, 24p13-16, 29q33-34, 211q22-25, 112q23-24, 117q22-25
72 216 0 1 18 1 25 21p32-36, 11q11-44, 24q11-28, 16p22-25, 26q21-27, 214q22-32,
117q21-25//112, 23, 2X
73 67 0 1 17 1 20 23p14-26, 24p14-16, 14q26-35, 15q31-35, 211q13-25, 214q22-32,
117q21-25//118, 22, 28
74 5 1 1 18 1 41 21p34-36, 112p24-25, 16p11-22, 16q11-27, 117q11-25//210
75 20 1 1 7 1 9 21p31-36, 11q23-44, 114q33-35, 117q21-25
76 16 0 0 45 0 45 11, 16, 17, 18, 113, 117, 23, 211
77 66 1 ND ND ND ND 112p24-25, 110p13-15, 210q25-26, 117q11-25//2X
78 23 1 1 12 0 12 21p32-36, 112p24-25, 117q11-25
79 84 0 0 23 0 23 22p24-25, 23p14-26, 24p11-16, 17p21-22, 17q11-36, 18p11-23,
211q14-25, 117q11-25//2X
80 14 1 0 12 0 12 21p31-36, 112p24-25, 13q11-29, 215q11-13, 117q11-25, 119p11-
13, 219q11-13
81 58 1 ND ND ND ND 21p32-36, 11q11-44, 112p24-25, 211p12-14, 211q14-21, 215q11-
13, 117q11-25//12, 23, 29, 213, 214
82 66 0 1 20 1 20 11q22-25, 17q22-36, 29p13-24, 211q14-25, 117q11-25//2Y
83 69 1 1 6 1 14 112p24-25
1In months.–21, MYCN-amplification; 0, no MYCN-amplification; ND, no data.–30, no event at all; 1, relapse, progression or toxic death; ND,
no data.–40, alive at last follow-up; 1, death; ND, no data.–51, gain; 2, loss; 11, amplification.
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terminal, except for one tumour that showed an interstitial 11q13–
q21 deletion. This interstitial deletion overlaps with a previous
cytogenetically detected 11q13–q21 deletion.21 Confirmation of
this putative second more proximal located SRO at 11q13–q21
awaits further investigations.
The present study shows a positive correlation between the
presence of deletion of 3p in NB tumors with 11q deletion and
without MNA. The occurrence of 3p loss was previously observed
by representational difference and LOH analysis.22 A further study
confirmed this finding and showed the presence of 3p deletion in
15% of investigated NB. The consensus region was defined by
markers D3S1286 and D3S1295 (3p25.3–p14.3), distal to the
FHIT gene.23 Our study provides further support for the non-
random involvement of 3p loss in neuroblastoma and also delin-
eates a critical region located in the distal part of 3p (3pter–p24).
The negative correlations between 11q loss and MNA and
between 11q loss and 1p deletion are particularly striking. On the
other hand, 11q loss is by necessity linked to gain of 17q due to the
well established prevalence of unbalanced translocation
der(11)t(11q;17q).24 This rearrangement, that results in concurrent
loss of distal 11q and gain of distal 17q, may account for up to 50%
of 11q loss events. Because 17q gain is an important predictor of
FIGURE 1 – Relative percentage of partial gains of chromosome 1q, 2p and 17q (above the horizontal axis) and partial losses of chromosome
1p, 3p and 11q (below the horizontal axis) . Bars in white indicate tumors with MYCN amplification (MNA); bars in gray indicate tumors without
MYCN amplification (MNNA).
FIGURE 2 – Interrelationship between MYCN-amplification, 1p dele-
tion and 11q deletion (as determined by CGH).
FIGURE 3 – Overview of CGH results for chromosome arms 3p and
11q. Lines on the left side of the ideogram represent losses, lines on
the right gains; bold bars represent amplification.
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adverse outcome,7,25 this physical interaction between 11q and 17q
is an important factor in considering the prognostic significance of
11q loss.
An interesting observation was the presence of 11q13 gain in 7
tumors and amplification in one. For the latter, previous molecular
analysis showed the presence of CCND1 amplification.26 In the
study of Breen et al.11 11q13 amplification was noted in 2 tumors.
Also, SAGE analyses of neuroblastoma cell lines confirmed the
occurrence of CCND1 overexpression.27 In 5 out of 7 cases 11q13
gain coincided with more distal 11q loss. The significance of this
observation remains to be resolved by study of additional tumors.
We also evaluated the prognostic significance of 11q deletions
among patients with Stage 4 neuroblastoma. More than 50% of
patients over 1 year of age with Stage 4 neuroblastoma will relapse
and die within 5 years after diagnosis and treatment. For some long
term survivors, however, favorable genetic prognostic factor(s)
remain to be identified. Compared with patients with 11q non-
deleted NB (mainly represented by patients harboring tumors with
1p deleted or MYCN amplified NB), the prognosis of patients with
11q deleted tumors is statistically similar and poor in our study of
Stage 4 tumors.
Guo et al.8 found a significantly better survival for patients
without vs. those with 11q deletion in tumors without MYCN
amplification (91% vs. 75% 3-year overall survival) in a cohort of
different stages. As CGH detected 11q deletion in only 7% of
localized tumors (Stage 1, 2 and 3 tumors), however, the 75%
3-year survival reported by Guo et al.8 seems high for tumors with
11q deletions. In the same way that the rate of 11q LOH seems
high for low stage tumors, the 75% survival in the study of Guo et
al.8 may be explained by the presence of near triploid low stage
tumors with whole chromosome 11 loss and typical favorable
prognosis. Most recently, Guo et al.18 have extended the analysis
of 11q LOH with the inclusion of 11p markers to segregate whole
chromosome loss from rearrangements resulting in unbalanced
deletion of distal 11q. With this distinction, 11q unbalanced LOH
is now highly correlated with age over 1 year at diagnosis and
Stage 4 disease. The 11q deletion prognostic value will need
further studies for metastatic patients treated with new treatment
regimes such as retinoic acid28 and for non-metastatic patients who
relapsed from tumors without MYCN amplification.
In conclusion, CGH showed 11q deletions in more than 50% of
Stage 4 neuroblastomas without MYCN amplification. This genetic
subgroup is also characterized by a positive correlation with 3p
deletions and an inverse correlation with 1p deletion. Although
11q deletion currently has no prognostic value in metastatic neu-
roblastoma, further studies remain necessary to evaluate its impact
for patients treated with new therapeutic regimens. Molecular
studies are required to identify a putative 11q suppressor gene
involved in neuroblastoma development.
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ABSTRACT
  Background Gain of genetic material from chromosome arm 17q (gain of segment 17q21–
qter) is the most frequent cytogenetic abnormality of neuroblastoma cells. This gain has been
associated with advanced disease, patients who are ≥ 1 year old, deletion of chromosome arm
1p, and amplification of the N-myc oncogene, all of which predict an adverse outcome. We
investigated these associations and evaluated the prognostic importance of the status of
chromosome 17.
  Methods We compiled molecular cytogenetic analyses of chromosome 17 in primary
neuroblastomas in 313 patients at six European centers. Clinical and survival information were
collected, along with data on 1p, N-myc, and ploidy.
  Results Unbalanced gain of segment 17q21–qter was found in 53.7 percent of the
tumors, whereas the chromosome was normal in 46.3 percent. The gain of 17q was
characteristic of advanced tumors and of tumors in children ≥ 1 year of age and was strongly
associated with the deletion of 1p and amplification of N-myc. No tumor showed amplification of
N-myc in the absence of either deletion of 1p or gain of 17q. Gain of 17q was a significant
predictive factor for adverse outcome in univariate analysis. Among the patients with this
abnormality, overall survival at five years was 30.6 percent (95 percent confidence interval, 21
to 40 percent), as compared with 86.0 percent (95 percent confidence interval, 78 to 91
percent) among those with normal 17q status. In multivariate analysis, gain of 17q was the
most powerful prognostic factor, followed by the presence of stage 4 disease and deletion of 1p
(hazard ratios, 3.4, 2.3, and 1.9, respectively).
  Conclusions Gain of chromosome segment 17q21–qter is an important prognostic factor in
children with neuroblastoma.
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BSTRACT
 
Background
 
Gain of genetic material from chro-
mosome arm 17q (gain of segment 17q21–qter) is
the most frequent cytogenetic abnormality of neuro-
blastoma cells. This gain has been associated with
advanced disease, patients who are »1 year old, de-
letion of chromosome arm 1p, and amplification of
the N
 
-myc
 
 oncogene, all of which predict an adverse
outcome. We investigated these associations and
evaluated the prognostic importance of the status of
chromosome 17.
 
Methods
 
We compiled molecular cytogenetic analy-
ses of chromosome 17 in primary neuroblastomas in
313 patients at six European centers. Clinical and
survival information were collected, along with data
on 1p, N
 
-myc,
 
 and ploidy.
 
Results
 
Unbalanced gain of segment 17q21–qter
was found in 53.7 percent of the tumors, whereas
the chromosome was normal in 46.3 percent. The
gain of 17q was characteristic of advanced tumors
and of tumors in children »1 year of age and was
strongly associated with the deletion of 1p and am-
plification of N
 
-myc.
 
 No tumor showed amplification
of N
 
-myc
 
 in the absence of either deletion of 1p or
gain of 17q. Gain of 17q was a significant predictive
factor for adverse outcome in univariate analysis.
Among the patients with this abnormality, overall
survival at five years was 30.6 percent (95 percent
confidence interval, 21 to 40 percent), as compared
with 86.0 percent (95 percent confidence interval, 78
to 91 percent) among those with normal 17q status.
In multivariate analysis, gain of 17q was the most
powerful prognostic factor, followed by the presence
of stage 4 disease and deletion of 1p (hazard ratios,
3.4, 2.3, and 1.9, respectively).
 
Conclusions
 
Gain of chromosome segment 17q21–
qter is an important prognostic factor in children with
neuroblastoma. (N Engl J Med 1999;340:1954-61.)
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ENETIC studies have an important role
in formulating the prognosis in children
with neuroblastoma, because certain ac-
quired genetic abnormalities in the tumor
cells correlate closely with the clinical outcome.
 
1
 
 Es-
tablished indicators of the aggressiveness of the tumor
and poor outcome include the deletion of the short
arm of chromosome 1 (1p),
 
2
 
 the amplification of the
N
 
-myc
 
 gene,
 
3
 
 and near diploidy or near tetraploidy.
 
2
 
Conversely, the presence of 1p, single copies of N
 
-myc,
G
 
near triploidy, and expression of the 
 
TRK
 
 gene
 
4
 
 are
significantly associated with a favorable prognosis.
Rearrangements of chromosome 17 in neuroblas-
toma cells, particularly those resulting in a gain of ma-
terial from the long arm of the chromosome (17q),
were first described in the early 1980s,
 
5,6
 
 but the ex-
tent of such abnormalities in neuroblastoma cells
was not apparent until fluorescence in situ hybridi-
zation and comparative genomic hybridization were
used to study neuroblastoma cells.
 
7-15
 
 These methods
revealed that the gain of material from chromosome
17 is the most frequent genetic abnormality of neu-
roblastoma cells, with an incidence ranging from 63
to 83 percent. This gain may consist of an entire chro-
mosome 17 (e.g., tetrasomy 17 in a triploid tumor)
or of only the distal segment of the long arm, 17q21–
qter. Such a partial gain is strongly associated with
risk factors: age of more than one year, presence of
advanced disease, deletion of 1p, amplification of the
N
 
-myc
 
 gene, and unfavorable ploidy.
The principal mechanism underlying partial gain
of 17q is an unbalanced translocation, with a variety
of partner chromosomes.
 
7-9,15
 
 The segment on the
partner chromosome distal to the breakpoint is lost,
and a segment of 17q translocates to that site. The
translocated segment is in effect an extra copy, be-
cause the cell also contains two or more normal chro-
mosomes 17. Hence, these translocations result in
unbalanced gain of the distal segment of 17q. The
most common site of the translocation is 1p, where
the gain of the distal portion of 17q is linked with the
loss of 1p (Fig. 1A and 1B).
In 1995, Caron
 
16
 
 reported that 20 of 53 neuro-
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Figure 1.
 
 Techniques Used to Determine Chromosome 17 Status.
Panel A shows the results obtained with cytogenetic analysis. G-banding identifies a gain of 17q12–qter as an unbalanced translo-
cation with 1p. Panel B shows the results obtained with fluorescence in situ hybridization of cells in metaphase. A paint probe for
chromosome 17 identifies a gain of genetic material from chromosome 17 on the short arm of chromosome 1 in addition to two
normal copies of chromosome 17. Panel C shows the results obtained with fluorescence in situ hybridization of cells in interphase
in which rhodamine-labeled centromeric probe and fluorescein-labeled myeloperoxidase (MPO) probe have been used. Panel D
shows the nucleus of a tumor with 17q gain by fluorescence in situ hybridization of cells in interphase (2 centromeric signals [cen],
3 MPO signals). Panel E shows a whole chromosome gain in a triploid tumor, also by fluorescence in situ hybridization of cells in
interphase (4 centromeric signals, 4 MPO signals). Panel F shows the results of comparative genomic hybridization for chromosome
17 with a green:red ratio of 1.0, indicating no gain with respect to ploidy. In Panel G the color ratio shifted to 1.25, indicating gain
of a whole chromosome. Panel H shows results of comparative genomic hybridization indicating gain of distal q arm (q21–qter).
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blastomas (38 percent) had gain of 17q and that pa-
tients with such tumors had a significantly worse
event-free survival at two years than those without
this feature. However, when the series was expanded
sufficiently to allow multivariate analysis,
 
17
 
 the pre-
dictive power of the 17q gain was marginal and was
not apparent when 1p or N
 
-myc
 
 status was added to
the model. Using cytogenetic techniques and fluores-
cence in situ hybridization, astowska et al.
 
18
 
 identi-
fied 17q gain in 28 of 45 neuroblastomas (62 per-
cent) and found that overall survival for patients with
17q gain was 13.5 percent at three years, as com-
pared with 100 percent for those without this ab-
normality. Multivariate analysis revealed a powerful
independent effect of 17q gain after other clinical and
genetic variables were taken into account.
In this study, we sought to confirm the associa-
tion of unbalanced 17q gain with other indicators of
high risk in patients with neuroblastoma and to test
the hypothesis that this abnormality is an independ-
ent predictor of tumor aggressiveness and poor clin-
ical outcome. To this end, we assembled a large series
of analyses in which the status of chromosome 17
was known and related this information to well-estab-
lished clinical and genetic risk factors and to rates of
relapse and mortality.
 
METHODS
 
Tumors
 
Inclusion in the study was based solely on the ability to define
the status of chromosome 17. The data on 313 patients with neu-
roblastoma for which the status of chromosome 17 in tumor cells
was established were collected from six European centers. The tu-
mor stage was classified according to the International Neuroblas-
toma Staging System.
 
19
 
 Similar treatment regimens were used in
the various centers for patients of the same age and with the same
stage of disease.
 
Genetic Analysis
 
Four centers provided results of comparative genomic hybridi-
zation. A complete description of this procedure is reported else-
where.
 
10-14,20,21
 
 In brief, tumor DNA and normal DNA from ref-
erence tissue were extracted and labeled by nick translation for
differential fluorescence detection (fluorescein vs. rhodamine).
Equal amounts of tumor and reference DNA were mixed and hy-
bridized to lymphocytes in metaphase. Images were captured by
a photomultiplying camera, and image-analysis software was used
to calculate the ratio of red to green fluorescence along chromo-
some lengths. Control experiments (competitive hybridization of
differentially labeled samples of normal DNA) were carried out
to establish the fluorescence-ratio thresholds for gain or loss of
chromosome regions.
Three centers contributed results from cytogenetic analysis
supplemented by fluorescence in situ hybridization.
 
9,15
 
 Chromo-
somes were prepared and banded according to standard proto-
cols. In some cases, the status of chromosome 17 was confirmed
by fluorescence in situ hybridization of cells in metaphase by using
chromosome 17 paints in conjunction with either Oncor myelo-
peroxidase probe, which maps to 17q21.3–q23, or yeast artificial-
chromosome probes mapping to 17q.
Oncor probes for either TP53 (locus 17p13) or chromosome
17 centromere in combination with differentially labeled myelo-
peroxidase probe were used for interphase fluorescence in situ hy-
bridization at one center. Determining relative numbers of red
and green signals in tumor nuclei allows a balanced status of 17q
to be distinguished from unbalanced gain (Fig. 1C, 1D, and 1E).
Examples of the results obtained with these techniques are
shown in Figure 1. Genetic factors other than the status of 17q
were assessed at individual centers by combinations of techniques.
The status of 1p was determined by comparative genomic hybrid-
ization or by fluorescence in situ hybridization with the use of
combinations of a pericentromeric probe for chromosome 1 with
probes derived from the 1p36 region,
 
22
 
 analysis of DNA micro-
satellite markers by the polymerase chain reaction,
 
23
 
 or cytogenetic
analysis. The status of N
 
-myc
 
 was determined by comparative ge-
nomic hybridization, fluorescence in situ hybridization, or South-
ern blotting, and ploidy was determined by flow cytometry or
cytogenetic analysis.
 
Definition of the Status of Chromosome 17
 
The status of chromosome 17 was defined as either gain of 17q
or normal. Gain of 17q denoted the gain of segment 17q21–qter.
The defining characteristics of 17q gain were a breakpoint in
17q11–q21 and an extra copy of the 17q segment distal to this
breakpoint in the chromosomal complement of the cell, resulting
in an increase in the number of copies of distal 17q as compared
with 17p. These gains almost always result from unbalanced
translocations. Normal status denoted no unbalanced gain of 17q
relative to 17pter–q12. It included tumors showing no gain or
loss of any part of chromosome 17 (e.g., two intact copies of 17
in a diploid nucleus or three in a triploid nucleus) and tumors
showing gain of an entire chromosome 17 in relation to the
ploidy level of the cell (e.g., four copies in a triploid nucleus). In
these cases there is no chromosome breakpoint, and there is a
normal ratio of 17p to 17q.
 
Statistical Analysis
 
Logistic-regression analysis was used to test the consistency of
the findings from the various centers. Descriptive statistical analy-
sis used 
 
x
 
2
 
 tests to identify the biologic characteristics of the com-
bined data set. In particular, the distribution of 17q gain was de-
termined in relation to established clinical and genetic factors.
The Kaplan–Meier method
 
24
 
 and the log-rank test were used
to estimate survival and progression-free survival. The predictive
significance of age, tumor stage, ploidy, and 1p, N
 
-myc,
 
 and 17q
status were tested in univariate analyses. After performing a strat-
ified subgroup analysis, we applied a stepwise Cox proportional-
hazards model (successively rejecting nonsignificant variables) to
test the hypothesis that 17q status has an independent influence
on outcome and to quantify the influence of 17q status with re-
spect to other clinical and genetic factors. In a separate analysis,
a multivariate model incorporating tumor stage, age, and N
 
-myc
 
status was extended to include 17q status in order to test the ad-
ditional predictive power that the variable of 17q status provides.
 
RESULTS
 
Most of the data were compiled from the results
of comparative genomic hybridization (68.7 percent);
in the remaining 31.3 percent of cases, the status of
chromosome 17 was determined by standard cyto-
genetic analysis supplemented with metaphase fluores-
cence in situ hybridization or by two-color interphase
fluorescence in situ hybridization. Data on 154 of
the 313 tumors (49.2 percent) have been previously
reported.
 
9-12,14,15
 
The median age of the patients at the time of di-
agnosis was 2.2 years. The median duration of follow-
up for survivors was 2.5 years (interquartile range,
1.0 to 4.4). Of the 313 tumors, 119 were from infants
less than one year of age and 194 were from children
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one or more years of age. According to the criteria
of the International Neuroblastoma Staging System,
44 of the tumors were classified as stage 1, 35 as stage
2, 49 as stage 3, 140 as stage 4, and 45 as stage 4S.
Supplementary analyses established the status of
1p in 265 of the tumors (84.7 percent); of these,
124 (46.8 percent) showed 1p deletion. Assessment of
the number of N
 
-myc
 
 copies was performed for 301
(96.2 percent), and gene amplification was detected
in 91 of these tumors (30.2 percent). Ploidy could be
classified in 126 tumors (40.3 percent); of these, 68
(54.0 percent) were within the near-diploid range, 36
(28.6 percent) were near-triploid, and 22 (17.5 per-
cent) were near-tetraploid. 
Of the 313 tumors, 145 (46.3 percent) had a nor-
mal 17q status and 168 (53.7 percent) showed 17q
gain. Twenty-six percent of the neuroblastomas from
the patients less than one year old showed 17q gain,
as compared with 71 percent of the tumors from the
older children. The proportions with 17q gain accord-
ing to tumor stage were as follows: 20 percent in
stage 1, 17 percent in stage 2, 51 percent in stage 3,
85 percent in stage 4, and 20 percent in stage 4S.
To assess the consistency of the data among cen-
ters, the results of genetic analyses (the status of 1p,
N
 
-myc
 
 and 17q) were studied by logistic-regression
analysis. No significant differences between labora-
tories were detected (P>0.1 for all analyses).
 
Correlations with Other Clinical and Genetic Prognostic 
Factors
 
Table 1 shows the relation between clinical and ge-
netic factors and the status of 17q. Gain of 17q was
strongly associated with stage 4 disease (
 
x
 
2
 
=114,
P<0.001 for the comparison with all other stages
combined). It was also significantly associated with
an age of one year or more at presentation (
 
x
 
2
 
=59,
P<0.001). Gain of 17q was strongly associated with
1p deletion (
 
x
 
2
 
=61, P<0.001), N
 
-myc
 
 amplification
(
 
x
 
2
 
=53, P<0.001), and diploidy or tetraploidy (
 
x
 
2
 
=
24, P<0.001), but not triploidy. Figure 2 shows the
interrelation of 17q gain, N
 
-myc
 
 amplification, and
1p deletion for the 260 tumors in which the pres-
ence or absence of all three abnormalities was known.
The status of 17q, 1p, and N
 
-myc
 
 was normal in 96
tumors, but these tumors had other acquired genetic
changes.
 
Univariate Analysis of Survival
 
At five years, the overall survival for the 313 chil-
dren was 55.9 percent (95 percent confidence interval,
48 to 63 percent), and progression-free survival was
46.4 percent (95 percent confidence interval, 39 to
54 percent). With a median follow-up of 24 months,
the projected overall 5-year survival of the 168 pa-
tients with 17q gain was 30.6 percent (95 percent
confidence interval, 21 to 40 percent), as compared
with 86.0 percent (95 percent confidence interval,
78 to 91 percent) for the 145 patients whose tumors
had normal 17q (Fig. 3A). This difference was sig-
nificant (P<0.001). 
In a univariate analysis of survival, age, tumor stage,
1p status, N
 
-myc
 
 status, and ploidy were all signifi-
 
*Percentages include all patients who could be
evaluated for a particular characteristic.
†P values were calculated with the 
 
x
 
2
 
 test.
‡The test for trend with 2 df was used for tumor
stage and ploidy.
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cantly associated with outcome (P<0.01 according
to the likelihood-ratio test) (Table 2). The discrimi-
native power of the status of 17q was significant in
subgroups in which 1p was not deleted (Fig. 3B) or
N-myc was not amplified (Fig. 3C) (P<0.001 for
both). Gain of 17q in tumor cells was associated with
significantly poorer outcomes in patients of any age
and with tumors of stages 1, 2, 3, or 4S (Table 3).
In the subgroup of tumors showing simultaneous 1p
deletion and N-myc amplification, there was a non-
significant trend toward additional adverse effects with
17q gain (Fig. 3D).
Multivariate Analysis of Survival
A stepwise Cox proportional-hazard procedure was
applied, incorporating age, tumor stage, and status
of 1p, 17q, and N-myc, to the 260 cases in which all
three genetic factors were known. Ploidy was not in-
Figure 3. Survival Rates According to the Status of Chromosome 17q.
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cluded in the multivariate analysis because of the rela-
tive paucity of data (ploidy was established for only 40
percent of the tumors). Age and the status of N-myc
were excluded from the final model (score test, P=0.4
and P=0.2, respectively). Remaining predictors of ad-
verse outcomes were 1p deletion (hazard ratio, 1.9; 95
percent confidence interval, 1.1 to 3.2; P=0.02),
stage 4 disease (hazard ratio 2.3; 95 percent confi-
dence interval, 1.3 to 4.0; P=0.004), and 17q gain
(hazard ratio, 3.4; 95 percent confidence interval, 1.7
to 6.6; P<0.001). When a multivariate model incor-
porating age, tumor stage, and N-myc status was ex-
tended to include the status of 17q, a significant
increase in predictive power was apparent (likelihood-
ratio statistic, +15.0; P<0.001).
DISCUSSION
The selection of the 313 neuroblastomas that
were included in this series was based on the ability
to determine the status of chromosome 17. With re-
gard to clinical characteristics, this series of patients
is broadly typical of other series of patients with this
tumor.25 We found that 54 percent of the tumors
showed gain of 17q12–qter (i.e., a gain of chromo-
somal material from the distal end of the long arm
of chromosome 17), whereas 46 percent had either
no gain of chromosome 17 or an additional copy of
the whole chromosome.
Our results confirm that 17q gain in neuroblasto-
ma is associated with advanced-stage disease and
with tumors in older children rather than infants.
Gain of 17q was very strongly linked to both 1p de-
letion and N-myc amplification; indeed, N-myc am-
plification was not found in any tumor without 1p
deletion, 17q gain, or both.
In the univariate analysis of survival, the status of
17q was a significant predictor of clinical outcome, as
were other clinical and genetic factors. In subgroup
analyses, 17q gain was a significant predictive factor
within tumor stage, in both infants and children one
year old or more, and in cases in which N-myc was
not amplified or 1p was not deleted. In the stepwise
multivariate analysis, the status of 17q was the most
significant predictive factor for clinical outcome, fol-
lowed by stage 4 disease and the status of 1p. The
status of N-myc and age were not statistically signif-
icant in this analysis.
Although neuroblastoma cells contain a variety of
chromosomal aberrations, abnormalities of chromo-
some 17 are the most common. Moreover, gain of
17q21–qter is strongly associated with tumor pro-
gression. We found significant correlations between
*Survival estimates and comparisons exclude patients who
were not evaluated for the particular category.
†P values were calculated with the log-rank test.
‡CI denotes confidence interval.
§Comparisons of tumor stage and ploidy were calculated
by the log-rank test for trend.
TABLE 2. SURVIVAL RATES OF 313 PATIENTS
WITH NEUROBLASTOMA ACCORDING TO CLINICAL
AND GENETIC FACTORS IN UNIVARIATE ANALYSIS.*
VARIABLE AND CATEGORY
NO. OF 
PATIENTS
5-YEAR 
SURVIVAL
P
VALUE†
% (95% CI)‡
Age 
<1 yr
»1 yr
119
194
82 (72–89)
42 (33–51) <0.001
Tumor stage§
1, 2, or 4S
3
4
124
49
140
91 (84–95)
62 (44–76)
25 (16–36) <0.001
Chromosome 17q
Normal 
Unbalanced gain
145
168
86 (78–91)
31 (21–40) <0.001
Chromosome 1p
Normal 
Deleted
141
124
77 (67–85)
31 (21–42) <0.001
N-myc gene
Single copy
Amplified
210
91
69 (60–77)
28 (16–41) <0.001
Ploidy§
Diploid
Tetraploid
Triploid
68
22
36
35 (21–50)
44 (13–72)
88 (71–95)
0.008
*Survival estimates and comparisons exclude patients who were not eval-
uated for the particular category.
†P values were calculated with the log-rank test.
‡CI denotes confidence interval.
TABLE 3. SURVIVAL RATES OF 313 PATIENTS
WITH NEUROBLASTOMA STRATIFIED ACCORDING TO
17q STATUS AND CLINICAL AND GENETIC FACTORS.*
VARIABLE AND
CATEGORY
NO. OF
PATIENTS 5-YEAR SURVIVAL
P
VALUE†
NORMAL 17q 17q GAIN
% (95% CI)‡
Age 
<1 yr
»1 yr
119
194
94 (84–98)
77 (61–87)
49 (26–69)
27 (17–38)
<0.001
<0.001
Tumor stage 
1, 2, or 4S
3
4
124
49
140
95 (87–98)
81 (50–94)
52 (26–74)
75 (50–89)
45 (22–66)
22 (13–33)
0.01
0.01
0.09
Chromosome 1p
Normal
Deleted
141
124
93 (82–98)
63 (40–79)
45 (26–62)
22 (12–35)
<0.001
0.01
N-myc gene
Normal 
Amplified
210
91
90 (81–95)
67 (34–86)
38 (21–54)
22 (12–36)
<0.001
0.05
Ploidy
Diploid
Tetraploid
Triploid
68
22
36
83 (57–94)
100 
100
19 (7–34)
35 (7–66)
49 (13–78)
<0.001
0.4
0.001
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17q gain and established clinical and genetic risk fac-
tors. As noted previously,6-9,15 a direct relation between
1p deletion and 17q gain is the well-recognized un-
balanced translocation t(1p;17q); it seems likely that
this rearrangement accounts for a high proportion
of 1p deletions in patients with neuroblastoma. Fur-
ther cytogenetic data will be necessary to clarify the
contribution of translocations of 17q to other sites of
reported loss of heterozygosity in neuroblastoma cells.
In this study, N-myc amplification was not found
in any tumor without concurrent 1p deletion, 17q
gain, or both. Caron also showed N-myc amplification
to be a subcategory of 1p loss and 17q gain, albeit
in a much smaller number of tumors.16 This finding
suggests that N-myc amplification is a late event in
the sequence of genetic lesions contributing to neu-
roblastoma.
The relation between 17q gain and N-myc ampli-
fication is obscure. Juxtaposition of amplified N-myc
and 17q material has repeatedly been observed in
neuroblastoma cell lines,7,8 but this finding is very
rare in primary tumors, in which N-myc amplification
usually takes the form of double minute chromo-
somes; involvement of 17q in these structures has
not been demonstrated. The functional interrelations
of 17q and N-myc (and 1p) remain to be clarified.
A number of potentially important genes, such as
nm23-H1 and the survivin gene (which are involved
in inhibiting apoptosis) and the gene for nerve
growth factor receptor (which is underexpressed in
neuroblastoma cells),26 are located in the commonly
gained segment of 17q. Investigations of such genes
may reveal the mechanism of the effect of 17q gain on
the behavior of neuroblastoma cells. Preliminary map-
ping has identified at least seven breakpoints within
the proximal half of 17q in neuroblastomas and neu-
roblastoma cell lines9,26; this finding argues against a
specific gene event (e.g., gene fusion), but coupled
with the gain of 17q material, may implicate a gene
dose effect. Loss of heterozygosity at the transloca-
tion partner sites may also be important.
The implications of our findings for clinical man-
agement follow from the increasing tendency to tai-
lor therapy on an individual basis according to risk
factors detected at the time of diagnosis. The objective
is to direct the most intensive treatments to children
with the most aggressive tumors, while sparing other
children from the adverse effects of unnecessarily in-
tensive therapy. For neuroblastoma, N-myc gene am-
plification has an important role in determining risk
and is used internationally to stratify therapy for
infants and for children with localized tumors. Specif-
ically, infants with stage 4S disease without N-myc am-
plification who are clinically well are simply observed,
whereas those with N-myc amplification with identical
clinical features receive intensive chemotherapy fol-
lowed by surgery, radiotherapy, and consolidation
with myeloablative therapy.27,28 However, the pres-
ence of N-myc amplification does not ensure com-
pletely accurate prognostic grouping, since 20 per-
cent of infants with metastatic disease and N-myc
amplification in the tumor are long-term survivors
and 20 percent of patients without N-myc amplifica-
tion have recurrence of tumors (Gerrard M: personal
communication).
The ongoing Localized Neuroblastoma European
Study is investigating the hypothesis that 1p allelic
loss is predictive of tumor recurrence in patients with
localized resectable (stage 2) neuroblastomas with-
out N-myc amplification. Preliminary results suggest
that not all recurring tumors have 1p deletion. There-
fore, additional molecular genetic markers are need-
ed to identify which tumors with normal 1p and no
amplification of N-myc are likely to recur.
In our series, gain of 17q emerged as a more im-
portant indicator of adverse outcome than any other
clinical or genetic factor, including 1p deletion and
N-myc amplification. The presence of this abnormality
identified a larger proportion of aggressive tumors and
was more closely linked to outcome than other mark-
ers. Furthermore, the status of 17q was informative
in all tumor stages and was predictive of the out-
come in infants and older children with neuroblas-
toma and in patients with tumors in which N-myc and
1p were both normal. We propose that the detection
of 17q gain in individual tumors at the time of diag-
nosis should be accorded a priority equal to that of
the determination of the status of 1p and N-myc. In
addition, we suggest that investigation of the status
of chromosome 17 should be incorporated into future
clinical trials in patients with neuroblastoma.
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ISCUSSION
In this Chapter, we applied comparative
genomic hybridization (CGH) in order to obtain a
genome wide overview of genetic aberrations in
neuroblastoma, and to gain insights in the
genetic heterogeneity of this enigmatic childhood
tumor.
In Paper I, we analyzed 36 primary untreated
neuroblastoma tumors of both high and low
stage. The major aims of this study were to
identify new frequently involved genetic
aberrations in neuroblastoma, to gain more
information on imbalances not extensively
studied so far, and to further characterize the
genetic heterogeneity of this tumor. During the
course of this work, 4 CGH studies on
neuroblastoma were published, including a small
series of 6 familial tumors1-4. Our aims were
therefore extended to a thorough comparison of
all published results.
One of the major findings in our study was the
presence of predominantly whole chromosome
gains and losses in low stage tumors (stages 1, 2
and 4S), while high stage (3 and 4) tumors
displayed mainly partial chromosome imbalances.
In addition, one or two extra copies of a complete
chromosome 17, and gain of the distal part of the
long arm of chromosome 17 were found to be the
most frequent abnormalities in the low and high
stage tumors, respectively. With one exception,
unbalanced 17q gain was only found in stage 3
and 4 tumors, in association with loss of 11q, or
1p and/or MNA. Partial chromosome losses were
most frequently observed for 1p, 3p and 11q.
Remarkably, 11q deletions were mainly found in
stage 4 tumors, often in association with 3p or
14q deletions. Paper I was the first to pinpoint at
a possible new genetic subgroup of aggressive
neuroblastomas characterized by 11q deletion in
the absence of 1p deletion or MNA.
In one primary tumor without evidence for MNA,
amplification of the 11q13 region was detected.
Subsequent Southern blot analysis demonstrated
amplification of the CCND1 (Cyclin D1) and EMS1
genes, often found amplified in breast cancer and
squamous cell carcinomas of the head and neck5.
Recently, three other primary tumors with 11q13
amplification were found (ref.6 and unpublished
results provided by Dr. Boavida, Lisbon,
Portugal). Furthermore, the observation of 11q13
gain (not amplification) in approximately 5% of
the primary tumors (see Paper II), and the fact
that low-copy 11q13 DNA amplification (< 10
copies) occurs in other tumor types opens the
possibility that 11q13 gain or amplification plays
a role in a subset of neuroblastomas.
Comparison of our results with 3 published CGH
reports revealed that the major findings in all
individual studies were concordant, but from this
analysis, it was apparent that the total number of
tumors in clinical and genetic subgroups was
relatively small for each individual study.
Moreover, associations between particular
imbalances in individual tumors could not always
be determined in the published reports due to the
applied data format. These observations
indicated the need for a larger sampling size and
a uniform data presentation, in order to delineate
more accurately the different genetic subgroups,
and to draw significant conclusions.
In Paper II, we therefore decided to collect 120
published CGH results from 4 studies1-3, 7, and re-
evaluate them together with data from 84 new
cases. This multicenter study yielded a
unprecedented overview of the genomic
imbalances in 204 primary untreated
neuroblastoma tumors. Many of the previously
observed characteristic CGH findings from
individual studies were confirmed and
strengthened by pooling all data. In addition, five
major genetic subgroups could be distinguished.
The largest and hitherto most well known
subgroup contained one third of all tumors, and
was characterized by unbalanced 17q gain, and
1p deletion and/or MNA. The second subgroup
comprised one fourth of all tumors, and showed
only numerical imbalances, revealing for the first
time a nonrandom pattern of gains for
chromosomes 1, 2, 6, 7, 8, 12, 13, 17, 18, and
22, and losses for chromosomes 3, 4, 9, 11, 14,
and X. This pattern of numerical imbalances was
typically observed in low stage tumors (showing
a near-triploid DNA content) from infants with
high survival rates. Particular patterns of whole
chromosome losses and gains have also been
observed in other pediatric tumors with good
prognosis, such as acute lymphoblastic
leukemia8. The biological significance of these
numerical chromosome changes is unknown, but
it’s remarkable that most of the chromosomes
that are underrepresented in low stage
neuroblastomas also show partial losses in high
stage tumors. It’s therefore possible that LOH of
the same (set of) gene(s) plays a role in both
subtypes. Similarly, gain of chromosome 17 and
unbalanced 17q gain are the most frequently
observed chromosomal imbalances in low and
high stage tumors, respectively.
This study further confirmed the existence of a
new third subgroup defined by 11q loss and
unbalanced 17q gain, in the absence of 1p loss
and/or MNA. The majority of these tumors
belonged to stage 4, and were significantly
correlated with loss of 3p, 4p and 14q. A fourth
subgroup contained tumors with predominantly
numerical chromosome changes in combination
with a few structural aberrations (excluding loss
of 1p, 11q or MNA). A last small subgroup
presented with unbalanced 17q gain only.
The initial observation in Paper I and
confirmation in Paper II of a subgroup of (mainly
stage 4) tumors with 11q deletion provided more
insight in the thus far ill defined genetic
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background of high stage tumors lacking MNA.
However, this group of tumors was still relatively
small in Paper II (19 stage 4 tumors with 11q
loss). In order to draw more reliable conclusions
and assess the prognostic value of 11q deletion,
a European multicenter study was set up where
50 additional stage 4 tumors were analyzed and
pooled with 33 published stage 4 cases (Paper
III).
In this study, 36 tumors were identified that
exhibited a partial 11q deletion, always
encompassing more than half of the distal end of
11q. Approximately 60% of stage 4 tumors
without MNA exhibited 11q deletions, whereas
loss of 11q was found in only a minority of
samples with MNA and/or 1p deletion. In addition
to typical absence of MNA and 1p deletion, stage
4 neuroblastomas with loss of 11q were
significantly associated with 3p deletions. These
data therefore strongly suggest that 11q
deletions define a distinct genetic subgroup of
advanced stage tumors. Survival analysis
demonstrated that patients with an 11q deleted
tumor had no significantly different survival
probability compared to patients whose tumor
bears intact chromosomes 11. The same holds
true after stratification for MNA, indicating that
the 11q status has no prognostic value in stage 4
patients. However, further studies remain
necessary to evaluate the impact of the 11q
status for patients treated with new therapeutic
regimens. In this respect, tumors with MNA or
11q deletion should be considered as separate
groups in optimization of treatment protocols,
and in evaluation of clinical results.
In a recent and large LOH study on a series of
310 primary neuroblastomas of all stages, LOH
was found for several 11q loci in as much as 43%
of the cases, with an SRO in the 11q23.3 region9.
As in our study, there was a strong inverse
correlation between 11q LOH and MNA. However,
a significant rate of 11q LOH was found in stage
1 and 2 (30 and 45%, respectively), as well as a
much higher survival probability for patients with
11q LOH (3 year survival of 75% vs. 35% in our
study). This may be explained by the presence of
near triploid low stage tumors in their series,
which often present with whole chromosome 11
loss and favorable prognosis, as shown in Paper
II. Recently, the aforementioned LOH study was
extended with 11p markers to segregate whole
chromosome 11 loss from rearrangements
leading to deletion of distal 11q10. With this
distinction, unbalanced 11q LOH was found in
22% of the cases – a figure in keeping with Paper
II - and was highly correlated with age over 1
year at diagnosis and stage 4 disease, confirming
the conclusions from Paper III.
As mentioned in Chapter 1, several lines of
evidence point at the presence of an 11q tumor
suppressor gene in neuroblastoma. Molecular
(cyto)genetic analyses (including this study)
revealed loss of 11q in approximately 15-30% of
the tumors. Furthermore, rare cases of
constitutional abnormalities of this region in
children who developed neuroblastoma have
been reported (reviewed in ref.11), and
chromosome 11 transfer experiments in cell line
NGP (harboring an 11q deletion) resulted in a
more differentiated phenotype12. Further
molecular studies are thus required to narrow
down the critical region of LOH and to identify the
putative tumor suppressor gene on 11q involved
in neuroblastoma development or progression.
One of the most striking findings in the CGH
analyses of neuroblastoma was the frequent
occurrence of extra chromosomes 17 or
unbalanced 17q gain in low and high stage
tumors, respectively. In view of the reported
association of unbalanced 17q gain with adverse
prognostic factors, we sought to test the
hypothesis that this abnormality was an
independent predictor for poor outcome (Paper
IV). To this end, clinical information and genetic
data (obtained by FISH and CGH) on at least the
17q, 1p, and MYCN status for 313 patients with
neuroblastoma were collected at six European
centers.
Unbalanced 17q gain was found in half of all
tumor samples, and was confirmed to be strongly
associated with stage 4 disease, age at diagnosis
over 1 year, DNA content in the diploid/tetraploid
range, MNA, and 1p deletion. In univariate
analyses of survival, the 17q status as well as the
above mentioned genetic and clinical factors were
significant predictors for patient outcome.
However, in a multivariate analysis with age,
stage, 1p, MNA and 17q as factors, 17q was the
most significant predictor for clinical outcome,
followed by stage 4 disease and 1p deletion. In
this analysis, MNA and age were no independent
prognostic factors. The lack of independent
discriminative power of MNA might be explained
by the fact that this genetic alteration was not
found in any tumor without concurrent 1p
deletion, 17q gain, or both. This suggests that
MNA is a later event in the sequence of genetic
alterations that lead to a clinically manifest
tumor.
Cytogenetic and metaphase FISH studies have
demonstrated that the principle mechanism
underlying partial gain of 17q is an unbalanced
translocation, with a variety of partner
chromosomes13-16. These translocations typically
result in concurrent loss of the partner
chromosome distal to the breakpoint, and gain of
a distal 17q segment. The most common sites of
these translocations are chromosome arms 1p
and 11q, and account for approximately half of
all 1p and 11q deletion events in neuroblastoma
(reviewed in ref.11). Similar 17q translocations
have been observed on many other chromosome
arms, including 3p, 4p, 9p, and 14q. The
significance of unbalanced 17q gain as a
mechanism for LOH on the partner chromosome
remains to be investigated, but could possibly
account for the observed adverse prognosis
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associated with partial 17q gain. Alternatively, in
view of the different survival probabilities for
patients whose tumor displays an extra copy of
the complete chromosome 17 or the distal 17q
fragment only, an imbalance of genes located on
opposite sides of the 17q breakpoint could be
responsible for the aggressive behavior.
The molecular mechanism leading to preferential
involvement of 17q in unbalanced translocations
is unknown. Recently, the 17q breakpoint of a
constitutional balanced t(1;17) in a patient who
developed neuroblastoma was located in a 25 kb
sequenced region, which is thought to be
genetically unstable17. The cloning and
sequencing of additional 17q breakpoints could
indicate whether sequences at or near these
breakpoints share homologous stretches that are
particularly prone to recombination in developing
neuroblasts. So far, breakpoint mapping in
tumors and cell lines has revealed that the 17q
breakpoints are scattered along the proximal half
of the long arm18, 19, which argues against a
specific gene effect (e.g. fusion gene). Although
it cannot be ruled out that functionally related
genes belonging to the same family are
implicated in these different breakpoints, the
mapping data strongly suggest that a gene
dosage effect of one or more genes on distal 17q
are involved in neuroblastoma development.
Possible candidate genes include the NME1/2
genes at 17q21.3 and the BIRC5 (survivin) gene
at 17q25. Increased expression of the metastasis
related NME1 gene was observed in advanced
stage neuroblastomas20-22, with missense
mutations in a small subset of these tumors21, 23.
Furthermore, the NME1/2 genes were recently
found to be MYCN downstream genes24, which
provides further support for a possible role of
these genes in unfavorable neuroblastomas.
Another gene which might be the target of
consistent gain of 17q in neuroblastoma is
BIRC5. This anti-apoptotic protein has been
associated with a more aggressive tumor
phenotype, and promotion of cell survival25, 26.
Clearly, additional studies are required to
substantiate a role of these genes in
neuroblastoma, or to identify other 17q candidate
genes responsible for tumor development or
progression.
Similar oncogenic mechanisms whereby an extra
copy of a single gene lead to specific cancer
types have been reported. A recent study
demonstrated that an extra copy of the ATR gene
due to isochromosome 3q formation contributes
to rhabdomyosarcoma27. Likewise, duplication of
a chromosome 7 carrying a mutated MET allele is
implicated in hereditary papillary renal cell
carcinoma28, and patients with Down’s syndrome
have a 10-20 fold increased risk of developing
leukemia29. The presence of extra copies of 17q
in the majority of both low (due to whole
chromosome gain) and high stage tumors implies
that genes on 17q are involved in the initiating
steps of neuroblastoma development. Further
research is warranted to elucidate the biological
role of chromosome 17 alterations in
neuroblastoma.
In conclusion, the 17q status was shown to be a
more important indicator of adverse outcome
than any other clinical or genetic factor, and it
allowed identification of a larger proportion of
prognostically poor tumors than any other
marker. We therefore suggest that assessment of
the 17q status in neuroblastoma should be
incorporated into future clinical trials.
In conclusion, Chapter 2 has illustrated the power
of CGH in whole genome screening for structural
and numerical chromosome aberrations in
neuroblastoma, in particular for the analysis of
localized tumors for which little genetic
information was available apart from ploidy, 1p
and MYCN status. A nonrandom pattern of whole
chromosome gains and losses was defined for
these tumors, with extra copies of chromosome
17 present in most cases. In contrast, partial
gain of 17q was the most frequently observed
abnormality in high stage tumors, and was shown
to be the most significant independent factor for
poor outcome. Within this group of high stage
tumors, two genetically distinct subgroups could
be delineated : a first well-known group of
tumors with 1p deletion, MNA or both; and a
newly identified group of tumors with loss of 11q,
often in association with loss of 3p.
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Background
Gene expression analysis plays an increasingly
important role in many fields of biological research.
Understanding patterns of expressed genes is expected
to provide insight into the complex regulatory networks
and will most probably lead to the identification of genes
relevant to new biological processes. Two recently
developed methods to measure transcript abundance
have gained much popularity and are frequently applied.
Microarrays allow the parallel analysis of thousands of
genes in two differentially labeled RNA populations [1],
while real-time reverse transcriptase PCR (RT-PCR)
provides the simultaneous measurement of gene
expression in many different samples for a limited
number of genes, and is especially suited when only a
small number of cells are available [2-4]. Both
techniques have the advantage of speed, throughput
and a high degree of potential automation compared to
conventional quantification methods, such as Northern
blot analysis, ribonuclease protection assay, or
competitive RT-PCR. Nevertheless, these novel
approaches require the same kind of normalization as
for the traditional methods of mRNA quantification.
Several variable factors need to be controlled for during
gene expression analysis, such as the amount of starting
material, enzymatic efficiencies, and differences
between tissues or cells in overall transcriptional activity.
Various strategies have been applied to normalize these
variations. Under controlled conditions of reproducible
extraction of good quality RNA, the gene transcript
number is ideally standardized to the number of cells,
but accurate enumeration of cells is often precluded, e.g.
when starting from solid tissue. Another frequently
applied normalization scalar is the RNA mass quantity,
especially in Northern blot analysis. Several arguments
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Background: Gene expression analysis plays an increasingly important role in many fields
of biological research, with real-time RT-PCR becoming the method of choice for high-
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sensitivity, reproducibility and large dynamic range of this methodology, the requirements for
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Although it has been reported that housekeeping gene expression can vary considerably, no
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validated as an accurate normalization factor by analyzing publicly available microarray
data.
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against the use of mass quantity can be raised. The
quality of RNA and related efficiency of the enzymatic
reactions are not taken into account. Moreover, in some
instances it is impossible to quantify this parameter, e.g.
when only minimal amounts of RNA are available from
microdissected tissues. Probably the strongest argument
against the use of total RNA mass for normalization is
the fact that this consists predominantly of ribosomal
RNA (rRNA) molecules that are not always
representative for the messenger RNA (mRNA) fraction,
which was recently evidenced by a significant imbalance
between ribosomal and messenger RNA content in
approximately 7.5% of mammary adenocarcinomas [5].
Also, it has been reported that  rRNA transcription is
affected by biological factors and drugs [6-8]. Further
drawbacks to the use of 18S or 28S rRNA molecules as
standards are their absence in mRNA purified samples,
and their high abundance compared to target mRNA
transcripts, the latter making it difficult to accurately
subtract the baseline value in real-time RT-PCR data
analysis.
To date, internal control genes are most frequently
used to normalize the mRNA fraction. This internal
control –often referred to as housekeeping gene– should
not vary in the tissues or cells under investigation, or in
response to experimental treatment. However, many
studies make use of these constitutively expressed
control genes without a proper validation of their
presumed expression stability. It is shown in the
literature though that housekeeping gene expression –
although occasionally constant in a given cell type or
experimental condition – may vary considerably
(reviewed in [9-12]). With the increased sensitivity,
reproducibility and large dynamic range of real-time RT-
PCR methods, the requirements for a proper internal
control gene have become increasingly stringent. In this
study, we performed an extensive evaluation of 10
commonly used housekeeping genes in 13 different
human tissues, and outlined a procedure for calculation
of a normalization factor based on multiple control genes
for more accurate and reliable normalization of gene
expression data. Furthermore, this normalization factor
was validated in a comparative study with frequently
applied microarray scaling factors using publicly
available microarray data.
Results
Expression profiling of housekeeping genes
Primers were designed for ten commonly used
housekeeping genes (ACTB, B2M, GAPD, HMBS,
HPRT1, RPL13A, SDHA, TBP, UBC and YWHAZ) (see
Table 1 for full gene name, alias, chromosomal
localization and function; and Table 2 for primer
sequences). Special attention was paid to select genes
that belong to different functional classes, which
significantly reduces the chance that genes might be co-
regulated.  The expression level of these ten internal
control genes was determined in 34 independently
prepared neuroblastoma cell lines, 20 short term
cultured normal fibroblast samples from different
individuals, 13 normal leukocyte samples, 9 normal bone
marrow samples, and 9 additional normal human tissues
from pooled organs (heart, brain, fetal brain, lung,
trachea, kidney, mammary gland, small intestine and
uterus). The raw expression values are available as a
tab delimited file (raw_data.txt).
Single control normalization error
To determine the possible errors related to the
common practice of using only one housekeeping gene
for normalization, we calculated the ratio of the ratios of
two control genes in two different samples (from the
same tissue panel) and termed it the single control
normalization error E (see Materials & Methods). For two
ideal internal control genes (constant ratio between the
genes in all samples), E equals 1. In practice, observed
E values are larger than one and constitute the
erroneous E-fold expression difference between two
samples depending on the specific housekeeping gene
used for normalization. For all 45 two-by-two
combinations of control genes and 865 two-by-two
sample combinations within the available tissue panels
(neuroblastoma, fibroblast, leukocyte, bone marrow and
a series of normal tissues from Clontech) (i.e. a total of
38,925 data points), E-values were calculated (Figure 1).
In addition, the systematic error distribution was
calculated by analysis of repeated runs of the same
control gene. The average 75th and 90th percentile E
values are 3.0 (range 2.1 - 3.9), and 6.4 (range 3.0 -
10.9), respectively.
Gene stability measure and ranking of selected
housekeeping genes
It is generally accepted that gene expression levels
should be normalized by a carefully selected stable
internal control gene. However, to validate the presumed
stable expression of a given control gene, prior
knowledge of a reliable measure to normalize this gene
in order to remove any non-specific variation is required.
To address this circular problem, we developed a gene
stability measure to determine the expression stability of
control genes based on non-normalized expression
levels. This measure relies on the principle that the
expression ratio of two ideal internal control genes is
identical in all samples, regardless of the experimental
condition or cell type. In this way, variation of the
expression ratios of two real life housekeeping genes
reflects the fact that one (or both) of the genes is (are)
Figure 1: Cumulative distribution plot of single control
normalization error values (E) for the different tissue
panels.
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not constantly expressed, with increasing ratio variation
according to decreasing expression stability. For every
control gene, we determined the pairwise variation with
all other control genes as the standard deviation of the
logarithmic transformed expression ratios, and defined
the internal control gene stability measure M as the
average pairwise variation of a particular gene with all
other control genes. Genes with the lowest M values
have the most stable expression. Assuming that the
control genes are not co-regulated, stepwise exclusion
of the gene with the highest M value results in a
combination of two constitutively expressed
housekeeping genes that have the most stable
expression in the tested samples. To manage the large
number of calculations, we have written a Visual Basic
Application (VBA) for Microsoft Excel -termed geNorm-
that automatically calculates the expression stability
measures M for all control genes in a given set of
samples (geNorm can be obtained from the authors on
request). The program allows elimination of the worst
scoring housekeeping gene (i.e. with the highest M
value) and recalculation of new M values for the
remaining genes. Using this VBA applet, we ranked the
10 control genes in the 5 tested tissue panels according
to their expression stability (Figure 2, and Table 3). In
addition, the systematic variation was calculated as the
pairwise variation V for repeated RT-PCR experiments
of the same gene, reflecting the inherent machine,
enzymatic and pipet variation.
Normalization factor calculation based on the geometric
mean of multiple control genes
From the above we concluded that in order to
measure expression levels accurately, normalization by
multiple instead of one single housekeeping gene is
required. Consequently, a normalization factor based
upon the expression levels of the best performing
housekeeping genes must be calculated. For accurate
averaging of the control genes, we propose to use the
geometric mean instead of the arithmetic mean, as the
former controls better for possible outlying values and
abundance differences between the different genes. The
number of genes used for geometric averaging is a trade
off between practical considerations and accuracy. It is
obvious that an accurate normalization factor should not
include the rather unstable genes that were observed in
some tissues. On the other hand, it remains relatively
impractical to quantify e.g. 8 control genes when only a
few target genes need to be studied, or when only
minimal amounts of RNA are available. Furthermore, it is
a waste of resources to quantify more genes than
necessary if all genes are relatively stably expressed
and if the normalization factor do not significantly change
whether or not more genes are included. Considering all
Figure 2: Average expression stability values (M) of
remaining control genes during stepwise exclusion of the
least stable control gene in the different tissue panels
(black circle: neuroblastoma; white circle: normal pool;
white square: bone marrow; black square: leukocyte;
gray circle: fibroblast, gray square: systematic error)
(see also Table 3 for the ranking of the genes according
to their expression stability).
Figure 3: Top: Pairwise variation (Vn/n+1) analysis
between the normalization factors NFn and NFn+1 to
determine the number of control genes required for
accurate normalization (arrowhead = optimal number of
control genes for normalization). Bottom: Selected
scatterplots of normalization factors before (x-axis) and
after (y-axis) inclusion of an (n+1)th control gene (r =
Spearman rank correlation coefficient). Low variation
values V correspond to high correlation coefficients. It is
clear that there is no need to include more than 3, 4 or 5
control genes for fibroblast (A), neuroblastoma (B) and
the normal pooled tissues (D), respectively. In contrast,
panel C demonstrates that inclusion of at least a fourth
gene is required for the normal pooled tissues.
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the above, we recommend the minimal use of the 3 most
stable internal control genes for calculation of an RT-
PCR normalization factor (NFn, n=3), and stepwise
inclusion of more control genes until the (n+1)th gene has
no significant contribution to the newly calculated
normalization factor (NFn+1). To determine the possible
need or use of including more than 3 genes for
normalization, the pairwise variation Vn/n+1 was calculated
between the two sequential normalization factors (NFn
and NFn+1) for all samples within the same tissue panel
(with aij=NFn,i and aik=NFn+1,i, n the number of genes
used for normalization (3≤n≤9), and i the sample index;
see Equation 2 and 3). A large variation means that the
added gene has a significant effect and should
preferably be included for calculation of a reliable
normalization factor. For all tissue types, normalization
factors were calculated for the three most stable control
genes (i.e. with the lowest M value) and for 7 additional
factors by stepwise inclusion of the most stable
remaining control gene. Pairwise variations were
subsequently calculated for every series of NFn and
NFn+1 normalization factors, reflecting the effect of
adding an (n+1)th gene (Figure 3 top). It is apparent that
the inclusion of a 4th gene has no significant effect (i.e.
low V3/4 value) for leukocytes, fibroblasts and bone
marrow. This is also illustrated by the nearly perfect
correlation between NF3 and NF4 values, as shown for
fibroblasts in Figure 3 bottom. Based on these data, we
decided to take 0.15 as a cut-off value, below which the
inclusion of an additional control gene is not required.
For neuroblastoma and the pool of normal tissues, one
and two additional genes, respectively, are necessary for
reliable normalization (see also Figure 3 bottom).  The
high V8/9 and V9/10 values for the normal pool,
neuroblastoma, and leukocyte panel corroborate very
well the findings obtained by stepwise exclusion of the
worst scoring control gene (Figure 2). This analysis
showed an initial steep decrease in average M value,
Table 1: Internal control genes evaluated in this study
symbol name function localization alias IMAGE*
ACTB beta actin cytoskeletal structural protein 7p15-p12 510455
B2M beta-2-microglobulin beta-chain of major histocompatibility complex class I
molecules
15q21-q22 51940
GAPD glyceraldehyde-3-phosphate dehydrogenase oxidoreductase in glycolysis and gluconeogenesis 12p13 510510
HMBS hydroxymethylbilane synthase heme synthesis, porphyrin metabolism 11q23 porphobilinogen
deaminase
245564
HPRT1 hypoxanthine phosphoribosyltransferase 1 purine synthesis in salvage pathway Xq26 345845
RPL13A ribosomal protein L13a structural component of the large 60S ribosomal subunit 19q13 23 kD highly
basic protein
-
SDHA succinate dehydrogenase complex, subunit A electron transporter in the TCA cycle and respiratory
chain
5p15 375812
TBP TATA box binding protein general RNA polymerase II transcription factor 6q27 280735
UBC ubiquitin C protein degradation 12q24 510582
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta
polypeptide
signal transduction by binding to phosphorylated serine
residues on a variety of signaling molecules
2p25 phospholipase
A2
416026
* IMAGE cDNA clone number according to [14]
Figure 4: Validation of the gene stability measure (A) and geometric averaging of carefully selected control genes for
normalization (B). A: Average gene-specific variation (determined as coefficient of variation, in %) for the 3 control genes
with the smallest variation within each tissue panel after normalization with 3 different factors calculated as the geometric
mean of the 3 control genes with the lowest (NF3(1-3)), highest (NF3(8-10)) and intermediate (NF3(6-8)) gene stability values
(as determined by geNorm) (NB: neuroblastoma, POOL: normal pooled tissues, LEU: leukocytes, BM: bone marrow,
FIB: fibroblasts). B: Comparison of frequently applied microarray scaling factors and the proposed RT-PCR
normalization factor based on the geometric mean of selected control genes (NF5:  geomean of the 5 control genes with
the lowest M value, NFM<0.7: geomean of control genes with M value lower than 0.7; see Result section), calculated for 8
hybridizations from publicly available microarray data [14].
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pointing at two aberrantly expressed control genes for
leukocytes and one unstable gene for neuroblastoma
and the pool of normal tissues. Furthermore, the need to
include additional control genes for these last two tissue
panels is in keeping with the high variation in control
gene expression as evidenced from Figure 2.
Validation of proposed real-time RT-PCR normalization
factors
To assess the validity of the established gene
stability measure, i.e. that genes with the lowest M
values have indeed the most stable expression, we
determined the gene-specific variation for each control
gene as the variation coefficient of the expression levels
after normalization. This coefficient should be minimal
for proper housekeeping genes. Three different
normalization factors were calculated, based on the
geometric mean of 3 genes with respectively the lowest
(NF3(1-3)), the highest (NF3(8-10)), and intermediate M
values (NF3(6-8)) (as determined by geNorm). We
subsequently determined the average gene-specific
variation of the 3 genes with the most stable expression
(i.e. the lowest variation coefficient) for each
normalization factor and within each tissue panel (Figure
4A). It is clear that the gene-specific variation in all tissue
panels is by far the smallest when the data are
normalized to NF3(1-3). This demonstrates that the gene
stability measure effectively identified the control genes
with the most stable expression. To verify that a high M
value is characteristic for an unstable or differentially
expressed gene, we analyzed the expression level of
MYCN  –a highly differentially expressed proto-
oncogene in neuroblastoma with prognostic value [13]–
together with the set of 10 housekeeping genes. MYCN
was readily identified as the most differentially
expressed gene, with an M value of 6.02 compared to
2.17 for the least stable control gene B2M in
neuroblastoma. It was further observed that
normalization with a single control gene consistently
resulted in significantly higher gene-specific variations of
the other control genes (data not shown), which
underscores the improved normalization by using
multiple housekeeping genes.
To further validate the accuracy of geometric
averaging of carefully selected control genes for
normalization, the geometric means of housekeeping
gene expression levels from publicly available
microarray data were compared with commonly applied
Table 2: Primer sequences internal control genes
symbol † forward primer reverse primer
ACTB CTGGAACGGTGAAGGTGACA AAGGGACTTCCTGTAACAATGCA
B2M TGCTGTCTCCATGTTTGATGTATCT TCTCTGCTCCCCACCTCTAAGT
GAPD TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG
HMBS * GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT
RPL13A CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT
YWHAZ ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT
† TBP primer sequences are described in [23]
* HMBS primer sequences kindly provided by E Mensink and L van de Locht
(Nijmegen, The Netherlands)
Table 3: Ranking of control genes according to their expression stability
(increasing from top to bottom) *
neuroblastoma fibroblast leukocyte bone marrow normal pool
B2M HMBS ACTB ACTB B2M
RPL13A B2M HMBS B2M ACTB
ACTB RPL13A HPRT1 HMBS YWHAZ
TBP SDHA SDHA TBP RPL13A
YWHAZ TBP TBP SDHA UBC
HMBS ACTB RPL13A GAPD TBP
UBC UBC GAPD HPRT1 HPRT1
SDHA YWHAZ B2M YWHAZ HMBS
HPRT1 - GAPD HPRT1 - GAPD UBC - YWHAZ UBC - RPL13A SDHA - GAPD
* the two most stable control genes can't be further ranked due to the required use of
gene ratios for expression stability measurements
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microarray normalization factors calculated for the same
data. To this purpose, an 8000 gene array data set [14]
was chosen containing 9 of the 10 control genes
evaluated in this RT-PCR study. Two commonly applied
microarray normalization factors (based on median ratio
normalization, and total intensity normalization) [15-17]
were determined for 8 randomly selected hybridization
sets. Subsequently, for each hybridization set, the
background corrected expression levels of 9
housekeeping genes for the two fluorescence channels
were imported in geNorm and ranked as described for
the RT-PCR data. As these microarray data originate
from hybridizations of cell lines from various histological
origin versus a reference pool of multiple cell lines, we
have calculated the geometric mean of the 5 most stable
control genes (NF5) for each hybridization set, in
accordance to the recommendations for reliable
normalization within a heterogeneous tissue panel (see
previous paragraph). Alternatively, internal control genes
were stepwise excluded until the M values of the
remaining genes were below 0.7 (experimental value
shown to eliminate the most variable and outlying genes
in this microarray dataset). Depending on the
hybridization set, 7 to 9 genes fitted this criterion, upon
which the geometric mean was calculated (NFM<0.7). Both
normalization factors (NF5 and NFM<0.7) were shown to
be similar to the calculated microarray normalization
factors (Figure 4B).
Tissue specific housekeeping gene expression
In order to compare the control gene expression
levels within the heterogeneous group of all 13 tested
tissues, the same set of control genes should be used
for normalization. We therefore calculated the geometric
mean of 6 control genes that were withheld from the set
of 10 genes after elimination of the two genes with the
highest M value within each tissue panel (i.e. B2M,
RPL13A, ACTB and HMBS) (see Table 3). Given the
large variety of tested tissues, this is the optimal strategy
to eliminate most variation, and to allow direct
comparison between the different samples. Under the
assumption of equal PCR threshold cycle values for
equal transcript numbers of different genes, an
estimation of the transcript abundance of the various
control genes can be made. Figure 5 shows that the 10
tested genes belong to various abundance classes, with
an approximately 400 fold expression difference
between the most abundant (ACTB) and most rare
(HMBS) transcript. Although the overall abundance of a
given control gene in the different tissues is relatively
similar, we clearly observe tissue specific expression
differences, e.g. B2M is 112 fold higher expressed in
leukocytes compared to fetal brain, and ACTB shows an
expression difference of 22 fold between fibroblasts and
heart tissue. It is also clear that some genes display a
relatively constant expression level (e.g. UBC and
HPRT1) compared to the differential expression pattern
of others (e.g. B2M and ACTB).
Discussion
Accurate normalization of gene expression levels is
an absolute prerequisite for reliable results, especially
Figure 5: Logarithmic histogram of the expression levels of 10 internal control genes determined in 13 different human
tissues.
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when the biological significance of subtle gene
expression differences is studied. Still, little attention has
been paid to the systematic study of normalization
procedures and the impact on the conclusions. For RT-
PCR, there is a general consensus of using a single
control gene for normalization purposes. A
comprehensive literature analysis of expression studies
published in high impact journals during 1999 indicated
that GAPD, ACTB, 18S and 28S rRNA were used as
single control genes for normalization in more than 90%
of the cases [11]. As numerous studies reported that
housekeeping gene expression can vary considerably [6,
9-12], the validity of the conclusions is highly dependent
on the applied control. Some laboratories have tried to
find the optimal control gene for their experimental
system, and often rRNA molecules were proposed as
best references. Caution has to be taken with these
studies, as often only the expression variation of tested
genes with respect to the mass loading of total RNA was
assessed. As the rRNA molecules make up the bulk of
total RNA, they should indeed correlate very well with
the total RNA mass, but that does not necessarily make
them good control genes. As outlined in the introduction,
total RNA and ribosomal RNA levels are no proper
references, due to the observed imbalance between
ribosomal and messenger RNA fractions.
In addition to the search for a stable control gene,
we aimed at determining the errors related to the
common practice of single control normalization. In this
study, we have provided evidence that a conventional
normalization strategy based on a single housekeeping
gene leads to erroneous normalization up to 3.0 and 6.4
fold in 25% and 10% of the cases, respectively, with
sporadic cases showing error values above 20. This
analysis demonstrated that a few control genes were
unstable and significantly differentially expressed in
some tissue panels, as evidenced from the 5.9 to 4.5
decrease in 90th percentile single control normalization
error value for neuroblastoma by leaving out the B2M
gene (not shown). This finding is in keeping with the
reported differential expression of B2M in
neuroblastoma, corresponding to the stage of
differentiation of the tumor cells [18]. The error
distribution curves not only reflect the expression
stability of the applied controls, but also the sample
heterogeneity within a tissue panel, as noticed from the
less steeper curve for the heterogeneous set of normal
pooled tissues compared to the other relatively
homogeneous tissue panels. With regard to this, the
issue has been raised that finding proper control genes
is even more important when working with tissues from
different histological origin [9].
The single control normalization error values
point at inherent noisy oscillations in expression level of
the control genes, a finding which has been corroborated
in other large scale reports where several thousand
genes were measured in different cells or tissues by
means of microarray analysis. No gene was found on an
8000 feature array that did not vary by ratios of at least 2
fold across a panel of 60 cell lines [14], and a set of
genes frequently used for normalization (including GAPD
and ACTB) was found to vary in expression by 7- to 23-
fold [9]. Taken all together, our data and these studies
clearly demonstrate that ideal and universal control
genes do not exist. This warrants the search for stably
expressed genes in each experimental system, and for
the development of an accurate normalization strategy.
In order to validate the expression stability of tested
control genes without any prior assumption of metric for
standardization, we had initially measured the correlation
between the raw, non-normalized expression levels of
any two control genes, which should be nearly perfect
for proper control genes. We observed however that the
data range between the minimum and maximum
expression levels, or any outlying value could have a
profound influence on the slope of the regression line,
and consequently on the value of the correlation
coefficient. This made Pearson and Spearman
correlation coefficients not suitable for this kind of
analysis. We have therefore developed a new stability
measure, based on the principle that the expression ratio
of two proper control genes should be identical in all
samples, regardless of the experimental condition or cell
type, with increasing ratio variation according to
decreasing expression stability of one (or both) of the
tested genes. The proposed standard deviation of log
transformed control gene ratios is a robust measure for
the variation between two control genes, as it does not
impose any requirements for normality or
homoscedasticity of the data points. Furthermore, this
measure is independent of the abundance difference
between the genes, and equally affected by any outlying
or extreme ratio (i.e. outliers for a sample with low or
high overall expression, or outliers caused by an
upregulated or downregulated gene have an equivalent
increase in pairwise variation V). Logarithmic
transformation of the ratios is required for symmetrical
distribution of the data around zero, resulting in equal
absolute values (but opposite signs) for a given ratio and
the inverse ratio. As a result, the standard deviation of
log transformed ratios is identical to the standard
deviation of log transformed inverse ratios, which makes
this measure characteristic for every combination of two
genes.
Having established a robust measure to assess the
expression variation between two control genes, we
subsequently defined a gene stability measure M as the
average pairwise variation between a particular gene
and all other control genes. Using our in-house
developed VBA applet geNorm, we ranked 10 commonly
used housekeeping genes belonging to different
functional and abundance classes according to their
expression stability in 5 tested tissue panels. The clear
decrease of the average gene stability measure M value
of the remaining control genes during stepwise exclusion
of the worst scoring gene points at gene-specific
expression stability differences and demonstrates that
the remaining genes are more stably expressed
compared to the excluded genes. Some tissue panels
show a relatively steep initial decline, which reflect the
exclusion of one or more aberrantly expressed control
genes (e.g. ACTB and HMBS for leukocytes), as also
noticed from the single control normalization error
analyses (cf. supra). The average gene stability values
of the remaining genes during stepwise elimination of
the least stable control genes also indicates tissue
specific differences, with bone marrow and the pool of
normal tissues having the lowest and highest overall
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expression variation, respectively. The latter is no
surprise, given the larger tissue heterogeneity in this
panel. The question if the observed high variation for
neuroblastoma is a cancer related phenomenon of
deregulated expression is currently under further
investigation. From these analyses, it is clear that there
is no universal control gene suitable for all cell types.
ACTB and B2M appear to be the worst scoring genes,
while UBC, GAPD and HPRT1 seem to be the best
overall control genes, each belonging to the four most
stable genes in 4 out of 5 tested tissues. However,
caution has to be taken with these generalizations. B2M
appears to be one of the least stable control genes, but
nevertheless is a good choice for normalization of
leukocyte expression levels. This clearly demonstrates
that a proper choice of housekeeping genes is highly
dependent on the tissues or cells under investigation.
This point is even made stronger when considering the
transcript abundance differences of some control genes
between the various tissues. The large expression
differences between the tested tissues for B2M and
ACTB for instance would definitely result in large
normalization errors when used for standardization.
Interestingly, the observed tissue specific expression of
these control genes is in keeping with their known role or
function: high B2M expression in leukocytes, where it’s a
major cell surface marker, and relatively low non-muscle
cytoskeletal ACTB expression in heart tissue that is
predominantly of muscular origin.
With the ability to rank control genes according to
their expression stability, and given the observed
inherent expression variation (resulting in relatively large
single control normalization errors), we proposed the use
of at least 3 proper control genes for calculation of a
normalization factor. We also presented a procedure to
determine whether or not more than 3 control genes
were required for reliable normalization. This analysis
clearly showed that 3 stable control genes sufficed for
accurate normalization of samples with relatively low
expression variation (e.g. leukocytes, fibroblasts and
bone marrow). For the other tissue panels, a fourth and
fifth control gene were required to capture the observed
variation in neuroblastoma and the pool of normal
human tissues, respectively.
The purpose of normalization is to remove the
sampling differences (such as input amount and RNA
quality) in order to identify real gene-specific variation.
For proper internal control genes, this variation should
be minimal or nihil. To validate the expression stability
measure M and the geNorm algorithm to identify the
most stable control genes in a set of samples, we have
calculated the gene-specific variation for each gene as
the coefficient of variation of normalized expression
levels. To this purpose, the raw expression values were
standardized to different normalization factors,
calculated as the geomean of the most, intermediate or
least stable control genes (as determined by geNorm).
The rationale of this analysis is that a normalization
factor based on proper internal control genes should
remove all non-specific variation. In contrast, unstable
control genes cannot completely remove the non-
specific variation, and even add additional variation,
resulting in larger so-called gene-specific variations for
the tested control genes. This analysis clearly
demonstrated that most non-specific variation was
removed when the most stable control genes (as
determined by geNorm) were used for normalization,
which proves that the novel stability measure and
presented strategy effectively allowed the assessment of
gene expression stability in the different tissue panels.
Further validation demonstrated that the geometric
mean of carefully selected control genes is an accurate
estimate for the mRNA transcript fraction, as determined
by comparison with frequently applied microarray
normalization factors. Although both RT-PCR
normalization factors based on geometric averaging are
relatively similar, the one based on at least 7 control
genes (i.e. NFM<0.7) is slightly more equivalent to the
microarray scaling factors. Two possible explanations
can account for this observation. First of all, the 5 most
stable control genes as determined by geNorm are
based on only 2 RNA samples (i.e. a Cy3 labeled
reference pool, and a Cy5 labeled test sample), in
contrast to the RT-PCR data, where 9 to 34 samples
were used, resulting in more reliable estimation of the
expression stability. Secondly,  recent technical reports
clearly state that array hybridization analyses experience
considerable –often underestimated– variation and
uncertainty at several levels. Accurate background
fluorescence correction  and spot quality assessment,
amongst others, have been described as critical issues
for reliable ratio estimation [19-21]. The higher variability
associated with array hybridization results might thus
explain the need for more control genes to normalize the
data. Nevertheless, this study clearly showed that
normalization based on the geometric mean of carefully
selected control genes result in equivalent ratio
estimation compared to commonly applied array scale
factors, which validates its use for RT-PCR
normalization. In addition, the presented method could
easily be applied to normalize gene expression levels
resulting from microarray hybridization experiments,
where only a limited number of genes are spotted,
including some housekeeping genes.
In conclusion, we described and validated a
procedure to identify the most stable control genes in a
given set of tissue samples, and to determine the
optimal number of genes required for reliable
normalization of RT-PCR data. The presented strategy
can be applied to any number or kind of genes or
tissues, and should allow more accurate gene
expression profiling. This is of utmost importance for
studying the biological significance of subtle expression
differences, and for confirmative and/or extended
analyses of microarray results by means of RT-PCR.
Materials and Methods
Sample preparation
Thirty-four neuroblastoma cell lines were grown to
subconfluency according to standard culture conditions.
RNA was isolated using the RNeasy Midi Kit (Qiagen)
according to the manufacturer's instructions. Nine RNA
samples from pooled normal human tissues (heart,
brain, fetal brain, lung, trachea, kidney, mammary gland,
small intestine and uterus) were obtained from Clontech.
Blood and fibroblast biopsies were obtained from 13 and
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14 different normal healthy individuals, respectively.
Thirteen leukocyte samples were isolated from 5 ml
fresh blood using Qiagen’s erythrocyte lysis buffer.
Fibroblast cells from 20 upper arm skin biopsies were
short time cultured (3-4 passages) according to standard
procedures. Bone marrow samples were obtained from 9
patients with no hematological malignancy. Total RNA of
leukocyte, fibroblast and bone marrow samples was
extracted using the Trizol reagent (Invitrogen), according
to the manufacturer.
Real-time RT-PCR
DNase treatment, cDNA synthesis, primer design
and SYBR Green I RT-PCR were performed as
described [22]. In brief, two micrograms of each total
RNA sample was treated with the RQ1 RNase-free
DNase according to the manufacturer (Promega).
Treated RNA samples were desalted prior to cDNA
synthesis using Microcon-100 spin columns (Millipore).
First strand cDNA was synthesized using random
hexamers and SuperscriptII RT-enzyme according to the
manufacturer (Invitrogen), and subsequently diluted with
nuclease free water (Sigma) to 12.5 ng/µl cDNA. RT-
PCR amplification mixtures (25 µl) contained 25 ng
template cDNA, 2X SYBR Green I Master Mix buffer
(12.5 µl) (Applied Biosystems) and 300 nM of forward
and reverse primer. Reactions were run on an ABI
PRISM 5700 Sequence Detector (Applied Biosystems).
The cycling conditions comprised 10 min polymerase
activation at 95° C and 40 cycles at 95° C for 15s and
60° C for 60s. Each assay included (in duplicate): a
standard curve of 4 serial dilution points of SK-N-SH or
IMR-32 cDNA (ranging from 50 ng to 50 pg), a no-
template control, and 25 ng of each test cDNA.
Sequence Detection Software (version 1.3) (Applied
Biosystems) results were exported as tab delimited text
files and imported in Microsoft Excel for further analysis.
The median coefficient of variation (based on calculated
quantities) of duplicated samples was 6%.
Single control normalization error E
For any given m tissue samples, real-time RT-PCR
gene expression levels aij of n internal control genes are
measured. For every combination of two tissue samples
p and q, and every combination of two internal control
genes j and k, the single control normalization error E
was calculated (1). This is the fold expression difference
between samples p and q when normalized to
housekeeping gene j or k.
( [ ]nkj ,1, ∈∀ , [ ]mqp ,1, ∈∀ , kj ≠ and qp ≠ ):
pj
pk
qk
qj
jkpq a
a
a
a
R ⋅=  (if R<1, then E=R-1, else E=R) (1)
Internal control gene stability measure M
For every combination of two internal control genes j and
k, an array Ajk of m elements is calculated which consist
of log2 transformed expression ratios aij/aik (2). We
define the pairwise variation Vjk for the control genes j
and k as the standard deviation of the Ajk elements (3).
The expression stability measure Mj for control gene j is
the arithmetic mean of all pairwise variations Vjk (4).
Array data normalization
Publicly available raw microarray data [14] were
downloaded as tab delimited files. Eight hybridization
data sets were randomly selected and imported in
Microsoft Excel software for further manipulation (MCF7,
DU-145, 786-0, BC2, K562, A549, U251,and SK-OV-3).
For each hybridization array, all spots with Cy3 or Cy5
fluorescence intensities below the average overall
background level plus one standard deviation were
discarded. Subsequently, a local background correction
for each spot was applied. Two scale factors were
calculated for each slide based on median ratio
normalization (median ratio set to 1) and total intensity
normalization (equalized sum of fluorescence intensities
for both channels). Nine housekeeping genes were
identified by BLAST similarity or keyword search against
the database of cDNA clones present on the array (see
IMAGE clones listed in Table 1).
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Subtractive expression profiling of neuroblastoma: identification of
new candidate genes and predictors for clinical outcome
Jo Vandesompele, et al. (in preparation)
INTRODUCTION
Neuroblastoma is one of the most frequent pediatric solid tumors, and accounts for more
deaths in childhood than any other cancer. Despite significant new insights in the genomic
heterogeneity of this malignancy, only few genes have been recognized to play a role in
neuroblastoma, and if so, only in a subgroup of tumors. In this respect, amplification and
overexpression of the proto-oncogene MYCN, and concurrent deletion or silencing of the CASP8
gene have been reported in a subset of aggressive high stage tumors1, 2. Clearly, additional
hitherto unidentified genes must be involved in this subgroup, as deletion of the distal part of
chromosome arm 1p, and gain of distal 17q are almost invariably found in these tumours3.
Furthermore, the critical genes located in other regions that show frequently loss of
heterozygosity (such as 3p, 4p, 9p, 11q, 14q and 18q) remain to be identified (for overview
see ref. 4). Of particular importance are deletions of chromosome 11q and 3p, which were
recently shown to delineate a distinct genetic subgroup of high stage tumors in the absence of
MYCN amplification, 1p deletion, or both5-7.
In an attempt to identify relevant neuroblastoma genes on a transcriptome wide basis, we
performed subtractive expression profiling between two neuroblastoma cell lines that belong to
different genetic subgroups (i.e. presence or absence of MYCN amplification, 1p- and 11q-
deletion). This PCR based strategy allows selective cloning of cDNA fragments that are
specifically expressed in each of the two cell lines8. The main advantages of this method are
the possibility to identify as yet unknown and low abundant differentially expressed genes, and
the physical availability of the isolated cDNA clones for downstream applications such as
Northern blot and microarray analysis. A non-redundant cDNA library of 300 different genes
was generated, of which 50 were used for real-time RT-PCR expression profiling of
neuroblastoma cell lines and primary tumors. In addition, we determined the expression level
of 26 genes that were selected as candidate neuroblastoma genes located in critical regions,
MYCN transcriptional target genes, markers for sympathetic nervous system development,
prognostic markers, or genes with a reported differential expression pattern in neuroblastoma.
All together, this resulted in an unprecedented number of neuroblastoma specific differentially
expressed genes that were studied on a large panel of both cell lines and primary tumors. The
major aims of this study were to find genes whose expression pattern was correlated with
known biological and clinical features, and improve tumor classification and prediction of
prognosis; to test the validity of the SSH procedure to generate neuroblastoma specific
differentially expressed cDNA libraries for downstream applications; and to assess the power of
real-time RT-PCR based expression profiling of a limited number of carefully selected
differentially expressed genes. Furthermore, the simultaneous analysis of both SSH clones and
literature based genes that were mostly studied as separate entities in previous reports
allowed us to determine associations between these genes, and interpret and validate the
expression data from hitherto unknown genes in neuroblastoma biology.
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MATERIAL & METHODS
Cell lines and tissues
Thirty-three neuroblastoma cell lines and one Ewing sarcoma line SK-N-MC (Table 1) were
karyotyped according to standard procedures. FISH-analysis with region specific probes and
chromosome paints were reported earlier for 15 cell lines9, 10. CGH data and M-FISH results on
16 cell lines have been published11, 12. Cell lines were tested for 1p-, 3p- and 11q deletion by
FISH, and tested for MYCN-amplification by FISH and Q-PCR analysis as described9, 13. Twenty-
seven primary NB tumors were staged according to the INSS14 (Table 2). All samples were
validated by the pathologist, contained more than 70% tumor cells and were analyzed for 1p-
deletion and MYCN-amplification as described above. Real-time PCR demonstrated marker
gene expression of GAP43 and HAND2 in all tumor samples. Nine normal control RNAs were
obtained from Clontech: adult brain (A), heart (B), kidney (C), liver (D), lung (E), trachea (F),
fetal brain (G), mammary gland (H), and uterus (I).
RNA extraction
Cell lines were grown to subconfluency in RPMI 1640 (Invitrogen) supplemented with
antibiotics, 15% fetal calf serum and 1% L-glutamine. Cells from 4 tissue culture flasks (75
cm2) were pelleted, quick frozen in liquid N2 and stored at –80° C. Tumor biopsies were
homogenized with an Ultra-Turrax T25 (IKA-Werke) in 2ml RNeasy lysis buffer (Qiagen). Total
RNA of cell lines and biopsies was isolated using the RNeasy Midi Kit (Qiagen), and mRNA was
extracted from SK-N-SH and IMR-32 with the FastTrack kit (Invitrogen), both according to the
manufacturer's instructions. RNA was quantified using the Ribogreen reagent (Molecular
Probes) on a TD-360 fluorometer (Turner Designs).
Suppression subtractive hybridization (SSH)
Starting from 2 µg of mRNA from cell lines SK-N-SH and IMR-32, SSH was performed with the
PCR-Select cDNA Subtraction kit (Clontech) as described by the manufacturer. The PCR
product mixture of putative differentially expressed genes was subcloned into the pGEM-T Easy
vector (Promega) and propagated in DH5α E. coli. Up to 1920 clones were picked, grown in
twenty 96-well plates and stored as glycerol stocks at -80° C for further analysis.
Differential screening to eliminate possible false positive clones was performed according to
the guidelines described in the Differential Screening kit (Clontech).
DNA sequencing and analysis
SSH clones were PCR amplified using SP6 and T7 vector specific sequences flanking the cloning
site. PCR products were exonuclease/phosphatase treated and cycle sequenced using
BigDyeTerminator chemistry on an ABI377 (Applied Biosystems) with primers that annealed to
the SP6 or T7 sequences. Similarity searches were performed using the BLAST algorithm after
removing vector and masking repeat sequences (RepeatMasker). Sequence alignment and EST
contig building were performed using the freely available BioEdit package15.
Northern blot hybridization
Fifteen µg of total RNA was mixed with an equal volume of denaturing buffer (66% DMSO,
12% glyoxal, 33 mM sodium phosphate buffer (pH 7.0)), incubated for 1 hr at 50° C, chilled
on ice, mixed with 1/10th volume of loading buffer, separated on 1% agarose gel prepared in
20 mM sodium phosphate buffer (pH 7.0) and blotted onto Hybond-N+ nylon membranes
(Amersham Biosciences). Methylene blue staining of blots was carried out to ensure equal RNA
loading. Blotted membranes were hybridized overnight at 65 °C in 1 mM EDTA, 0.5 M sodium
phosphate (pH 7.2), 1% BSA and 7% SDS. DNA probes for hybridization were obtained by PCR
amplification of SSH clones of interest. After purification of PCR products on a QIAquick column
(Qiagen), probes were labeled with αP32-dCTP by random primer labeling (MEGAprime,
Amersham Biosciences) and purified on a Micro Bio-spin P-30 column (Bio-Rad). After
hybridization, membranes were washed four times at 65° C for 30 min in buffers with 1 mM
EDTA, 1% SDS and decreasing concentrations of sodium phosphate (pH 7.2) (500 mM, 250
mM, 100 mM and 50 mM). Washed membranes were exposed to a phosphor imaging screen
and scanned on a Personal FX phosphorimager (Bio-Rad).
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Real-time PCR
Gene copy determination using real-time quantitative PCR based on SYBR Green I chemistry
and two reference genes (BCMA and SDC4) was performed as described13.
Relative gene expression levels were determined using an optimized two-step SYBR Green I
RT-PCR assay16 with minor modifications. After establishment of amplification efficiencies
>95% for all primer pairs, the comparative Ct method was used for quantification. PCR
reagents were obtained from Applied Biosystems or Eurogentec as SYBR Green I mastermixes
and used according to the manufacturer’s instructions. Reactions were run on an ABI5700
(Applied Biosystems) or I-Cycler (Bio-Rad). Gene expression levels were normalized using the
geometric mean of the 4 most stable internal control genes in neuroblastoma (i.e. UBC,
HPRT1, SDHA and GAPD) as reported previously17.
Based on chromosomal localization and possible function, 50 SSH clones were initially selected
for further study of their expression pattern in neuroblastoma. Furthermore, 26 additional
known genes were also quantified. Of these, 7 genes were selected based on their reported
differential expression pattern in neuroblastoma, 10 genes were neural crest or (sympathetic)
lineage marker genes, 7 genes were selected as candidate neuroblastoma genes in critical
regions of frequent loss or gain, and 2 were reported MYCN transcriptional target genes. The
expression levels of all 76 genes were determined in the cell line and normal tissue panel. Due
to minimal amounts of available biopsy RNA, only 37 genes (of which 27 SSH clones) were
quantified in the primary tumors. These genes were predominantly selected as genes with the
highest coefficient of variation in expression level observed in the cell lines. The complete
expression data matrix is available as tab delimited file from the authors on request. Primer
sequences for all tested genes are also available and will be deposited in a public database for
real-time PCR primers, which is under construction (www.realtimepcr.ht.st).
Expression data mining
Univariate survival analysis was performed with the Kaplan-Meier method and log-rank
statistic. The predictive significance of multiple variables were tested through Cox proportional
hazards modelling. Hierarchical cluster analysis and visualization was performed with Cluster
and TreeView18. The gene expression data matrix for cluster analysis was log transformed and
subsequently mean centered for the rows (genes). The SAM algorithm was used for supervised
identification of differentially expressed genes between predefined sample goups19. Principal
component analysis was performed using the java-based J-Express package20, to reduce the
dimensionality into two or three viewable dimensions, representing linear combinations of
genes that account for most variance in the original data set. Non-parametric Mann-Whitney
testing was used for identification of significantly differentially expressed genes between
samples with or without a specific genetic defect (a two-sided p value below 0.05 was
considered statistically significant).
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RESULTS
Subtractive cDNA cloning and non-redundant library generation
In order to isolate specifically expressed genes in each cell line, two parallel subtractions were
carried out with IMR-32 as tester and SK-N-SH as driver, and vice versa. From each
subtraction, a cDNA library of 960 clones was generated. After differential screening, 281 and
265 cDNA clones were retained as IMR-32 or SK-N-SH specific transcripts, respectively, and
sequenced. BLAST similarity searches querying the nr and human EST database resulted in a
non-redundant list of 241 known genes, 47 UniGene clusters, and 15 anonymous ESTs (of
which 7 showed no similarity with clones present in the human EST database). For each unique
gene or transcript, a representative clone was selected and re-arrayed.
Interestingly, a large fraction of the isolated clones are implicated in processes related to
tumor biology or development, such as genes coding for transcription factors, homeobox
genes, cell cycle controllers, cell adhesion proteins, proto-oncogenes, tumor suppressor genes,
and genes involved in signal transduction or chromatin remodelling. A detailed list of all clone
entries will be published elsewhere.
Validation of the subtracted cDNA library
Thirty-six randomly selected cDNA clones belonging to different genes or transcripts were used
as a probe for Northern blot analysis of SK-N-SH and IMR-32 (Figure 1). Five and 7 clones
were exclusively expressed in SK-N-SH and IMR-32, respectively. Thirteen and 3 clones were
at least 3 fold higher expressed in SK-N-SH and IMR-32, respectively. Eight clones were
equally abundant in both cell lines. Summarizing, 78% (28/36) of the isolated SSH clones were
differentially expressed in one or the other cell line. The identification of cDNA clones belonging
to genes known to be amplified and overexpressed in IMR-32 (i.e. MYCN, DDX1, NAG) further
demonstrated the validity of the library. Seventy percent of the non-redundant database
entries contained only 1 cDNA clone, highlighting the normalizing power of the subtractive
procedure which results in equalized clone abundance.
Characterization of the cell line panel
Hierarchical cluster analysis of the cell line and normal tissue expression data matrix with
different similarity measures and cluster algorithms systematically resulted in grouping of the
normal samples as expected, and clustering of three neuroblastoma cell lines together with the
Ewing sarcoma line SK-N-MC (i.e. NB-3, NN-1 and STA-NB-9) (data not shown). Interestingly,
these cell lines displayed a relatively low expression of HAND2, a typical neural crest derived
and neuroblastoma gene expression marker21. To investigate if these cell lines were of true
neuroblastic origin, additional neural crest, (sympathetic) nervous system and other lineage
specific marker genes (ARIX, PMX2B, KIT, NPY, CHGA, NOTCH1, HRY, and GAP43) and a Ewing
sarcoma specific marker (MIC2) were quantified. Subsequent multiclass SAM analysis of the
complete gene expression data matrix based on 3 predefined sample classes (i.e. normal
human tissues, the 4 above mentioned cell lines, and the remaining neuroblastoma cell lines)
resulted in a list of 25 genes that were significantly differentially expressed in at least one
sample class (q<0.01). Hierarchical cluster and principal component analysis of this gene set
clearly demonstrated separate grouping of the 4 above mentioned cell lines (Figure 2). In
addition, two other cell lines (GI-M-EN and SJNB-12) also displayed a deviating expression
profile and clustered away form the remaining neuroblastoma cell lines. Careful examination of
the expression patterns indicated that NN-1, NB-3, STA-NB-9, GI-M-EN, and SK-N-MC
completely lacked any sympathetic marker normally expressed in neuroblastoma cell lines. In
contrast, SJNB-12 exhibits expression of some genuine neuroblastoma and/or early neural
crest markers, such as the transcription factors ARIX and PHOX2B.
Additional evidence that corroborates the observed deviating expression patterns comes from
cytogenetic and immunocytochemical analyses of these cell lines. Chromosome karyotyping
and (M)-FISH studies indicated that NN-1, NB-3 and STA-NB-9 either do not exhibit any
chromosomal aberration, or no genetic defect typically observed in a neuroblastoma cell line
(e.g. gain of 17q, MYCN amplification, or deletion of 1p or 11q) (data not shown).
Furthermore, cell line SJNB-12 was shown to have MYC amplification (unpublished data), which
has never been reported before in a neuroblastoma tumor. Immunocytochemical APAAP assays
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demonstrated absence of GD2 disialoganglioside molecules in NN-1, NB-3, STA-NB-9, and SK-
N-MC, and a heterogeneous GD2 pattern (i.e. both positive and negative cells) for SJNB-12
and GI-M-EN (not shown).
As the above mentioned cell lines clustered together with the PNET family tumor SK-N-MC, the
lines were tested for 19 specific solid tumor gene fusions by means of a real-time multiplex
RT-PCR as described22. Besides the confirmative finding of a FLI1-EWS fusion in SK-N-MC, no
other specific translocations were detected. Based on the above presented data we decided to
exclude NN-1, NB-3, STA-NB-9, GI-M-EN and SJNB-12 for further analysis of neuroblastoma
specific gene expression patterns.
Identification of deletion related gene expression signatures
To identify genes whose expression pattern is related to specific genetic defects in
neuroblastoma, we dichotomized the cell line panel with respect to presence or absence of
deletion of 11q or 3p (see Table 1). Stratification for deletion of 1p was not possible as only 2
cell lines contained intact 1p chromosomes. For identification of deletion related genes, we
tested which genes had a significant (p<0.05) different mean expression in the two cell line
groups (Table 3), and eliminated sporadic genes that were included due to presence of one or
two strong outlying values.
Two genes were found to be higher expressed in 3p deleted cell lines, and 3 were decreased,
one of which is the VHL tumor suppressor gene on 3p25. Scatterplot analysis indicated that 3p
deleted cell lines group together in the bottom left section characterized by low VHL and NME1
expression (Figure 3A).
With respect to the 11q status, three genes were found to be higher expressed in deleted cell
lines, and 5 genes (of which 3 are located on 11q23~q24) were significantly decreased in
expression. PCA analysis of the expression levels of these 8 genes in 19 neuroblastoma cell
lines allowed a perfect classification of the cell lines based on their 11q status (Figure 3B). The
expression pattern of two representative genes (IGF2 and MCAM) is depicted in Figure 3C.
Identification of MYCN downstream genes
Using the same strategy as outlined above, we identified 19 and 13 genes that were
significantly differentially expressed in MYCN amplified vs. single copy neuroblastoma cell lines
and primary tumor samples, respectively (Table 3). In parallel, supervised SAM analysis with a
quantitative response metric (i.e. MYCN expression level) was applied, and yielded a similar
set of genes (not shown).
In order to provide further clues for identification of MYCN transcriptional target genes or their
downstream effectors, we compared the expression level in SK-N-SH and SKMYC2 cells. The
latter cell line consists of stably transfected SK-N-SH cells with a constitutive MYCN expression
vector23, and it was shown that these cells displayed a 500 fold increase in MYCN expression
compared to the parental cells, a level which is similar to the transcript abundance in the
MYCN amplified IMR-32 cells (data not shown). Of 70 genes tested, 28 displayed a more than
2-fold expression difference (13 upregulated, and 15 downregulated), of which 10 were also
differentially expressed in MYCN amplified vs. single copy cell lines, tumors or both (Table 4,
Figure 4).
Survival analysis
Twenty-seven neuroblastoma patients for which high-quality RNA was available from tumor
samples prior to therapy were subjected to SAM censored survival analysis. Twelve genes were
identified that might be correlated with patient survival probability (q-value < 0.05). Kaplan-
Meier survival analysis of the tumor samples dichotomized with respect to the median
expression level of these genes confirmed the prognostic value for 8 of the 12 genes (log rank
statistic < 0.05: Hs.28462, MEIS1, GAP43, CALM2; <0.01: MYCN, VHL, DKK3, CD44) (Figure
5, middle). Complete linkage hierarchical cluster analysis based on the Spearman rank
correlation coefficient as a similarity measure showed three patient clusters (Figure 5, top).
Cluster 1 contains 8 patients (all stage 3 or 4) with a 100% mortality rate. Cluster 2 comprises
8 patients, of which 3 died of disease (i.e. 3/3 stage 4 tumors in this cluster). Interesting to
note, 2 of these 3 patients survived more than 6 years after initial diagnosis (see Table 2).
Cluster 3 contains 11 patients that are still alive, and which all have a favorable stage of
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disease (1, 2 or 4S) (median follow-up 54 months). Principal component analysis
demonstrated that the first two components (explaining 61.3% of the expression variation)
were able to classify 24/27 patients according to disease outcome (Figure 5, bottom right). To
investigate the independent prognostic power of these 12 survival correlated genes, Cox
regression analysis was performed. Forward conditional entering of the genes indicated that
MYCN and VHL were the most significantly independent prognostic predictors, while backward
entering retained the VHL, DKK3, MEIS2 and NPY genes (Figure5, bottom left)
Identification of novel amplified and overexpressed transcripts
In addition to the isolation of the 3 known co-amplified genes located at 2p24 in cell line IMR-
32 (i.e. MYCN, DDX1 and NAG, see above), 16 other partial cDNA clones in the SSH library
were shown to be amplified and overexpressed in cell line IMR32. One clone was part of the
MEIS1 homeobox gene (2p14) that was recently shown to be amplified in IMR-3224, 25.
Extensive transcript mapping, homology searches and EST contig building indicated that 11
other cDNA clones presumably belonged to 2 novel genes. One is located close to the MEIS1
gene, but appears to be only highly expressed in IMR-32. A second transcript is located 500 kb
telomeric to NAG, and is amplified in 12% of 75 studied MYCN amplified neuroblastomas. The
4 remaining clones are located in the large 150 kb intron of NAG between exon 4 and 5, and
were shown to be amplified and overexpressed in 45% of the MYCN amplified neuroblastomas.
BLAST analysis of the human EST database with exon 4 and 5 of the NAG gene as a query
sequence failed to identify an EST clone that contained both exons, whereas multiple clones
were picked-up that contained either exon 4 or exon 5. Furthermore, RT-PCR with a forward
primer in exon 4 and a reverse primer in exon 7 failed to yield the expected band of 341 bp in
IMR-32 or SK-N-SH. In contrast, a sharp and single band of approximately 3 kb was amplified.
Furthermore, Northern blot analysis estimated the NAG transcript size to be 2.5 kb longer
compared to the published sequence. Sequence contig assembly using our 4 SSH clones,
public ESTs selected by BLAST, and the human genome sequence allowed in silico cloning of a
2.7 kb transcript fragment between exon 4 and 5. These data indicate that the published NAG
gene is probably misannotated and should contain 21 more exons between former exon 4 and
5. The elongated NAG gene sequence is predicted to contain an upstream start codon resulting
in in-frame addition of 537 amino acids in front of the former protein sequence. Further
characterization of these novel transcripts and curated NAG gene, and determination of their
relevance in neuroblastoma is currently ongoing.
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DISCUSSION
Despite recent new insights in the genetic heterogeneity of neuroblastoma, most of the genes
as well as the developmental and differentiation pathways involved in its pathogenesis remain
to be elucidated. As recognition of the underlying molecular defects and their downstream
effects is of great importance for better diagnosis, classification, outcome prediction and
development of tailored treatment protocols and new drugs, we sought to identify additional
relevant neuroblastoma genes. For this purpose, a subtractive cDNA cloning strategy was
applied to isolate differentially expressed genes by comparing two neuroblastoma cell lines
belonging to different genetic subgroups (i.e. with or without MYCN amplification, and deletion
of 1p and 11q). A non-redundant set of 300 cDNA clones was isolated, for which extrapolated
Northern blot results indicated that 75% of the clones represent true differentially expressed
transcripts. Here we report on the expression pattern of 50 of these clones, in conjunction with
literature based candidate genes, prognostic markers, or genes with a reported differential
expression pattern in neuroblastoma.
We adopted a supervised strategy for identification of aberration and prognosis related gene
expression signatures in a validated and representative panel of neuroblastoma cell lines and
primary tumors. In an attempt to understand the molecular switches that are responsible for
the oncogenetic properties of MYCN overexpression, we identified 12 and 18 genes that were
shown to have a significantly altered expression in MYCN amplified vs. single copy number
tumors and cell lines, respectively. In this list are two novel transcripts included with unknown
function and no homology to other genes, and located in critical regions of loss in high stage
tumors (UniGene clusters Hs.28462 at 11q23.3, and Hs.182594 at 14q32). The majority of the
genes identified in this study have not been reported in the context of neuroblastoma biology
nor MYCN amplification. Increased expression of NCL and RPS25 has been described in a SAGE
profiling study of the MYCN model system SH-EP26, and BCAT1 is a known transcriptional
target of MYC27.
Cell lines and tumors have only 4 genes in common that are differentially expressed with
respect to the MYCN status (SOS1, CALM2, DKK3 and MYCN itself). In addition to MYCN, these
3 genes might represent true and relevant differential expression markers that discriminate
between MYCN amplified and single copy neuroblastomas, and might help explain the
biological differences between these two genetic subgroups. In this respect, the decreased
expression of the human son of sevenless homolog 1 (SOS1), which is amongst others
involved in RAS mediated NGF signalling, is in keeping with the observed decreased or absent
expression of the high affinity NGF receptor NTRK1 in advanced stage MYCN amplified
neuroblastomas. Further evidence that an altered RAS pathway might play a role in MYCN
amplified tumors is provided by the observed decreased calmodulin (CALM2) expression, a
gene which is implicated in RASGRF1 mediated RAS activation28. Furthermore, high HRAS
expression has been associated with low MYCN expression and favorable patient outcome29, 30,
and was recently suggested to play a role in the spontaneous regression of neuroblastoma31.
To determine which of the above identified genes are MYCN downstream targets, we tested
their expression level in a MYCN cell line model system, that consists of stably MYCN
transfected  cells and their parental non-amplified counterparts with a 500 fold lower MYCN
expression. As positive controls for both MYCN dependent induction and repression of gene
expression, two additional genes (i.e. INHBA and ID2) were quantified. As expected, the
angiogenesis inhibitor activin A (INHBA) was strongly downregulated in the SKMYC2 cells32.
ID2 gene expression levels however remained unchanged, in contrast to a reported MYCN
dependent induction33. Similar contrasting observations in another laboratory prompted us to
analyze the relation between ID2 and MYCN content in further detail in neuroblastoma cell
lines and primary tumors, demonstrating a clear lack of correlation between ID2 and MYCN,
and absence of prognosis related predictive power of ID2 expression levels (manuscript in
preparation34).
In general, MYCN appears to be a more potent transcriptional silencer, with 7 genes being
repressed by more than 15-fold, while no gene was induced more than 6.5 fold. The
upregulation of three ribosomal proteins RPS25, RPL13A and RPL11 is in keeping with
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published data, where a role for MYCN in enhanced expression of a large set of genes
functioning in ribosome biogenesis and protein synthesis has been described26. The finding that
some genes involved in neuronal differentiation are induced (NEUROD1, CHGA, STMN2) with
increased MYCN expression, while others are repressed (NPY, GAP43) is puzzling and deserves
further study. In this context, it is noteworthy that there are apparently conflicting reports on
the role of MYCN in cellular differentiation, with some studies indicating preferential MYCN
expression during organogenesis and cell differentiation35, 36, while others describing that
exogenous MYCN overexpression inhibits induced differentiation of neuroblastoma cells37, 38.
Overall, our expression data provide possible insight into the way MYCN exerts it malignant
effects, i.e. by promotion of angiogenesis (INHBA) and cell proliferation (DKK3, CDKN1C), by
inhibition of apoptosis (TGM2), and by altering adhesion properties (CD44, HXB), possibly
leading to enhanced invasive capacity. Another possible very interesting MYCN target gene
identified in this study is the mortalization related and candidate tumor suppressor gene DKK3.
An almost 6 fold reduction in expression level has been observed in SKMYC2 cells, with a
general decreased expression in both MYCN amplified cell lines and tumors. DKK3 belongs to a
family of secretory glycoproteins, with some members having the ability to antagonize WNT
proto-oncogene signalling. DKK3 is down-regulated in a series of different immortalized and
tumor-derived cell lines, and primary tumor samples, in part by promoter hypermethylation39,
40. Exogenous DKK3 over-expression in tumor cells was shown to inhibit cell growth41. Further
evidence that this gene might play an important role in the biology of specific neuroblastoma
subgroups, comes from the observed strong independent predictive power for patient
outcome, as determined in the panel of primary tumors (see further). Further studies are
required to confirm a mechanistic link between MYCN and the DKK3 gene (as well as the other
identified putative transcriptional target genes), and to determine the biological consequences
of an altered expression level.
Upon the search for deletion related class I and II tumor suppressor genes, five genes were
found to be differentially expressed in neuroblastoma cell lines harboring a 3p deletion
compared to cell lines without this genetic defect. The gene that displayed the most
significantly reduced expression level in deleted cell lines is the Von Hippel Lindau (VHL) tumor
suppressor gene. In view of the location of this gene in the –still large- critical region of 3p loss
in neuroblastoma42, its established role in pheochromocytoma43 (like neuroblastoma a neural
crest derived tumor), and its demonstrated strong independent prognostic power in
multivariate analysis of primary tumor samples (see further), we propose this gene as a
potential target of 3p loss in neuroblastoma. Preliminary mutation analysis however yielded no
basepair alteration in the VHL coding region of 26 neuroblastoma tumors, nor aberrant VHL
promoter methylation (Hoebeeck et al., unpublished results). In analogy with recent reports of
haploinsufficiency of other suppressor genes involved in familial cancer syndromes (i.e. APC
and PTEN44, 45), the observed 2-3 fold expression difference suggests that a similar mechanism
could play a role in this subset of 3p deleted neuroblastomas.
With respect to 11q, a set of 8 genes was found that perfectly classified the neuroblastoma cell
lines based on their 11q deletion status. Interestingly, 3 of the identified genes are located on
chromosome region 11q23-q24 (NCAM, MCAM, and SRPR), which is commonly lost in
metastatic neuroblastoma tumors. In view of the delineation of a shortest region of overlap
between markers D11S1340 and D11S129946, the melanoma cell adhesion molecule MCAM
with a putative role in neural crest development is a good positional and functional candidate
tumor suppressor gene for the 11q23 locus. However, it has been reported that increased
MCAM expression is correlated with development of metastatic melanoma47, in which 11q23
LOH has been reported as a late event48. Further study is required to clarify this apparent
discrepancy. In addition, it remains to be determined whether these gene expression changes
are relevant to the specific genetic subgroups of neuroblastoma, or merely reflect a bystander
dosage effect due to loss of one allele.
In analogy to recent reports where microarray based gene expression profiling is used to
predict the clinical outcome of patients with various types of cancer, a supervised learning
method was applied to search for specific predictor genes for survival probability. Twelve
genes were identified, of which only 3 were previously shown to be correlated with prognosis
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in neuroblastoma (CD44, NTRK1, and MYCN). Depending on the feeding mechanism,
multivariate regression analyses attributed independent prognostic power to 4 new markers
(VHL, DKK3, NPY and MEIS2). Subsequent hierarchical cluster and principal component
analysis allowed reliable classification of 24/27 patients according to outcome, which
outperforms any current system based on a single gene or genetic defect. Still, some deceased
patients were mistakenly classified in the prognostic favorable group. As it turned out, patient
9 had a very slow growing primary tumor that could be controlled for more than 5 years by
repeated MIBG therapy. Patient 41 was originally diagnosed with a  stage 4S tumor, which was
later revised to stage 4. This patient was in complete remission for more than 5 years, after
which a new and aggressive stage 4 tumor was diagnosed resulting in death of the patient.
The first diagnosed tumor was analyzed in this study. The clinical course of these patients
could partially explain their classification in the favorable group. Clearly, additional markers are
needed to identify the patients at risk which now mistakenly clustered. The next step will be to
test the predictive power of the identified expression signature on an extended series of
primary tumors, and to develop a robust classifier for accurate disease course prediction.
Using a combination of primary tumor samples, cancer cell lines, and a transfected model
system, we have identified a substantial number of relevant neuroblastoma genes which
deserve further study. As reported in other human cancers, we also observed expression
patterns differences between cell lines and primary tumors, which might be explained by
sampling differences, in vitro effects, and the heterogeneity of tumor tissue compared tot
relatively homogenous cell line populations. More important in this study, the observed
discrepancy might be attributed to a fundamental biological difference between MYCN single
copy cell lines and tumors, with the former being derived from aggressively growing and
metastasizing cells, while the latter include a large fraction of prognostically favorable localized
tumors. Likewise, the observation that not all putative MYCN downstream genes found in
SKMYC2 cells are differentially expressed in MYCN amplified vs. single copy cell lines and/or
tumors probably indicates a certain tissue or cell specific effect of MYCN overexpression (due
to presence or absence of the appropriate cofactor proteins, in part depending on the
differentiation status of the cells). The importance of the cellular context for MYCN to exert its
transcriptional effect is underscored by the current lack of any consistent marker that is
differentially expressed in MYCN amplified vs. single copy tumors, with the exception of the
recently identified minichromosome maintenance protein MCM749. Caution has therefore to be
taken not to restrict to specific cell line model systems, and to apply a level of validation that
includes clinical tumor samples.
In view of the importance of amplified oncogenes in the development of many types of tumors,
the identification of novel overexpressed genes in cell line IMR-32 might be of particular
importance. Although we recently demonstrated that the frequently co-amplified DDX1 and
NAG genes do not result in diminished event-free or overall survival probability compared to
MNA tumors without amplification of these genes13, the possibility remains that co-amplified
and overexpressed genes influence the malignant phenotype of the MNA tumors. The presence
of the 4 known and 2 novel amplified genes in the IMR-32 SSH cDNA library, and the
identification of not yet annotated NAG exons, clearly illustrate the power and efficiency of the
applied subtractive methodology to clone amplified and overexpressed genes in tumors.
In conclusion, we demonstrated the combinatorial power of subtractive cDNA cloning and real-
time PCR expression profiling to identify several genes previously unknown to be involved in
neuroblastoma biology, and to designate specific gene expression patterns in the different
genetic subgroups of this childhood neoplasm. We provided evidence that the VHL tumor
suppressor gene and the MCAM adhesion molecule might be the critical targets of 3p and 11q
loss, respectively. Furthermore, insight was gained into the mechanisms responsible for the
specific malignant phenotype associated with MYCN amplification, including a consistent
downregulation of the mortalization related DKK3 gene. Finally, several new prognostic marker
genes were identified and allowed reliable patient classification with respect to survival
probability.
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FIGURES
Figure 1: Five representative Northern blot results from 36 tested SSH clones hybridized to IMR-32 (right
lane) and SK-N-SH (left). A: MME, SK-N-SH specific expression (found for 5/36 clones); B: DDX1, IMR-32
specific expression (7/36); C: MEIS2, >3 fold higher expression in SK-N-SH (13/36); D: NAG, >3 fold higher
expression in IMR-32 (3/36); and E: MTCO2, equal abundance (8/36).
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Figure 2:
Top: Average linkage hierarchical cluster analysis of neuroblastoma cell lines and normal tissues
(columns) for 25 genes (rows) identified by SAM as tissue of origin classifiers (red: high expression,
blue: low expression, gray: missing value; see Table 1 for names and genetic features of the cell lines)
(normal tissues: adult brain (A), heart (B), kidney (C), liver (D), lung (E), trachea (F), fetal brain (G),
mammary gland (H), and uterus (I)
Bottom: 3D projection of the same cell lines and normal tissues on the three major principal
components (PC) of the 25 genes used for hierarchical clustering (blue: normal human tissues, green:
neuroblastoma cell lines, red: atypical or non-neuroblastoma cell lines)
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Figure 3:
A: Scatterplot of neuroblastoma cell lines according to their VHL and NME1 expression level (green: 3p
deleted; black: intact 3p).
B: Projection of neuroblastoma cell lines on the first two principal components (PC) that capture 53.1%
variance of the 8 genes that displayed a significantly differential expression level with respect to the 11q
status (see Table 3) (red: 11q deleted; blue: intact 11q).
C: Log transformed and mean centered expression level of two genes from the set that was used in panel
B for PCA analysis (red: expression level in cell lines with 11q deletion; blue: intact 11q).
Figure 4:
Overview of the number of genes that were found to be significantly (p<0.05) differentially expressed
between MYCN amplified vs. single copy cell lines (19/76 tested genes) or primary tumor biopsies
(13/37), or that displayed a more than 2-fold expression difference when comparing stably MYCN
transfected SKMYC2 cells with the parental single copy MYCN cell line SK-N-SH (28/70 tested genes).
Genes that were differentially expressed in more than one system (i.e. cell lines, tumors, or transfected
SKMYC2 cells) are indicated in the respective Venn diagram intersections
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Figure 5:
Top: complete linkage hierarchical cluster analysis of primary tumor samples (columns) for 12 genes
(rows) identified by SAM as prognostic predictors (top) (red: high expression, blue: low expression;
green: alive, purple: dead; see Table 2 for clinical and genetic features of patients and tumors).
Middle: Kaplan-Meier survival curves for two representative genes, patients are dichotomized with
respect to the median gene expression.
Bottom right: Projection of the patients to the first two principal components of the 12 genes used for
hierarchical clustering (green: alive; purple: dead)
Bottom left: 3D scatterplot of patients according to the tumoral expression of 3 genes identified by
backward Cox regression analysis as most independent predictors for patient outcome (green: alive,
purple: dead).
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Table 1: Genetic features of studied cell lines
number name MNA a 1p del b 3p del b 11q del b
1 CHP 134 amp del no no
2 CHP 901 amp del del -
3 CLB-GA no - del del
4 GI-ME-N no del no del
5 IMR-32 amp del no del
6 LA-N-1 amp del no no
7 LA-N-5 amp del no no
8 LA-N-6 no del del del
9 N206 amp del no del
10 NB-3 no - no -
11 NBL-S no - no del
12 NGP amp del no del
13 NLF amp del - no
14 NMB amp del no -
15 NN-1 no no no no
16 SJNB-1 no del no -
17 SJNB-10 amp del - no
18 SJNB-12 no del del no
19 SJNB-6 amp del del no
20 SJNB-8 amp del no no
21 SK-N-AS no del del del
22 SK-N-BE amp del del -
23 SK-N-FI no no no no
24 SK-N-MC no del del -
25 SK-N-SH no no no no
26 SMS-KAN amp del no no
27 SMS-KCNR amp del no no
28 STA-NB-10 amp del no -
29 STA-NB-12 amp del no no
30 STA-NB-3 amp del no -
31 STA-NB-8 amp del no -
32 STA-NB-9 no no no -
33 TR-14 amp del no -
34 UHG-NP amp del no -
a: MNA: MYCN amplification; amp: amplification; no: normal
b: del: deletion; no: normal; - not tested or not informative
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Table 2: Clinical and genetic features of neuroblastoma patients
sample stage a 1p del b MNA c age d status OS e
PT_5 1 no no 0.92 alive 36.76
PT_21 1 no no 17.17 alive 122.33
PT_22 1 no no 5.69 alive 35.63
PT_23 1 no no 3.42 alive 20.75
PT_24 1 no no 6.64 alive 122.90
PT_25 1 no no 1.45 alive 12.92
PT_38 1 no no 13.25 alive 21.57
PT_43 1 no no 4.34 alive 19.13
PT_3 2 no no 10.62 alive 107.07
PT_11 2 no no 14.53 alive 57.63
PT_19 2 del no 10.98 alive 93.27
PT_20 2 no no 18.74 alive 50.33
PT_6 3 del amp 22.39 dead 17.82
PT_14 3 no no 62.83 alive 25.91
PT_28 3 no no 7.50 alive 70.47
PT_30 3 no no 7.43 alive 15.77
PT_42 3 no amp 17.13 dead 7.43
PT_9 4 no no 63.83 dead 84.80
PT_10 4 no no 56.82 dead 21.60
PT_12 4 del amp 57.51 dead 25.10
PT_15 4 del amp 34.20 dead 28.17
PT_17 4 no no 50.21 dead 18.67
PT_27 4 del amp 19.60 dead 6.63
PT_37 4 del amp 46.50 dead 8.90
PT_41 4 no no 3.26 dead 72.23
PT_44 4 del amp 11.77 dead 13.51
PT_4 4S no no 2.47 alive 112.97
a: INSS stage14
b: MNA: MYCN amplification; amp: amplification; no: normal
c: del: deletion; no: normal
d: age at diagnosis (in months)
e: overall survival (in months from diagnosis till death or last follow-up)
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Table 3: Genetic aberration related gene expression differences
11q deletion related p value a change b
IGF2 0.002 up
MCAM 0.002 down
NTRK1 0.011 up
SRPR 0.011 down
MME 0.030 down
CHGA 0.030 up
NCAM 0.037 down
PIM1 0.046 down
3p deletion related p value change
VHL <0.001 down
RGS5 0.006 up
NME1 0.007 down
MSTP032 0.011 up
CTNNB1 0.028 down
MNA related (T) c p value change
MYCN*° <0.001 up
GAP43* <0.001 down
CD44* <0.001 down
Hs.28462 <0.001 up
CALM2° <0.001 down
MEIS1 0.001 down
VHL 0.003 down
SOS1° 0.004 down
HAND2 0.009 down
NTRK1* 0.014 down
DKK3*° 0.025 down
HXB* 0.030 down
NPY* 0.037 down
MNA related (C) d p value change
MYCN*° <0.001 up
Hs.182594 0.001 up
NCL- 0.001 up
BCAT1 0.002 up
SOS1° 0.006 down
NME1- 0.006 up
MYC 0.007 down
RPS25*- 0.007 up
TNFRSF10B 0.014 up
HRY#- 0.014 down
CHD3*- 0.017 up
IGF2 0.020 down
CALM2° 0.027 down
MSTP032- 0.027 down
PMX2B#- 0.031 down
CTNNB1- 0.036 up
DKK3*° 0.042 down
RGS5 0.042 down
S100A6* 0.048 down
a: Mann-Whitney exact significance (2 times the one-sided p statistic)
b: up: higher expression in samples with the genetic effect; down: decreased expression in
samples with the genetic defect under study
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c: MNA: MYCN amplification; T: primary tumor samples; *: also differentially expressed in
SKMYC2 (see Table 4); °: differentially expressed in both cell lines and primary tumor samples
d: C: cell lines; -: not tested in primary tumor samples; #: not tested in SKMYC2 cells (see
Table 4)
Table 4: Differentially expressed genes in SKMYC2 vs. SK-N-SH a
downregulated b ratio c
PMX1 1921.14
TGFBI 443.04
NPY (T) 69.83
TGM2 48.36
INHBA 31.41
HXB (T) 16.97
CD44 (T) 16.17
DKK3 (T,C) 5.68
S100A6 (C) 5.06
GAP43 (T) 4.69
CDKN1C 3.09
IGF2 2.80
NTRK2 2.77
NTRK1 (T) 2.70
LTBP1 2.50
upregulated b ratio d
MYCN (T,C) 490.33
ASCL1 6.58
NEUROD1 5.72
CHGA 4.57
RPL13A 3.85
STMN2 2.79
RPS25 (C) 2.68
MEIS2 2.52
RGS5 2.35
CHD3 (C) 2.28
TMOD 2.21
MAB21L1 2.18
RPL11 2.13
a: only genes with an expression difference of more than 2 fold are listed; two independent
RNA extractions were performed (coefficient of variation for ratio’s < 35%)
b: also differentially expressed in MYCN amplified vs. single copy cell lines (C), or primary
tumors (T)
c: SK-N-SH/SKMYC2
d: SKMYC2/SK-N-SH
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ISCUSSION
Gene expression analysis plays an increasingly
important role in many fields of biological
research. Two recently developed methods to
measure transcript levels have gained much
popularity and are frequently applied.
Microarrays permit the parallel analysis of
thousands of genes in two differentially labeled
RNA populations, while real-time reverse
transcriptase PCR (RT-PCR) provides the
simultaneous measurement of gene expression in
many different samples for a limited number of
genes, and is especially suited when only a small
number of cells are available, e.g. small tumor
biopsies or microdissected cells. Both techniques
have the advantage of speed, throughput and a
high degree of potential automation compared to
conventional quantification methods, such as
Northern blot analysis, ribonuclease protection
assay, or competitive RT-PCR. Real-time PCR has
additional advantages over the conventional and
former PCR based quantification methods in
terms of accuracy, sensitivity, dynamic range of
quantification, and absence of post-PCR
manipulations.
Since the initial description of the real-time PCR
methodology, sequence-specific fluorescence-
labeled probes have been considered as a
standard detection format in many diagnostic and
research applications1, 2. However, these probes
–due to the relatively high cost- are not suited
for quantification of multiple sequences. In Paper
V of this thesis, we therefore optimized and
validated a real-time PCR assay using the SYBR
Green I dye, which is a much more economical
alternative to quantify any given sequence
because it is a non-specific DNA minor-groove
binder that fluoresces when bound to double-
stranded DNA. The lack of additional specificity -
otherwise provided by a sequence-specific probe-
can be compensated for by melting curve
analysis, which allows accurate assessment of
PCR specificity3.
Although advertised for by many leading life
science companies, we discovered that a one-
step RT-PCR using SYBR Green I for online
monitoring of PCR cycle progression might
obscure the true result in quantitative assays.
Indeed, we observed that the reverse
transcriptase enzyme and gene-specific primers
conspire to produce primer-dimer (PD) artefacts
that are efficiently co-amplified with the target
(and detected by the generic binding dye SYBR
Green I) during the PCR phase. For samples
where the gene of interest is of low abundance
(and PD are readily formed), this problem is of
particular importance. So far, extensive primer-
dimer formation during one-step RT-PCR has not
been described yet, because most one-step
assays use specific probes as a detection format.
However, caution has to be taken, as these
probes do not allow to the experimenter to
determine the effect of PD on the quantitative
results. The introduction of a two-step RT-PCR
(i.e. cDNA synthesis using random hexamer or
oligo(dT) primers, and PCR are performed in
separate tubes) completely eliminated this
problem.
Further validation of the real-time PCR illustrated
the prerequisite -and efficacy- of DNase
treatment of RNA prior to cDNA synthesis, to
ensure that data are not confounded by genomic
contamination and the inevitable presence of
pseudogenes. This step also significantly
facilitated primer design, as there is no further
need to exclude the possibility of genomic
contamination during RT-PCR. Determination of
the intra- and inter-assay variation of our
established method showed that DNase
treatment, cDNA synthesis and RT-PCR were very
reproducible. In conclusion, we provided evidence
that a two-step real-time quantitative RT-PCR
based on SYBR Green I detection chemistry and
DNase treated RNA as template is the method of
choice for sensitive and reproducible transcript
abundance measurements for a large series of
different genes.
With the advent of sensitive and accurate gene
expression technologies such as the above
described real-time quantitative RT-PCR, the
requirements for a proper internal control or so-
called housekeeping gene have become
increasingly stringent. Although many studies
have reported that housekeeping gene
expression can vary considerably, no study has
systematically addressed the critical issues of
using housekeeping genes, nor proposed an
adequate workaround. In Paper VI of this thesis,
we rigorously measured the expression level of
10 common housekeeping genes in 85 samples
from 13 different human tissues. Special
attention was paid to select genes that belong to
different functional and abundance classes, which
significantly reduced the fact that genes might be
co-regulated. We firmly demonstrated that the
common practice of using a single housekeeping
gene for normalization (such as beta actin, or
glyceraldehyde-3-phosphate dehydrogenase),
can result in erroneous normalization by at least
a factor 3 in 25% of any tested samples.  In
order to address the expression stability of a
given control gene in a series of tissue samples,
we developed a conceptually novel and robust
gene expression stability measure, and outlined
an algorithm to determine the most stable and
hence reliable housekeepers in a given tissue
panel. The algorithm is based on repeated gene
stability measurements and subsequent
elimination of the least stable control gene. To
handle the large amount of calculations, a Visual
Basic application for Microsoft Excel (termed
geNorm) was developed and is freely available
from the authors on request (Figure 1).
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We also presented a procedure to determine how
many control genes are required for reliable
normalization. It turned out that 3 genes sufficed
for samples with relatively low expression
variation, but that other tissues or cell types
required a fourth or fifth control gene to deal with
the observed expression variation. Finally, we
validated the expression stability measure and
the geNorm algorithm on two levels. First, we
showed that most non-specific expression
variation (which should be completely absent
after perfect normalization conditions) was
removed when stable control genes (as
determined by geNorm) were used for
normalization, in contrast to the use of random
housekeeping genes. Further validation based on
publicly available microarray data demonstrated
that our proposed normalization factor was
equivalent to frequently applied microarray
normalization factors.
In conclusion, we described and validated a
procedure to identify the most stable control
genes in a given set of tissue samples, and to
determine the optimal number of genes required
for reliable normalization of RT-PCR data. The
presented strategy can be applied to any number
or kind of genes or tissues, and should allow
more accurate gene expression profiling. This is
of utmost importance for studying the biological
significance of subtle expression differences.
The power of genome-wide expression profiling in
the study of cancer is demonstrated by an ever
increasing number of high impact papers that
describe the presence of specific gene expression
signatures that allow more accurate diagnosis4, 5,
tumor classification6-10, and patient outcome
prediction11-13, compared to current clinical-
genetic or morphology based criteria. Two major
strategies are being used to accomplish a
genome-wide cancer transcriptome profile, i.e.
serial analysis of gene expression (SAGE14) and
microarray analysis15, with real-time quantitative
PCR technology being most frequently used to
confirm and extend obtained results. From a
conceptual point of view, the SAGE methodology
is superior, as it generates absolute data, which
can easily be integrated into existing SAGE
databases, for further data mining and
comparison with other transcriptomes. However,
the significant amount of workload to generate a
SAGE based transcriptome excludes its general
application to study complex biological problems
that require testing of multiple samples to draw
significant conclusions (such as the
aforementioned applications). In contrast,
microarrays permit the parallel analysis of
thousands of genes in a way that allows study of
a far greater number of samples (up to 300
different samples in a recent report4). With the
advent of these high-throughput technologies
and the generation of vast amounts of data, a
new era of computing based biological data
mining has emerged. Whereas until recently
mainly exploratory tools were used (such as
hierarchical clustering16 or self organizing
maps17), analysis is now more and more shifted
towards supervised learning strategies, like
neural networking5 and harvesting of expression
trees18.
With respect to the genome wide expression
analysis of neuroblastoma, only a limited number
of reports have been published. Two studies
aimed at identification of MYCN downstream
genes and their effectors by comparing the
expression profile of MYCN amplified
neuroblastoma cells with single copy tumor cells.
A SAGE based study revealed a list of genes
involved in ribosome biogenesis and protein
synthesis, demonstrating that MYCN functions in
part as a regulator of cell growth19. Filter array
hybridization analysis of 3 neuroblastoma cell
lines and various other MYC amplified cancer cell
lines identified both MYCN and MYC putative
target genes, the majority of which involved in
cell cycle regulation20. A more global expression
profiling analysis of predominantly
neuroblastoma cell lines was performed in a
microarray study where an artificial neural
network model was developed for classification
and diagnostic prediction of small round blue cell
tumors, which are childhood neoplasms with a
similar histological appearance (see Chapter 1)5.
Several marker genes not previously associated
with neuroblastoma were identified.
Although the above cited studies yielded valuable
information, they do not provide significant
insight into the molecular basis of the various
genetic subgroups of neuroblastoma, nor do they
propose new marker genes for improved
classification or patient outcome prediction.
In Paper VII of this thesis, we therefore
attempted to identify relevant neuroblastoma
genes on a transcriptome wide basis, using a
combination of subtractive cDNA cloning of
differentially expressed genes, and subsequent
real-time PCR profiling of both neuroblastoma cell
lines and primary tumors. Typical gene
Figure 1: Splash screen of the geNorm applet during
startup from Microsoft Excel.
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expression signatures were found associated with
major genetic defects and patient outcome.
Combination of differential analysis of MYCN
amplified versus single copy cell lines and
tumors, and a MYCN overexpressing cell line
model system identified the mortalization related
DKK3 gene as a strong candidate MYCN
transcriptionally repressed gene, in part
responsible for the oncogenic mechanism
associated with MCYN overexpression. In view of
the observed decreased expression in 3p or 11q
deleted cell lines, the VHL and MCAM genes were
suggested to be candidate neuroblastoma tumor
suppressor genes for the 3p and 11q critical
region, respectively. Further evidence that VHL
might play an important role in a subgroup of
neuroblastoma, comes from its observed
independent predictive power in a set of 12
genes that allowed improved prediction of patient
survival probability.
The majority of the genes identified in this study
have not been reported in the context of
neuroblastoma biology, and underscore the
efficacy of subtractive expression profiling in the
study of cancer. In view of the rather surprising
limited number of differentially expressed genes
observed in SAGE profiling studies of cancerous
vs. normal tissues (i.e. a few hundred
transcripts) (reviewed in ref. 21), our non-
redundant library of 300 clones might contain
already a significant fraction of the relevant
neuroblastoma genes, and thus holds great
promise for our planned microarray based
identification and further study of potential new
targets for diagnosis, prognosis and therapy of
neuroblastoma. Overall, subtractive cDNA cloning
proves to be a very valuable and economic
strategy for generating relevant differentially
expressed clones for downstream applications
such as microarray profiling. This is in contrast to
common microarray based screening strategies,
where typically 5.000 to 10.000 random clones
are studied to end up with a set of a few tens to
hundreds of genes of putative interest.
Furthermore, current cDNA arrays are somewhat
limited in a way that predominantly known genes
and isolated EST clones with a moderate to high
abundance are present. However, microarrays
based on subtractive cDNA libraries would be
enriched for both differentially expressed and low
abundant transcripts, thus maximizing the
efficiency for identification of relevant and new
genes. Future research strategies in our
laboratory therefore include the generation of
additional subtractive cDNA libraries based on
different model systems (e.g. microcell mediated
chromosome transferred cell lines, and normal
neuroblast precursors vs. malignant tumor cells).
Subsequent custom microarray expression
profiling of well characterized neuroblastoma
samples is aimed at elucidation of the pathways
disturbed in the different genetic subgroups, and
identification of a prognostic set of marker genes
that allow sensitive discrimination of patients that
require intensive treatment, and others that
benefit with milder therapeutic interventions,
resulting in significantly decreased adverse
treatment side-effects.
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SUMMARY
Neuroblastoma is defined as one disease, but there’s increasing evidence that it may comprise
several biological subtypes. Indeed, this enigmatic childhood tumor displays a remarkably variable
clinical course, ranging from spontaneous regression or maturation into benign ganglioneuroma,
to aggressive proliferation with widespread metastasis and fatal outcome of the patient. This
hallmark of clinical variability reflects the underlying genetic heterogeneity of the tumoral cells.
In the first part of this thesis, we illustrated the power of comparative genomic hybridization in
whole genome screening for structural and numerical chromosome aberrations in neuroblastoma,
in particular for the analysis of localized tumors and high stage neuroblastomas lacking MYCN
amplification, for which little genetic information was available. One of the major findings was the
presence of a nonrandom pattern of whole chromosome gains and losses in low stage,
prognostically favorable tumors, while high stage tumors mainly displayed partial chromosome
imbalances. In keeping with this, extra chromosomes 17 or unbalanced 17q gain was found to be
the most frequently genetic abnormality in low and high stage tumors, respectively, suggesting a
possible gene dosage effect of one or more genes on 17q in neuroblastoma pathogenesis. Further
study indicated that the 17q status was the most significant predictor for clinical outcome, and
should therefore be incorporated in future clinical trials. Finally, a new genetic subgroup of
aggressive neuroblastoma tumors was delineated, characterized by the presence of deletions of
the long arm of chromosome 11, often in association with loss of 3p, but typically without  MYCN
amplification.
In the second part of this thesis, we attempted to identify relevant neuroblastoma genes on a
transcriptome wide basis, using a combination of subtractive cDNA cloning of differentially
expressed genes, and subsequent real time PCR profiling in both neuroblastoma cell lines and
primary tumors. To this purpose, we first optimized the PCR assay, and demonstrated that a two-
step real time quantitative RT-PCR based on SYBR Green I detection chemistry and DNase treated
RNA as template is the method of choice for sensitive and reproducible transcript abundance
measurements for a large series of different genes. Furthermore, we provided an adequate
workaround for an old problem in gene expression studies, i.e. normalization of expression levels.
We developed a conceptually novel and robust gene expression stability measure, outlined an
algorithm to determine the most stable and hence reliable housekeepers in a given tissue panel,
and presented a procedure to determine the optimal number of genes required for reliable
normalization of RT-PCR data. This strategy should allow more accurate gene expression profiling,
which is of utmost importance for studying the biological significance of subtle expression
differences.
Gene expression data mining revealed typical expression signatures that were associated with
major genetic defects and patient outcome. Several candidate MYCN transcriptional target genes
were identified based on a combination of expression profiling of cell lines, primary biopsies, and a
transfected MYCN overexpressing cell line, and might shed light on the way MYCN exerts its
oncogenetic effects. Furthermore, putative class I and II tumor suppressor genes were identified
for the critical regions of loss on chromosome arms 3p and 11q. Finally, several new prognostic
marker genes were identified and allowed reliable patient classification with respect to survival
probability.
In conclusion, we have provided significant new insights in the genetic heterogeneity of
neuroblastoma, which resulted in a more accurate and detailed genetic subgroup classification,
and identification of a strong predictive factor for patient outcome. Additionally, we have identified
a substantial number of relevant neuroblastoma genes that deserve further study, and provided a
technical framework for future isolation and analysis of differentially expressed genes in other
genetic subgroups of neuroblastoma.
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RÉSUMÉ
L’étude du neuroblastome est de grand intérêt puisqu’il comprend différents sous-types
biologiques. En effet, chez l’enfant il est énigmatique et connaît une évolution clinique imprévisible
pouvant aller d’une régression spontanée ou d’une maturation jusqu'à la formation d’un
ganglioneurome bénin ou encore d’une prolifération agressive avec des métastases généralisées à
l'issue fatale. Cette variabilité clinique reflète l’hétérogénéité génétique des cellules tumorales.
Cette thèse présente dans sa première partie l’intérêt de l’hybridation génomique comparative
pour l’étude du caryotype. L’étude des aberrations de nombre et de structure des chromosomes
du neuroblastome est particulièrement intéressante dans les tumeurs localisées et surtout dans
les neuroblastomes à un stade avancé qui n’ont pas d’amplification MYCN. Grâce à la CGH
l’identification d’anomalies de nombres, de pertes et de gains des chromosomes est possible dans
des tumeurs localisés à pronostic favorable ainsi que la détection de déséquilibres de structures
dans les tumeurs avancées. Spécifiquement, un chromosome 17 en extra ou un gain du bras 17q
est l’anomalie cytogénétique la plus courante dans les tumeurs qu’elles soient localisées ou
avancées. Ceci suggère que le 17q est impliqué dans la pathogénèse du neuroblastome. Des
études ultérieures démontrent l’importance d’un contrôle du 17q comme élément prédictif de
l’évolution clinique. La présence de délétion cytogénétique dans le bras 11q associé à la perte du
bras 3p montre un nouveau sous-groupe et se retrouve dans les neuroblastomes agressifs qui
n’ont pas d’amplification MYCN.
Dans la seconde partie de cette thèse nous avons comme but l’identification des gènes relevants
du neuroblastome. Pour cette détection de gènes nous combinons le clonage subtractif des gènes
exprimés différemment et de PCR en temps réel de lignées de neuroblastomes en de tumeurs
primaires. L’optimisation de la technique PCR, par RT-PCR quantitative en 2 temps avec détection
en SYBR Green I précédé d’un traitement DNAse de l’ARN, a prouvé être de grande reproduction
dans une méthode sensible pour la mesure de transcrits d’une large série de gènes. Ensuite, nous
avons trouvé la solution adéquate d’un vieux problème dans l’étude de l ’expression de gènes en
normalisant les niveaux de l' expression. Pour cela, nous avons conçu un nouveau paramètre pour
mesurer la stabilité de l ‘expression d’un gène, tout comme un algorithme pour identifier dans une
série d’échantillons les gènes les plus stables et aussi les plus fiables dans un tissu bien
déterminé. Nous présentons également une technique de détermination du nombre idéal de gènes
nécessaires à une bonne normalisation de la RT-PCR. La méthode présentée offre la possibilité de
mesurer de façon plus précise les niveaux d’expression génique. Ceci est de grande importance
dans l’étude de l’importance biologique de différences subtiles d’expression.
Les analyses démontrent que des signatures spécifiques d’expression peuvent être associées aux
principaux défauts génétiques et aussi à un pronostic pour les patients. Un nombre de gènes
candidats réglés par MYCN ont été identifié en combinant l’analyse de lignées cellulaires, de
biopsies de tumeurs primaires, et d’une lignée transfectée ayant MYCN en surexpression. Ce
travail a permis de mettre en évidence les méchanismes moléculaires des effets oncogénétiques
de la protéine MYCN. Ensuite les gènes candidats suppresseurs de tumeurs de la classe I et II
pour la région critique de perte en 3p et 11q ont été identifiés. Enfin, nous avons également
identifié une série de gènes marqueurs d’intérêt pronostique afin de classifier les patients selon
leur espérance de vie.
En conclusion, nous apportons de nouvelles perspectives dans l’hétérogénéité génétique du
neuroblastome qui aboutissent à une classification plus exacte et détaillée des différents sous-
groupes, et à l’identification d’un facteur conclusif pour le pronostic.
Ensuite nous avons identifié un nombre considérable de gènes neuroblastomes importants qui
méritent une étude plus approfondie. Finalement nous avons développé un encadrement
technique qui permet d'isoler et d'analyser d’autres gènes différentiels dans d’autres sous-groupes
de neuroblastomes.
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SAMENVATTING
Neuroblastoom wordt gedefinieerd als één tumortype, maar meer en meer lijkt het erop dat
deze vorm van kanker verschillende biologische subtypes omvat. Neuroblastoom komt voor bij
kinderen en vertoont een merkwaardig variabel klinisch verloop, gaande van spontane
regressie of maturatie naar een goedaardig ganglioneuroom bij de ene patiënt, tot een
agressief groeiende tumor met wijdverspreide uitzaaiingen en snel overlijden bij de andere
patiënt. Deze typische klinische variabiliteit reflecteert ten dele de genetische heterogeniteit
van de tumorcellen.
In het eerste deel van deze thesis hebben we de kracht geïllustreerd van vergelijkende
genoomhybridisatie bij de studie van structurele en numerieke chromosoomafwijkingen in
neuroblastoom. Deze methodologie is voornamelijk interessant gebleken voor de analyse van
gelokaliseerde tumoren en metastaserende neuroblastomen zonder amplificatie van het MYCN
proto-oncogen, voor dewelke voorheen slechts weinig genetische informatie beschikbaar was.
Een belangrijke bevinding was de aanwezigheid van een specifiek patroon van numerieke
chromosoomafwijkingen in prognostisch gunstige lage stadia tumoren, tegenover voornamelijk
partiële chromosoomdefecten in hoge stadia neuroblastomen. Daarnaast werd aangetoond dat
een extra chromosoom 17 of ongebalanceerde 17q toename de meest frequente genetische
afwijking vormt in respectievelijk lage en hoge stadia neuroblastomen. Een verder
doorgedreven analyse resulteerde in de identificatie van de 17q status als de meest
significante voorspellende parameter voor de overlevingskansen van de patiënt, wat
suggereert dat dit genetisch kenmerk in toekomstige klinische studies zou moeten
geïncorporeerd worden. Tot slot werd een nieuwe genetische subgroep van agressieve
neuroblastomen afgebakend, die gekenmerkt worden door een deletie van de lange arm van
chromosoom 11, vaak in combinatie met een deletie van de korte arm van chromosoom 3, en
zonder amplificatie van MYCN.
In het tweede deel van deze thesis beoogden we relevante neuroblastoomgenen te
identificeren op basis van een combinatie van subtractieve cDNA klonering van differentieel
geëxprimeerde genen en real time PCR profilering van neuroblastoom cellijnen en primaire
tumoren. Hiertoe hebben we eerst de PCR methode geoptimaliseerd, waarbij aangetoond werd
dat een tweestaps real time kwantitatieve RT-PCR op basis van SYBR Green I detectie en
voorafgaande DNase-behandeling van het RNA, de aangewezen methode is voor gevoelige en
reproduceerbare metingen van transcriptniveaus van een grote reeks verschillende genen.
Verder hebben we een doeltreffende oplossing aangeboden voor een oud zeer bij
expressiestudies, namelijk de normalisatie van expressieniveaus. We hebben een robuuste en
conceptueel nieuwe genexpressie-stabiliteitsparameter ontwikkeld, gekoppeld aan een
algoritme om de meest stabiele en dus betrouwbare huishoudgenen in een gegeven
stalenreeks te identificeren. Daarnaast werd een procedure voorgesteld om het optimaal aantal
genen te bepalen nodig voor een betrouwbare normalisatie van RT-PCR resultaten. De
voorgestelde methode biedt de mogelijkheid om correct genexpressieniveaus te meten, wat
van groot belang is voor de studie van de biologische significantie van subtiele
expressieverschillen.
Data-analyse toonde aan dat typische genexpressie-signaturen geassocieerd konden worden
aan de belangrijkste genetische defecten en aan de prognose van de neuroblastoompatiënten.
Een aantal kandidaat MYCN transcriptionele doelwitgenen werden geïdentificeerd op basis van
een gecombineerde analyse van cellijnen, primaire tumorbiopsiën, en een stabiel
getransfecteerde cellijn waarin MYCN tot overexpressie komt. Deze bevindingen bieden
mogelijks inzicht in de moleculaire mechanismen waarop het MYCN proteïne zijn
oncogenetische effecten uitoefent. Verder werden mogelijke klasse I en II tumorsuppressor-
genen voor de kritische regio’s van verlies op chromosoomarmen 3p and 11q geïdentificeerd.
Tenslotte werd ook een reeks van prognostische merkergenen geïdentificeerd, die de
mogelijkheid bieden om op een betrouwbare wijze patiënten te classificeren volgens hun
overlevingskansen.
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Samengevat kunnen we stellen dat we belangrijke nieuwe inzichten gekregen hebben in de
genetische heterogeniteit van neuroblastoom, wat resulteerde in een meer nauwkeurige en
gedetailleerde subgroepclassificatie, alsook de identificatie van een sterke prognostische
parameter. Bijkomend hebben we een substantieel aantal relevante neuroblastoomgenen
geïdentificeerd die verdere studie verdienen, en een technisch kader ontwikkeld voor
toekomstige isolaties en analyses van differentieel geëxprimeerde genen in andere genetische
subgroepen van neuroblastoom.
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ABBREVIATIONS
bHLH-LZ basic Helix-Loop-Helix/Leucine Zipper
CGH Comparative Genomic Hybridization
cM centiMorgan
CNS Central Nervous System
EFS Event Free Survival
FISH Fluorescent In Situ Hybridization
HVA Homovanillic Acid
INPC International Neuroblastoma Pathology Classification
kb kilobases (one thousand basepairs)
LOH Loss Of Heterozygosity
Mb Megabases (one million basepairs)
M-FISH Multicolour FISH
MKI Mitosis-Karyorrhexis Index
MNA MYCN Amplification
NB Neuroblastoma
OS Overall Survival
PCA Principle Component Analysis
PCR Polymerase Chain Reaction
PD Primer Dimers
PNET Primitive Neuroectodermal Tumor
PNS Peripheral Nervous System
RT Reverse Transcriptase
SAM Significance Analysis of Microarray data
SIF Small Intensely Fluorescent
SNS Sympathetic Nervous System
SRO Shortest Region of Overlap
SSH Suppression Subtractive Hybridization
VMA Vanillylmandelic Acid
two weeks before the Ph.D. thesis is due
« I think you have to be a little more specific
here in step two … »
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